Search Result
Results for "
Acid Inhibitors
" in MedChemExpress (MCE) Product Catalog:
9985
Inhibitors & Agonists
20
Biochemical Assay Reagents
107
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-N1717
-
-
-
- HY-W000932
-
|
|
Bacterial
|
Infection
|
|
Butylboronic acid is a competitive soybean urease inhibitor with an IC50 of 2.9 mM and a Ki of 1.5 mM .
|
-
-
- HY-B0493
-
|
|
Chloride Channel
COX
|
Inflammation/Immunology
Cancer
|
|
Niflumic acid is a calcium-activated chloride channel blocker and COX-2 inhibitor with the IC50 value of 100 nM. Niflumic acid induces apoptosis through caspase-8/Bid/Bax pathway in lung cancer cells. Niflumic acide exhibits anti-tumor activity by affecting the expression of ERK1/2 and the activity of MMP2 and MMP9. Niflumic acid has orally bioactivity. Niflumic acid acts on rheumatoid arthritis .
|
-
-
- HY-12642
-
|
|
Parasite
|
Infection
Inflammation/Immunology
|
|
Diethylcarbamazine citrate is an orally active anthropoidal compound. Diethylcarbamazine citrate is an inhibitor of arachidonic acid metabolism of filaria microfilaria. Diethylcarbamazine citrate has anti-inflammatory and antiparasitic activity .
|
-
-
- HY-B0493R
-
|
|
Chloride Channel
COX
|
Inflammation/Immunology
|
|
Niflumic acid (Standard) is the analytical standard of Niflumic acid. This product is intended for research and analytical applications. Niflumic acid is a calcium-activated chloride channel blocker and COX-2 inhibitor with the IC50 value of 100 nM. Niflumic acid induces apoptosis through caspase-8/Bid/Bax pathway in lung cancer cells. Niflumic acide exhibits anti-tumor activity by affecting the expression of ERK1/2 and the activity of MMP2 and MMP9. Niflumic acid has orally bioactivity. Niflumic acid acts on rheumatoid arthritis .
|
-
-
- HY-169739
-
-
-
- HY-W104816
-
-
-
- HY-N12604
-
|
|
NF-κB
|
Others
|
|
Penicisteck acid F (Compound 2) is a Marine derived tanzanic acid derivative that is a NF-κB inhibitor. Penicisteck acid F inhibits osteoclast expression by decreasing RANKL-induced IκBα degradation, NF-κB p65 nuclear translocation, NFATc1 activation and nuclear translocation, and related mRNA expression. Penicisteck acid F can be used in osteoporosis research .
|
-
-
- HY-158235
-
|
|
Tyrosinase
|
Others
|
|
Tyrosinase-IN-27 (compound 6f) is a tyrosinase (TYR) inhibitor (IC50: 0.88 μM) that statically quenches TYR. Tyrosinase-IN-27 increases the hydrophobicity of the enzyme microenvironment by binding to TYR, reducing the content of α-helices in the enzyme and changing its secondary structure. Tyrosinase-IN-27 can be used in the food industry to effectively inhibit the browning of lotus root slices. .
|
-
-
- HY-P10274
-
-
-
- HY-125144
-
|
|
Na+/H+ Exchanger (NHE)
|
Cardiovascular Disease
|
|
BIIB 513 is an inhibitor of NHE 1 that protects against myocardial ischemia. BIIB 513 inhibits acid load recovery with an IC50 of 27 nmol/L in cells expressing wild-type NHE 1 under acute acid load .
|
-
-
- HY-137121
-
|
|
Bacterial
|
Infection
|
|
YKAs3003 is a potent inhibitor of Escherichia coli KAS III (ecKAS III) with antibacterial activity. The minimum inhibitory concentrations (MICs) of YKAs3003 against a variety of bacteria ranged from 128 to 256 μg/mL .
|
-
-
- HY-12642R
-
|
|
Parasite
|
Infection
Inflammation/Immunology
|
|
Diethylcarbamazine (citrate) (Standard) is the analytical standard of Diethylcarbamazine (citrate). This product is intended for research and analytical applications. Diethylcarbamazine citrate is an orally active anthropoidal compound. Diethylcarbamazine citrate is an inhibitor of arachidonic acid metabolism of filaria microfilaria. Diethylcarbamazine citrate has anti-inflammatory and antiparasitic activity .
|
-
-
- HY-156358
-
-
-
- HY-155247
-
|
|
Tyrosinase
|
Others
|
|
Tyrosinase-IN-14 (compound 7m) is a tyrosinase inhibitor that reduces the catalytic activity of tyrosinase by changing its secondary structure. Tyrosinase-IN-14 has low cytotoxicity and anti-browning activity in fruits. Tyrosinase-IN-14 effectively inhibits banana browning during storage .
|
-
-
- HY-124408
-
|
|
Fungal
|
Infection
|
|
Mepronil, a compound belonging to the carboxyamine group of fungicides, has a particularly strong bactericidal effect on basidiomycete fungi. Mepronil acts as a single point inhibitor of the succinate ubiquinone reductase or succinate dehydrogenase complex. Mepronil can be used in the study of cross resistance and biological infection .
|
-
-
- HY-N12267
-
|
(E/Z)-Terrestribisamide
|
Melanocortin Receptor
|
Metabolic Disease
|
|
N,N′-Diferuloylputrescine ((E/Z)-Terrestribisamide) is a inhibitor of pigmentation with 57% reduction. N,N′-Diferuloylputrescine significantly reduces the protein level of MITF. N,N′-Diferuloylputrescine has strong antioxidant activities as radical scavengers against reactive oxygen species .
|
-
-
- HY-157538
-
|
|
PDHK
|
Cardiovascular Disease
|
|
PDK4-IN-2 (compound 8) is a pyruvate dehydrogenase kinase 4 (PDK4) inhibitor with an IC50 of 46 µM. PDK4-IN-2 improves ejection fraction of failing hearts by regulating bioenergetics via activation of the tricarboxylic acid cycle .
|
-
-
- HY-158570
-
|
|
Bacterial
|
Infection
|
|
(2E)-Eicosenoic acid is an inhibitor of Mycobacterium tuberculosis protein tyrosine phosphatase A (PtpA). (2E)-Eicosenoic acid exhibits strong inhibitory activity against PtpA with an IC50 value in the low micromolar range. (2E)-Eicosenoic acid can be used for research on Mycobacterium tuberculosis infection .
|
-
-
- HY-150766
-
|
|
Bacterial
|
Infection
|
|
KPC-2-IN-1, boronic acid derivative, is a potent KPC-2 inhibitor with Ki of 0.032 μM. KPC-2-IN-1 enhances the activity of cefotaxime in KPC-2 expressing E. coli. KPC-2-IN-1 exhibits well tolerated in human HEK-293 cells, which can be used for the study of E. coli resistance to β-lactam antibiotics .
|
-
-
- HY-124408R
-
|
|
Fungal
|
Infection
|
|
Mepronil (Standard) is the analytical standard of Mepronil. This product is intended for research and analytical applications. Mepronil, a compound belonging to the carboxyamine group of fungicides, has a particularly strong bactericidal effect on basidiomycete fungi. Mepronil acts as a single point inhibitor of the succinate ubiquinone reductase or succinate dehydrogenase complex. Mepronil can be used in the study of cross resistance and biological infection .
|
-
-
- HY-163771
-
|
|
Pyruvate Carboxylase (PC)
|
Metabolic Disease
|
|
Pyruvate Carboxylase-IN-5 (compound 6m) is a pyruvate carboxylase inhibitor with high selectivity and permeability. Pyruvate carboxylase is a mitochondrial enzyme that catalyzes the carboxylation of pyruvate to oxaloacetate, a process that plays an important role in maintaining steady-state levels of Krebs cycle intermediates, which are precursors for the synthesis of biomacromolecules such as amino acids, fatty acids, and glucose .
|
-
-
- HY-126221B
-
|
Emeriamine TFA
|
Biochemical Assay Reagents
|
Metabolic Disease
|
|
(R)-Aminocarnitine (Emeriamine) TFA is a fatty acid oxidation inhibitor that reduces hyperglycemia and ketosis. (R)-Aminocarnitine TFA can be used in the study of metabolic diseases .
|
-
-
- HY-P3695
-
|
|
FGFR
|
Cancer
|
|
VSPPLTLGQLLS is a small peptide FGFR3 inhibitor, peptide P3, inhibits FGFR3 phosphorylation. VSPPLTLGQLLS inhibits 9-cisRA-induced tracheal lymphangiogenesis and blocks lymphatic endothelial cell (LEC) proliferation, migration, and tubule formation .
|
-
-
- HY-P3695A
-
|
|
FGFR
|
Cancer
|
|
VSPPLTLGQLLS TFA is a small peptide FGFR3 inhibitor, peptide P3, inhibits FGFR3 phosphorylation. VSPPLTLGQLLS TFA inhibits 9-cisRA-induced tracheal lymphangiogenesis and blocks lymphatic endothelial cell (LEC) proliferation, migration, and tubule formation .
|
-
-
- HY-110288
-
|
|
Sialyltransferase
|
Metabolic Disease
|
|
3FAx-Neu5Ac (Compound 8), a Sialic acid peracetylated analog, is a sialyltransferase inhibitor. 3FAx-Neu5Ac substantially reduces expression of the sialylated ligand sialyl Lewis X .
|
-
-
- HY-P10007
-
|
Z-GPFL-CHO
|
Proteasome
|
Cancer
|
|
Z-Gly-Pro-Phe-Leu-CHO (Z-GPFL-CHO) is a tetrapeptide aldehyde that acts as a highly selective and potent proteasomal inhibitor (Ki = 1.5 µM for branched chain amino acid preferring, 2.3 µM for small neutral amino acid preferring, and 40.5 µM for chymotrypsin-like activities; IC50 = 3.1 µM for peptidyl-glutamyl peptide hydrolyzing activity) .
|
-
-
- HY-120050
-
|
|
Phospholipase
|
Inflammation/Immunology
|
|
GK470 (compound 28) is an inhibitor of group IVA cytosolic phospholipase A2 (GIVA cPLA2) with an IC50 of 300 nM in vesicle assays. GK470 has anti-inflammatory activity, inhibiting the release of arachidonic acid in SW982 fibroblast-like synoviocytes with an IC50 value of 0.6 μM. GK470 exhibits comparable anti-inflammatory effects to Methotrexate (HY-14519) in a preventive collagen-induced arthritis model and significantly reduces plasma PGE2 levels .
|
-
-
- HY-15295
-
|
TAK-438
|
Proton Pump
|
Metabolic Disease
Cancer
|
|
Vonoprazan Fumarate (TAK-438), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan Fumarate inhibits H +,K +-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan Fumarate is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease .
|
-
-
- HY-115319
-
|
|
Ferroptosis
|
Inflammation/Immunology
|
|
CP-24879 (hydrochloride) is a potent, selective and combined delta5D/delta6D inhibitor. CP-24879 (hydrochloride) can significantly reduce intracellular lipid accumulation and inflammatory injury in hepatocytes. CP-24879 (hydrochloride) exhibits superior antisteatotic and anti-inflammatory actions in fat-1 and ω-3-treated hepatocytes, and can be used for non-alcoholic steatohepatitis research .
|
-
-
- HY-100007A
-
|
TAK-438 hydrochloride
|
Proton Pump
Bacterial
|
Infection
Endocrinology
Cancer
|
|
Vonoprazan hydrochloride, a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan hydrochloride inhibits H +,K +-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan hydrochloride is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease. Vonoprazan hydrochloride can be used for eradication of Helicobacter pylori .
|
-
-
- HY-100007
-
|
TAK-438 free base
|
Proton Pump
Bacterial
|
Endocrinology
Cancer
|
|
Vonoprazan (TAK-438 free base), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan inhibits H +,K +-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease. Vonoprazan can be used for eradication of Helicobacter pylori .
|
-
-
- HY-137325
-
|
|
Guanylate Cyclase
|
Others
|
|
2-Chloro-ATP is a soluble guanylate cyclase inhibitor that increases intracellular calcium concentration at low concentrations through a mechanism independent of inositol phosphate production .
|
-
-
- HY-D1543
-
|
|
DNA Stain
|
Infection
|
|
Pyronin B is an organic cationic dye used for the staining of bacteria, mycobacteria and ribonucleic acids. Pyronin B is also used as a small hydrophobic (SH) protein channel inhibitor .
|
-
-
- HY-100007R
-
|
TAK-438 (Standard)
|
Reference Standards
Proton Pump
Bacterial
|
Endocrinology
|
|
Vonoprazan (Standard) is the analytical standard of Vonoprazan. This product is intended for research and analytical applications. Vonoprazan (TAK-438 free base), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan inhibits H +,K +-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease. Vonoprazan can be used for eradication of Helicobacter pylori .
|
-
-
- HY-168053
-
|
|
Others
|
Inflammation/Immunology
|
|
HMGB1-IN-3 (compound E) is a glycyrrhizic acid derivative with strong inhibitory activity against HMGB1 (high mobility group protein 1) and can be used in the study of intracerebral hemorrhage .
|
-
-
- HY-B1876
-
|
|
Acetolactate Synthase (ALS)
Photosystem II
Fungal
|
Others
|
|
Nicosulfuron is efficient, harmless, antifungal and selective herbicide belonging to the sulfonylurea family. Nicosulfuron is also a photosynthetic system inhibitor and inhibits acetolactate synthase (ALS) enzyme activity. Nicosulfuron degradation by Plectosphaerella cucumerina AR1 is glucose concentration dependent in planktonic lifestyle. Nicosulfuron enhances the glycolysis pathway and tricarboxylic acid cycle to improve the adaptability of sweet maize. Nicosulfuron reduces the synthesis of branched-chain amino acids (BCAAs), which is proming for maize cultivation .
|
-
-
- HY-163188
-
|
|
COX
Lipoxygenase
|
Inflammation/Immunology
|
|
COX-2/LOX-IN-2 (compound 6) is a dual inhibitor of COX-2/LOX with IC50s of 7.0 μM and 27.5 μM, respectively. COX-2/LOX-IN-2 has antioxidant activity and has the potential to be used in the development of nonsteroidal anti-inflammatory drugs (tNSAIDs) .
|
-
-
- HY-110354
-
|
G28UCM
|
Fatty Acid Synthase (FASN)
Bacterial
Antibiotic
|
Infection
Cancer
|
|
UCM05 (G28UCM) is a potent inhibitor of fatty acid synthase (FASN) shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines. UCM05 is a Filamentous temperature-sensitive protein Z (FtsZ) inhibitor and inhibits the growth of the Gram-positive bacterium B. subtilis with MIC values of 100 μM but lack activity on the Gram-negative bacterium E. coli.
|
-
-
- HY-P4115
-
|
|
FABP
|
Cancer
|
|
CooP is a linear glioblastoma-targeting nonapeptide. CooP binds to the mammary-derived growth inhibitor/fatty acid binding protein 3 (FABP3) in the glioblastoma cells and its associated vasculature. CooP is used for the targeted delivery of chemotherapy and different nanoparticles .
|
-
-
- HY-124744
-
|
|
FAAH
|
Neurological Disease
|
|
ASP 8477 is an orally active and selective fatty acid amide hydrolase (FAAH) inhibitor with IC50 values of 3.99, 1.65, and 57.3 nM for human FAAH-1, FAAH-1 (P129T), and FAAH-2, respectively. ASP 8477 has central nervous system activity and can be used in analgesia research .
|
-
-
- HY-W403633
-
|
|
Bacterial
|
Infection
|
|
Hexahydrohippuric acid is a metabolite of Shikimate acid in both liver and kidney, under microbial metabolism effect. Hexahydrohippuric acid is made of cyclohexane carboxylic acid and glycinamide, and shows antibacterial activity .
|
-
-
- HY-118783
-
|
(±)-2-Hexyl-4-pentynoic Acid
|
HDAC
HSP
|
Neurological Disease
|
|
2-Hexyl-4-pentynoic acid ((±)-2-Hexyl-4-pentynoic acid), valproic acid (VPA) derivative, exhibits potential roles of HDAC inhibition (IC50=13 μM) and HSP70 induction. Potent neuroprotective effects. 2-Hexyl-4-pentynoic acid causes histone hyperacetylation and protect against glutamate-induced excitotoxicity in cultured neurons . 2-Hexyl-4-pentynoic acid is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
-
- HY-W007390
-
|
|
Bacterial
Drug Intermediate
|
Infection
|
|
Methyl 2-amino-5-bromobenzoate (Compound 8/12) is a biochemical reagent. Methyl 2-amino-5-bromobenzoate can be used to synthesize 2-benzamidobenzoic acid, a known FabH inhibitor. Derivatives of methyl 2-amino-5-bromobenzoate also inhibit PqsD, the pqs quorum sensing (QS) system, of Pseudomonas aeruginosa .
|
-
-
- HY-157157
-
|
|
Protein Arginine Deiminase
|
Cancer
|
|
PAD4-IN-3 (compound 4B) is a PAD4 inhibitor with antitumor activity in vitro and in vivo. PAD4-IN-3 was covalently linked to RGD sequence peptide-modified chitosan (K-CRGDV), resulting in an enhanced oxidative stress-responsive nanoagent. K-CRGDV-PAD4-IN-3 can actively target tumors, inhibit PAD4 activity, block the formation of neutrophil extracellular traps (NETs), and improve the tumor immune microenvironment in response to the tumor microenvironment .
|
-
-
- HY-110354R
-
|
|
Fatty Acid Synthase (FASN)
Bacterial
Antibiotic
|
Infection
Cancer
|
|
Lysipressin (Standard) is the analytical standard of Lysipressin. This product is intended for research and analytical applications. Lysipressin (Lysine vasopressin) is antidiuretic hormone that have been found in pigs and some marsupial families. Lysipressin induces contraction of the rabbit urinary bladder smooth muscle, activate adenylate-cyclase .
|
-
-
- HY-149003
-
|
|
PARP
Apoptosis
|
Cancer
|
|
PARP1-IN-10 (compound 12c) is a no-cytotoxicity and potent PARP1 inhibitor with an IC50 value of 50.62 nM in vitro. PARP1-IN-10 causes cell cycle arrest at G2/M phase and apoptosis, and enhances the cytotoxicity of temozolomide (TMZ) .
|
-
-
- HY-155376
-
|
|
mTOR
|
Cancer
|
|
mTOR inhibitor-14 (compound 14c) is a potent mTOR inhibitor. mTOR inhibitor-14 also shows minimal CYP2C8 inhibition. mTOR inhibitor-14 can inhibit tumor growth .
|
-
-
- HY-162025
-
|
|
mTOR
PI3K
|
Cancer
|
|
mTOR inhibitor-17 (Compound 9e) is a selective inhibitor for mTOR. mTOR inhibitor-10 inhibits mTOR and PI3K-α, with IC50 of 0.68 and 1359 nM. mTOR inhibitor-10 inhibits proliferation of LNCaP with IC50 of 40 nM .
|
-
-
- HY-162024
-
|
|
mTOR
PI3K
|
Cancer
|
|
mTOR inhibitor-16 (Compound 9f) is a selective inhibitor for mTOR. mTOR inhibitor-10 inhibits mTOR and PI3K-α, with IC50 of 1.25 and 82 nM. mTOR inhibitor-10 inhibits proliferation of LNCaP with IC50 of 140 nM .
|
-
- HY-162023
-
|
|
mTOR
PI3K
|
Cancer
|
|
mTOR inhibitor-10 (Compound 9c) is a selective inhibitor for mTOR. mTOR inhibitor-10 inhibits mTOR and PI3K-α, with IC50 of 0.7 and 825 nM. mTOR inhibitor-10 inhibits proliferation of LNCaP with IC50 of 87 nM .
|
-
- HY-152195
-
|
|
Apoptosis
|
Cancer
|
|
ChoKα inhibitor-5 is a sulphur-containing choline kinase inhibitor. ChoKα inhibitor-5 can inhibit HChoK α1 with an IC50 value of 0.64 μM. ChoKα inhibitor-5 also can induce apoptosis. ChoKα inhibitor-5 can be used for the research of cancer .
|
-
- HY-152191
-
|
|
Apoptosis
|
Cancer
|
|
ChoKα inhibitor-3 is a sulphur-containing choline kinase inhibitor. ChoKα inhibitor-3 can inhibit HChoK α1 with an IC50 value of 0.66 μM. ChoKα inhibitor-3 also can induce apoptosis. ChoKα inhibitor-3 can be used for the research of cancer .
|
-
- HY-132243
-
|
|
Nuclear Factor of activated T Cells (NFAT)
|
Inflammation/Immunology
|
|
NFAT Inhibitor-3 (Compound 10) is a factor nuclear factor of activated T cells (NFAT) inhibitor. NFAT Inhibitor-3 inhibits IL-2 production. NFAT Inhibitor-3 binds in a sequence-selective manner directly to DNA. NFAT Inhibitor-3 can be used for the research of transcription factor dysregulation .
|
-
- HY-119937
-
|
|
ROCK
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
ROCK inhibitor-2 (compound 6) is a selective dual inhibitor of ROCK1 and ROCK2, with IC50 values of 160 nM and 21 nM, respectively. ROCK inhibitor-2 inhibits pMYPT1 with IC50 of 75 nM. ROCK inhibitor-2 exhibits antitumor activity .
|
-
- HY-164632
-
|
|
Ras
|
Cancer
|
|
KRAS inhibitor-32 (compound 139A) is a KRAS inhibitor. KRAS inhibitor-32 can be used in anti-cancer research .
|
-
- HY-156019
-
|
|
FGFR
|
Cancer
|
|
FGFR1 inhibitor-10 (Compound 4i) is an FGFR1 inhibitor (IC50: 28 nM). FGFR1 inhibitor-10 inhibits the phosphorylation of FGFR1. FGFR1 inhibitor-10 has anti-angiogenic, anti-invasion activity, and anti-tumor effect .
|
-
- HY-169310
-
|
|
ATM/ATR
|
Cancer
|
|
ATM Inhibitor-11 (Compound 1) is an inhibitor for ATM with an IC50 of 0.32 nM. ATM Inhibitor-11 inhibits the KAP1 phosphorylation with an IC50 of 0.97 nM. ATM Inhibitor-11 exhibits high exposure in the brain, heart and plasma of ICR mouse. ATM Inhibitor-11 exhibits anti-tumor efficacy in NCI-H441 xenograft mouse model .
|
-
- HY-144687
-
|
|
ATM/ATR
PI3K
mTOR
|
Cancer
|
|
ATM Inhibitor-4 (compound 39) is a potent and selective ATM inhibitor, with an IC50 of 0.32 nM. ATM Inhibitor-4 shows stronger inhibition of PI3K kinases family. ATM Inhibitor-4 shows a full inhibition of mTOR at 1 μM. ATM Inhibitor-4 exhibits favorable metabolic stability .
|
-
- HY-168442
-
|
|
Ras
PERK
|
Cancer
|
|
KRAS inhibitor-40 (Compound 41) is a KRAS inhibitor that interferes with the KRAS G12C-BRAF complex. KRAS inhibitor-40 inhibits the ERK phosphorylation of KRAS downstream signaling pathway. KRAS inhibitor-40 can inhibit the proliferation of tumor cells with different KRAS mutation types and has antitumor activity .
|
-
- HY-162976
-
|
|
Ras
|
Cancer
|
|
KRAS inhibitor-35 (compound 72) is a KRAS inhibitor, with IC50 of 2 nM. KRAS inhibitor-35 can be used in tumor research .
|
-
- HY-148367A
-
-
- HY-151287
-
|
|
Ras
|
Cancer
|
|
KRAS inhibitor-20 is a small molecular inhibitor of KRas G12C, the oncogenic mutant. KRAS inhibitor-20 inhibits KRas G12C with the IC50 value <10 nM .
|
-
- HY-163177
-
|
|
HIV
|
Infection
|
|
HIV-1 inhibitor-63 (compound S17) is a potent HIV-1 inhibitor. HIV-1 inhibitor-63 inhibits integrase-Ku70 complex formation with an IC50 value of 12 µM. HIV-1 inhibitor-63 inhibits HIV-1 post-integration DNA repair .
|
-
- HY-147322
-
|
|
YAP
|
Cancer
|
|
YAP/TAZ inhibitor-2 is a potent and orally active TEAD-YAP/TAZ inhibitor with an EC50 value of 3 nM. YAP/TAZ inhibitor-2 shows anti-proliferative activity. YAP/TAZ inhibitor-2 shows antitumor activity .
|
-
- HY-118911
-
|
|
ATM/ATR
|
Cancer
|
|
ATM Inhibitor-10 (compound 74), a 3-quinoline carboxamide, is a highly selective and orally active ATM inhibitor (IC50: 0.6 nM). ATM Inhibitor-10 has anti-tumor activity in SW620 xenograft models. ATM Inhibitor-10 is synergistic with Top I inhibitors .
|
-
- HY-153787
-
|
|
ATM/ATR
|
Cancer
|
|
ATM inhibitor-6 (A-193) is a selective ATM kinase inhibitor. ATM inhibitor-6 can be used in cancer research .
|
-
- HY-167871
-
-
- HY-169669
-
|
|
FGFR
|
Cancer
|
|
FGFR1 inhibitor-17 (Compound 92) is a potent FGFR1 inhibitor. FGFR1 inhibitor-17 is promising for research of cancers .
|
-
- HY-162974
-
|
|
Ras
|
Cancer
|
|
KRAS inhibitor-34 (compound 27) is a KRAS inhibitor, with IC50 of 6.4 nM. KRAS inhibitor-34 can be used in tumor research .
|
-
- HY-137471
-
|
RIN1
|
Notch
|
Cancer
|
|
RBPJ Inhibitor-1 (RIN1), the first RBPJ inhibitor, blocks the functional interaction of RBPJ with SHARP. RBPJ Inhibitor-1 (RIN1) inhibits NOTCH-dependent tumor cell proliferation .
|
-
- HY-131344
-
|
|
mTOR
Autophagy
|
Cancer
|
|
mTOR inhibitor-8 is an mTOR inhibitor and autophagy inducer. mTOR inhibitor-8 inhibits the activity of mTOR via FKBP12 and induces autophagy of A549 human lung cancer cells .
|
-
- HY-144686
-
|
|
ATM/ATR
PI3K
mTOR
|
Cancer
|
|
ATM Inhibitor-3 (compound 34) is a potent and selective ATM inhibitor, with an IC50 of 0.71 nM. ATM Inhibitor-3 shows inhibition of PI3K kinases family. ATM Inhibitor-3 exhibits favorable metabolic stability .
|
-
- HY-122158
-
-
- HY-170929
-
|
|
Bcl-2 Family
Cytochrome P450
Apoptosis
Caspase
|
Cancer
|
|
EMT inhibitor-3 (compound 11i) is a epithelial-mesenchymal transition (EMT) inhibitor. EMT inhibitor-3 inhibits neuroblastoma SK-N-SH cells with an IC50 of 2.5 μM. EMT inhibitor-3 inhibits SK-N-SH cell proliferation, migration, and invasion. EMT inhibitor-3 increases the Bax/Bcl-2 protein expression ratio, promotes Cytochrome C ( HY-125857) release from mitochondria, and activates caspases 9 and caspases 3, inducing mitochondria-mediated endogenous tumor cell Apoptosis. EMT inhibitor-3 is potential for cancer research .
|
-
- HY-149487
-
|
|
FGFR
|
Cancer
|
|
FGFR1 inhibitor-8 (Compound 9) is a FGFR1 inhibitor (IC50s: 0.5 nM). FGFR1 inhibitor-8 binds to the ATP-binding pocket of FGFR1. FGFR1 inhibitor-8 has anticancer activity .
|
-
- HY-136123
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
Tubulin inhibitor 8 (Compound 33b) is a tubulin inhibitor and a potent inhibitor of multiple cancer cell lines. Tubulin inhibitor 8 inhibits tubulin polymerization with an IC50 of 0.73 μM. Tubulin inhibitor 8 inhibits K562 cell growth with an IC50 of 14 nM .
|
-
- HY-136122
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
Tubulin inhibitor 7 (Compound 33c) is a tubulin inhibitor and a potent inhibitor of multiple cancer cell lines. Tubulin inhibitor 7 inhibits tubulin polymerization with an IC50 of 0.52 μM. Tubulin inhibitor 7 inhibits K562 cell growth with an IC50 of 11 nM .
|
-
- HY-149488
-
|
|
FGFR
|
Cancer
|
|
FGFR1 inhibitor-9 (Compound 7) is an FGFR1 inhibitor (IC50s: 0.85 nM). FGFR1 inhibitor-9 binds to the ATP-binding pocket of FGFR1. FGFR1 inhibitor-9 has anticancer activity .
|
-
- HY-172095
-
|
|
Epigenetic Reader Domain
Apoptosis
|
Cancer
|
|
BRD4 Inhibitor-39 (compound 12m) is an orally available BRD4 inhibitor with an IC50 value of 0.02 μM. BRD4 Inhibitor-39 induces apoptosis. BRD4 Inhibitor-39 has anti-tumor activity .
|
-
- HY-136121
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
Tubulin inhibitor 6 (Compound 14b) is a tubulin inhibitor and a potent inhibitor of multiple cancer cell lines. Tubulin inhibitor 6 inhibits tubulin polymerization with an IC50 of 0.87 μM. Tubulin inhibitor 6 inhibits K562 cell growth with an IC50 of 840 nM .
|
-
- HY-154957
-
|
|
mTOR
|
Neurological Disease
|
|
mTOR inhibitor-11 (Compound 9) is a brain-penetrant mTOR inhibitor (IC50: 21 nM for pS6). mTOR inhibitor-11 also inhibits pCHK1 and PDE4D with IC50s of 17.2 and 17.0 μM. mTOR inhibitor-11 can be used for research of CNS disease .
|
-
- HY-151619
-
|
|
Epoxide Hydrolase
|
Inflammation/Immunology
|
|
sEH inhibitor-12 (compound 34) is a sEH inhibitor with an IC50 value of 0.7 μM. sEH inhibitor-12 inhibits the 5-lipoxygenase-activating protein (FLAP)-mediated leukotriene (LT) biosynthesis with an IC50 value of 2.9 μM. sEH inhibitor-12 can be used for the research of inflammation .
|
-
- HY-136704
-
|
|
Glutaminase
|
Cancer
|
|
GLS1 Inhibitor-1 (Compound 27) is an orally active inhibitor for glutaminase 1 (GLS1) with an IC50 of 0.021 μM. GLS1 Inhibitor-1 inhibits the proliferation of PC-3 with an IC50 of 0.3 nM. GLS1 Inhibitor-1 exhibits antitumor efficacy against NCI-H1703 with GI50 of 0.011 μM. GLS1 Inhibitor-1 exhibits moderate pharmacokinetic characteristics .
|
-
- HY-152536
-
|
|
NO Synthase
|
Cancer
|
|
iNOS inhibitor-10 is an iNOS inhibitor (IC50: 65 nM). iNOS inhibitor-10 has antiproliferative effect against triple negative breast cancer cells .
|
-
- HY-151617
-
-
- HY-146617
-
|
|
Glutaminase
Apoptosis
|
Cancer
|
|
GLS1 Inhibitor-4 (compound 41e) is a potent GLS1 inhibitor with an IC50 of 11.86 nM. GLS1 Inhibitor-4 shows antiproliferative activity, good metabolic stability, robust GLS1 binding affinity. GLS1 Inhibitor-4 blocks the glutamine metabolism and induce the production of ROS. GLS1 Inhibitor-4 induces apoptosis and shows antitumor activity .
|
-
- HY-W261325
-
|
|
FGFR
|
Cancer
|
|
FGFR1 inhibitor-15 (Compound 23) is an FGFR1 inhibitor with an IC50 of 27 μM. FGFR1 inhibitor-15 can be used in the study of cancer .
|
-
- HY-149693
-
|
|
Aurora Kinase
|
Cancer
|
|
Aurora kinase inhibitor-11 (compound 25) is an inhibitor of Aurora Kinase with an IC50 of 0.14 μM. Aurora kinase inhibitor-11 has anticancer activity .
|
-
- HY-139624
-
|
|
JNK
|
Others
|
|
JNK3 inhibitor-1 is a potent and selective JNK3 inhibitor (IC50 = 0.005 μM). JNK3 inhibitor-1 is orally bioavailable and brain penetrant.
|
-
- HY-159476
-
|
|
Ras
|
Cancer
|
|
KRAS inhibitor-26 (compound 194a) is a potent KRAS G12V inhibitor (IC50: ≤100 nM). KRAS inhibitor-26 can be used for cancer research .
|
-
- HY-172789
-
|
|
mTOR
Apoptosis
|
Cancer
|
|
mTOR inhibitor-27 (Compound 7e) is a mammalian target of rapamycin (mTOR) inhibitor with an IC50 value of 5.47 μM. mTOR inhibitor-27 can induce tumor cell apoptosis and arrest the cell cycle in the S-phase, thereby inhibiting cancer cell growth. mTOR inhibitor-27 is promising for research of cancers, such as skin cancer .
|
-
- HY-145436
-
|
|
Ras
|
Cancer
|
|
KRAS inhibitor-11 (compound 12) is a KRAS inhibitor .
|
-
- HY-146616
-
|
|
Glutaminase
|
Cancer
|
|
GLS1 Inhibitor-3 (compound C147) is a potent GLS1 inhibitor with an IC50 of 27.98 nM. GLS1 Inhibitor-3 shows antiproliferative activity .
|
-
- HY-154958
-
|
|
mTOR
|
Neurological Disease
|
|
mTOR inhibitor-12 (Compound 11) is a selective brain penetrant mTOR inhibitor without genotoxicity risk. mTOR inhibitor-12 can be used for the research of CNS diseases .
|
-
- HY-151996
-
|
|
Microtubule/Tubulin
|
Cardiovascular Disease
|
|
Tubulin inhibitor 31 is a potent tubulin inhibitor with an IC50 value of 4 µM. Tubulin inhibitor 31 shows anti-proliferative activity. Tubulin inhibitor 31 inhibits the HUVEC migration .
|
-
- HY-147993
-
|
|
Aurora Kinase
|
Cancer
|
|
Aurora kinase inhibitor-10 (Compound 6c) is an orally active Aurora B inhibitor with an IC50 of 8 nM. Aurora kinase inhibitor-10 shows antitumor activity .
|
-
- HY-162091
-
|
|
Topoisomerase
|
Cancer
|
|
Topoisomerase I inhibitor 13 (Compound G11) is a Topo I inhibitor that inhibits cancer cell proliferation. Topoisomerase I inhibitor 13 significantly inhibits tumor growth in vivo .
|
-
- HY-153433
-
|
|
Cholinesterase (ChE)
|
Neurological Disease
|
|
Serine Hydrolase inhibitor-21 (compound 8), a pyridine, is a serine hydrolase inhibitor with a Ki of 429 nM for BuChE. Serine Hydrolase inhibitor-21 has the potential for Alzheimer's disease research .
|
-
- HY-146088
-
|
|
HIV
|
Infection
|
|
HIV-1 inhibitor-31 (compound 4) is a potent HIV-1 inhibitor. HIV-1 inhibitor-31 can be used for researching AIDS .
|
-
- HY-139607
-
|
|
Monoamine Oxidase
|
Inflammation/Immunology
|
|
SSAO inhibitor-1 is a semicarbazide-sensitive amine oxidase (SSAO) inhibitor. SSAO inhibitor-1 has anti-inflammatory activity and can be used for liver diseases research .
|
-
- HY-157814
-
|
|
Apoptosis
Epigenetic Reader Domain
|
Cancer
|
|
Menin-MLL inhibitor-25 (compound A6) is a potent Menin-MLL interaction inhibitor with an IC50 value of 0.38 µM. Menin-MLL inhibitor-25 shows anti-proliferative activity. Menin-MLL inhibitor-25 induces apoptosis and cell cycle arrest at G0/G1 phase. Menin-MLL inhibitor-25 reverses the differentiation arrest .
|
-
- HY-149866
-
|
|
Cytochrome P450
HIV
Reverse Transcriptase
|
Infection
|
|
HIV-1 inhibitor-58 (Compound 10c) is a broad-spectrum antiviral agent. HIV-1 inhibitor-58 is a non-nucleoside reverse transcriptase inhibitor. HIV-1 inhibitor-58 inhibits WT strain IIIB, NNRTI-resistant strains (such as K103N and E138K) in MT-4 cells, with EC50 less than 50 nM. HIV-1 inhibitor-58 also inhibits CYP2C9 and CYP2C19 (IC50: 2.06 μM, 1.91 μM). HIV-1 inhibitor-58 can be used for HIV infection reserch .
|
-
- HY-170381
-
|
|
α-synuclein
|
Neurological Disease
|
|
α-syn aggregation inhibitor-1 (Compound 2e) is an inhibitor for α-syn aggregation. α-syn aggregation inhibitor-1 inhibits the cell viability of SH-SY5Y .
|
-
- HY-101998
-
-
- HY-169710
-
|
|
FGFR
|
Cancer
|
|
FGFR1 inhibitor-16 (Compound 89) is an FGFR1 inhibitor. FGFR1 inhibitor-16 exhibits an inhibitory rate of 53.00% against FGFR1 at a concentration of 50 μM and 24.95% at 10 μM. FGFR1 inhibitor-16 can be used in the study of cancer .
|
-
- HY-145909
-
|
|
Epigenetic Reader Domain
|
Cancer
|
|
BRD4 Inhibitor-17 (Compound 5i) is a potent inhibitor of BRD4 with an IC50 of 0.33 μM. BRD4 Inhibitor-17 plays crucial role in regulating transcription of inflammatory, proliferation and cell cycle genes. BRD4 Inhibitor-17 serves as potential antidotes for arsenicals .
|
-
- HY-148838
-
|
|
c-Myc
|
Cancer
|
|
c-Myc inhibitor 8 (compound 56) is a c-Myc inhibitor. c-Myc inhibitor 8 effectively inhibits cell viability of a variety of cancer cells. c-Myc inhibitor 8 inhibits human prostate and lung cancer growth in mouse models. c-Myc inhibitor 8 can be used for cancer research .
|
-
- HY-150963
-
|
|
Renin
|
Cardiovascular Disease
|
|
Renin inhibitor-1 (compound 26) is a potent and orally active renin inhibitor with IC50s of 0.9, 1.8 nM for rh-renin and hPRA, respectively. Renin inhibitor-1 shows antihypertensive efficacy. Renin inhibitor-1 has the potential for the research of hypertension and cardiovascular/renal diseases .
|
-
- HY-152209
-
|
|
Epigenetic Reader Domain
|
Cancer
|
|
BRD4 Inhibitor-26 is a bromodomain protein 4 (BRD4) inhibitor/nitric oxide-donator. BRD4 Inhibitor-26 inhibits BRD4 (BD1) and BRD4 (BD2) with IC50 values of 0.82 μM and 1.94 μM, respectively. BRD4 Inhibitor-26 can be used for the research of ovarian cancer .
|
-
- HY-141525
-
-
- HY-400902
-
|
|
YAP
|
Cancer
|
|
YAP/TAZ inhibitor-3 (Compound 24) is a YAP/TAZ inhibitor. YAP/TAZ inhibitor-3 shows firefly luciferase inhibitory activity, with an IC50 < 0.1 μM .
|
-
- HY-151288
-
|
|
Ras
|
Cancer
|
|
KRAS inhibitor-21 (22b) is a KRAS G12C inhibitor with an IC50 value of <0.01 μM. KRAS inhibitor-21 can be used in cancer research .
|
-
- HY-163190
-
|
|
Bacterial
|
Infection
|
|
NDM-1 inhibitor-4 (compound 27) is a NDM-1 inhibitor with Ki of 1.7 μM. NDM-1 inhibitor-4 has antimicrobial effect .
|
-
- HY-147375
-
|
|
Epigenetic Reader Domain
|
Cancer
|
|
Bromodomain inhibitor-10 (compound 128) is a potent bromodomain inhibitor with Kds of 15.0, 2500 nM for BRD4-1 and BRD4-2, respectively. Bromodomain inhibitor-10 inhibits the production of IL12p40 .
|
-
- HY-147374
-
|
|
Epigenetic Reader Domain
|
Metabolic Disease
Inflammation/Immunology
|
|
Bromodomain inhibitor-9 is a Bromodomains inhibitor that selectively inhibits BRD4-1 (Kd: 12 nM). Bromodomain inhibitor-9 can be used in the research of diseases or conditions associated with systemic or tissue inflammation, lipid metabolism, fibrosis or chronic autoimmune diseases .
|
-
- HY-168859
-
|
|
JNK
GSK-3
Amyloid-β
|
Neurological Disease
|
|
JNK3 inhibitor-9 (Compound 24a) is a potent, selective and BBB-permeable JNK3 inhibitor with an IC50 value of 12 nM. JNK3 inhibitor-9 also potently inhibits GSK3α/β (IC50s: 14 and 35 nM, respectively) involved in Tau phosphorylation. JNK3 inhibitor-9 reduces c-Jun and APP phosphorylation. JNK3 inhibitor-9 protects neurons from Aβ1-42 toxicity .
|
-
- HY-161986
-
|
|
HIV
|
Infection
|
|
HIV-1 inhibitor-74 (compound 10c) is a potent HIV-1 inhibitor with an EC50 value of 0.0047 µM for HIV-1 IIIB. HIV-1 inhibitor-74 shows cytotoxicity. HIV-1 inhibitor-74 inhibits WT HIV-1 RT activity with an IC50 value of 0.134 µM. HIV-1 inhibitor-74 shows broad-spectrum anti HIV-1 activity .
|
-
- HY-144991
-
|
|
Aurora Kinase
|
Cancer
|
|
Aurora kinase inhibitor-8 is a highly selective inhibitor of the Aurora kinases.
|
-
- HY-112851
-
-
- HY-159121
-
-
- HY-18353
-
|
|
mTOR
|
Cancer
|
|
mTOR inhibitor-3 is a remarkably selective mTOR inhibitor with a Ki of 1.5 nM. mTOR inhibitor-3 suppresses mTORC1 and mTORC2 in cellular and in vivo pharmacokinetic (PK)/pharmacodynamic (PD) experiments.
|
-
- HY-157460
-
|
|
Epigenetic Reader Domain
|
Cancer
|
|
BRD4 Inhibitor-29 (SQ-17) is a BRD4 inhibitor, with an IC50 of <100 nM. BRD4 Inhibitor-29 shows antiproliferative effect against prostate cancer cells .
|
-
- HY-155090
-
|
|
ATM/ATR
|
Cancer
|
|
ATM Inhibitor-8 (Compound 10r) is a highly potent, selective and orally active ATM inhibitor,with an IC50 of 1.15 nM. ATM Inhibitor-8 exhibits anti-tumor activity .
|
-
- HY-155211
-
|
|
mTOR
PI3K
|
Cancer
|
|
mTOR inhibitor-13 (compound 9g), an aryl ureido compound, is a potent and selective mTOR inhibitor with an IC50 of 0.29 nM. mTOR inhibitor-13 also inhibits PI3K-α with an IC50 of 119 nM .
|
-
- HY-176435
-
|
|
mTOR
|
Cancer
|
|
mTOR inhibitor-28 (SM-3) is a potent mTOR inhibitor. mTOR inhibitor-28 inhibits A549, H292, and H460 cells with IC50s of 72.74, 67.66, and 43.24 μM, respectively .
|
-
- HY-142468
-
|
|
HIV
|
Infection
|
|
HIV-1 inhibitor-12 is potent HIV-1 inhibitor. HIV-1 inhibitor-12 inhibits HIV-1 capsid protein polymerization with an IC50 of 9 nM (WO2021104413A1, compound 1-1a) .
|
-
- HY-143272
-
|
|
FGFR
|
Cancer
|
|
FGFR1 inhibitor-6 is a potent FGFR1 inhibitor with an IC50 value of 16.31 nM. FGFR1 inhibitor-6 shows cytotoxic activities. FGFR1 inhibitor-6 induces apoptosis and cell cycle arrest at pre-G1 and G2/M phase .
|
-
- HY-148373
-
|
|
Epigenetic Reader Domain
|
Cancer
|
|
BRM/BRG1 ATP Inhibitor-3 is a BRG1/BRM inhibitor. BRM/BRG1 ATP Inhibitor-3 inhibits BRM and BRG1 with IC50 values of 10.4 nM and 19.3 nM, respectively. BRM/BRG1 ATP Inhibitor-3 can be used for the research of cancers and BAF complex-related disorders .
|
-
- HY-157397A
-
|
|
Acyltransferase
|
Neurological Disease
|
|
ANAT inhibitor-4 tetralithium (compound BA2) is potent N-acetyltransferase (ANAT) inhibitor with a Ki value of 48 nM. ANAT inhibitor-4 tetralithium has the potential for canavan disease (CD) research .
|
-
- HY-176419
-
|
|
Ras
|
Cancer
|
|
KRAS inhibitor-42 (compound 8) is a potent USP7 inhibitor. KRAS inhibitor-42 has high affinity against GDP-bound KRASG12D with a Ki of 2.7 μM .
|
-
- HY-169153
-
|
|
MAP3K
|
Inflammation/Immunology
|
|
Cot inhibitor-3 (Compound 33) is a potent and selective cancer osaka thyroid (COT) kinase inhibitor, with an IC50 of 4 nM. Cot inhibitor-3 can be used to prevent inflammation-driven lameness .
|
-
- HY-118933
-
|
SJA6017
|
Proteasome
|
Others
|
|
Calpain Inhibitor VI (SJA6017) is a synthesized peptide aldehyde inhibitor of calpain. Calpain Inhibitor VI inhibits purified m-calpain with the IC50 of 80 nM. Calpain Inhibitor VI can be used for the research of cataract .
|
-
- HY-P4914
-
|
|
Sex Pheromone
|
Others
|
|
Sex Pheromone Inhibitor iPD1 is a sex pheromone inhibitor. Sex Pheromone Inhibitor iPD1 inhibits the sex pheromone cPD1 .
|
-
- HY-153692A
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
(R)-WRN inhibitor 1 is the R-isomer of WRN inhibitor 1 (example 7). WRN inhibitor 1 is a WRN inhibitor with anticancer activity .
|
-
- HY-153745
-
|
|
Trk Receptor
|
Cancer
|
|
Protein kinase inhibitor 5 is a potent TRK-A inhibitor with an IC50 value of 1.8 nM. Protein kinase inhibitor 5 inhibits cell viability .
|
-
- HY-112911
-
-
- HY-149519
-
|
|
Epigenetic Reader Domain
|
Cancer
|
|
BRD4 Inhibitor-28 (Compound 18) is an orally active BRD4 Inhibitor. BRD4 Inhibitor-28 inhibits BRD40-BD1, BRD40-BD2 with IC50s of 15, 55 nM. BRD4 Inhibitor-28 also inhibits BRD2-BD1, BRD3-BD1, BRDT-BD1 with IC50s of 19, 25, 68 nM. BRD4 Inhibitor-28 has anti-melanoma activity .
|
-
- HY-164350
-
|
|
Ras
ERK
p38 MAPK
|
Cancer
|
|
KRAS inhibitor-27 (Compound 15h) is the inhibitor for KRAS. KRAS inhibitor-27 inhibits KRAS G12D/G12V mutated cells AsPC-1, SW620 and KRAS wildtype cell HT-29 with IC50 of 378, 0.6 and 3230 nM, respectively. KRAS inhibitor-27 inhibits ERK phosphorylation (IC50 in cell AsPC-1 and SW620 is 0.6 nM and 1 nM), reduces the expression of DUSP4, thereby inhibiting MAPK signaling pathway .
|
-
- HY-137497
-
|
|
Ras
Apoptosis
|
Cancer
|
|
KRAS inhibitor-9, a potent KRAS inhibitor (Kd=92 μM), blocks the formation of GTP-KRAS and downstream activation of KRAS. KRAS inhibitor-9 binds to KRAS G12D, KRAS G12C and KRAS Q61H protein with a moderate binding affinity. KRAS inhibitor-9 causes G2/M cell cycle arrest and induces apoptosis. KRAS inhibitor-9 selectively inhibits the proliferation of NSCLC cells with KRAS mutation but not normal lung cells .
|
-
- HY-146208
-
|
|
Epigenetic Reader Domain
|
Cancer
|
|
BRD4 Inhibitor-20 is a potent orally active bromodomain protein 4 (BRD4) inhibitor. BRD4 Inhibitor-20 has inhibitory activity for BRD4 (BD1) and BRD4 (BD2) with IC50 values of 19 nM and 28 nM, respectively. BRD4 Inhibitor-20 also has anti-proliferation activities in cancer cell lines. BRD4 Inhibitor-20 can be used for the research of kinds of cancer, such as colon cancer .
|
-
- HY-146660
-
|
|
c-Myc
Epigenetic Reader Domain
Apoptosis
|
Cancer
|
|
BRD4 Inhibitor-18 is a highly potent BRD4 inhibitor with an IC50 value of 110 nM. BRD4 Inhibitor-18 has a hydrophobic acetylcyclopentanyl side chain. BRD4 Inhibitor-18 can significantly suppress the proliferation of MV-4-11 cells with high BRD4 level. BRD4 Inhibitor-18 has apoptosis-promoting and G0/G1 cycle-arresting activity .
|
-
- HY-143235
-
|
|
Epigenetic Reader Domain
Apoptosis
Bcl-2 Family
Caspase
c-Myc
|
Cancer
|
|
BRD4 Inhibitor-15 (compound 13) is a potent BRD4 inhibitor, with an IC50 of 18 nM. BRD4 Inhibitor-15 induces apoptosis of 22RV1 cells by regulating Bcl-2/Bax proteins and activating caspase-3 signaling pathway. BRD4 Inhibitor-15 down-regulates the c-Myc level in 22RV1 cells. BRD4 Inhibitor-15 can be used for prostate cancer research .
|
-
- HY-147891
-
|
|
Apoptosis
|
Cancer
|
|
Angiogenesis inhibitor 3 (compound 8) is a potent angiogenesis inhibitor. Angiogenesis inhibitor 3 inhibits the proliferation of HUVEC and HCT-15 cells, with IC50 values of 1.00 and 0.71 μM. Angiogenesis inhibitor 3 induces the apoptosis of HUVEC and HCT-15 cells. Angiogenesis inhibitor 3 shows anticancer activity, and suppresses the invasion of cancer cells. Angiogenesis inhibitor 3 inhibits the angiogenesis in zebrafish embryos .
|
-
- HY-152200
-
|
|
HIV Protease
Reverse Transcriptase
|
Infection
Inflammation/Immunology
|
|
HIV-1 inhibitor-53 is a dual HIV-1 protease and reverse transcriptase inhibitor. HIV-1 inhibitor-53 inhibits HIV-1 protease (PR) and reverse transcriptase (RT) activity with IC50 values of 1.93 nM and 2.35 μM, respectively. HIV-1 inhibitor-53 can be used for the research of acquired immune deficiency syndrome (AIDS) .
|
-
- HY-147890
-
|
|
Apoptosis
|
Cancer
|
|
Angiogenesis inhibitor 2 (compound 72) is a potent angiogenesis inhibitor. Angiogenesis inhibitor 2 inhibits the proliferation of HUVEC and HCT-15 cells, with IC50 values of 1.93 and 0.21 μM. Angiogenesis inhibitor 2 induces the apoptosis of HUVEC and HCT-15 cells. Angiogenesis inhibitor 2 shows anticancer activity, and suppresses the invasion of cancer cells. Angiogenesis inhibitor 2 inhibits the angiogenesis in zebrafish embryos .
|
-
- HY-163362
-
|
|
Reverse Transcriptase
PKC
HIV
|
Infection
|
|
HIV-1 inhibitor-65 (compound 3c) is an inhibitor of HIV-1 (EC50: 2.9 nM) and an activator of protein kinase C (PKC). HIV-1 inhibitor-65 inhibits syncytium formation (EC50: 7.0 nM) and inhibits HIV-1 entry and HIV-1 reverse transcriptase .
|
-
- HY-151962
-
|
|
JNK
Apoptosis
GSK-3
p38 MAPK
|
Neurological Disease
|
|
JNK3 inhibitor-5 (Compound 22b) is a potent and selective JNK3 inhibitor with an IC50 of 0.379 nM. JNK3 inhibitor-5 effectively protects the neuronal cells against amyloid beta-induced apoptosis. JNK3 inhibitor-5 has a high cell permeability and is predicted as BBB permeable .
|
-
- HY-124639
-
|
|
CDK
|
Cancer
|
|
CDK9 inhibitor HH1 is a potent and selectively CDK9 inhibitor. CDK9 inhibitor HH1 inhibits the transcription of CDK. CDK9 inhibitor HH1 can be used in research of cancer .
|
-
- HY-169587
-
|
|
Ser/Thr Kinase
Bacterial
|
Infection
|
|
Protein kinase G inhibitor-3 (Compound 177) is an inhibitor of mycobacterial serine/threonine protein kinases. Protein kinase G inhibitor-3 can be used in the research of diseases related to mycobacterial infections .
|
-
- HY-148573
-
-
- HY-47597
-
|
|
Bacterial
|
Infection
|
|
Protein kinase G inhibitor-2 (Compound 266) is a mycobacterial protein kinase G inhibitor, with an IC50 of 3 μM. Protein kinase G inhibitor-2 can be used for mycobacterial infection research .
|
-
- HY-156554
-
|
|
Raf
|
Cancer
|
|
Raf inhibitor 3 (Example 30) is a Raf inhibitor. Raf inhibitor 3 inhibits B-Raf and C-Raf with IC50 values less than 15 nM. Raf inhibitor 3 can be used for research of cancers .
|
-
- HY-146711
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
Tubulin inhibitor 24 is a potent tubulin inhibitor. Tubulin inhibitor 24 inhibits tubulin polymerization. Tubulin inhibitor 24 induces cell cycle arrest at the G2/M phase in a concentration-dependent manner. Tubulin inhibitor 24 shows antitumor activity with no obvious toxicity .
|
-
- HY-112373
-
|
|
Aurora Kinase
|
Others
|
|
Aurora kinase inhibitor-3 is a strong and selective Aurora A kinase inhibitor with an IC50 of 42 nM, and weakly inhibits EGFR with an IC50 of >10 μM. Aurora kinase inhibitor-3 has a binding mode with the cyclopropanecarboxylic acid moiety directed towards the solvent exposed region of the ATP-binding pocket .
|
-
- HY-147750
-
|
|
Phosphodiesterase (PDE)
|
Neurological Disease
Cancer
|
|
TDP1 Inhibitor-2 (compound 5) is a potent inhibitor for TDP1 (tyrosyl-DNA phosphodiesterase 1), with an IC50 of 99 nM. TDP1 Inhibitor-2 also can inhibit SCAN1 (spinocerebellar ataxia syndrome with axonal neuropathy), with an IC50 of 3.5 μM .
|
-
- HY-151616
-
|
|
Epoxide Hydrolase
|
Cardiovascular Disease
Metabolic Disease
Inflammation/Immunology
|
|
sEH inhibitor-10 (Compound 37) is a selective soluble epoxide hydrolase (sEH) inhibitor (IC50=0.5 μM). sEH inhibitor-10 maintains high cycloeicosatrienoic acid (EETs) levels by inhibiting sEH, thereby reducing inflammation, regulating endothelial tone, improving mitochondrial function, and reducing oxidative stress. sEH inhibitor-10 has good research potential in metabolic, renal and cardiovascular diseases .
|
-
- HY-122914
-
|
|
Ras
|
Cancer
|
|
KRAS inhibitor-3 is an inhibitor of KRAS inhibitor. KRAS inhibitor-3 binds to WT and oncogenic KRAS mutants with high affinity (KD: 0.28 μM for KRAS WT, 0.63 μM for KRAS G12C, 0.37 μM for KRAS G12D, 0.74 μM for KRAS Q61H). KRAS inhibitor-3 also disrupts interaction of KRAS with Raf .
|
-
- HY-173329
-
|
|
Ras
|
Cancer
|
|
KRAS inhibitor-41 is an inhibitor of KRAS with IC50 values of <0.01 μM for KRAS G12D and KRAS G12V. KRAS inhibitor-41 inhibits RAS mutant cell lines, GP2D (KRAS-G12D) and SW620 (KRAS-G12V). KRAS inhibitor-41 can be used in cancer research .
|
-
- HY-148043
-
|
|
Zinc Finger Protein
|
Others
|
|
Schnurri-3 inhibitor-1 is a potent schnurri-3 inhibitor which is an essential regulator of adult bone formation. Schnurri-3 inhibitor-1 can inhibit Shn3 with EF1alpha promoter in osteoblast cell line Shn3FFL with an AC50 value of 2.09 μM. Schnurri-3 inhibitor-1 can be used to research osteoporosis .
|
-
- HY-162971
-
|
|
Ras
|
Cancer
|
|
KRAS inhibitor-33 (compound 115a) is an inhibitor of pyridopyrimidine kras (IC50 ≤ 100nM) .
|
-
- HY-139629
-
-
- HY-142253
-
|
|
HIV
|
Infection
|
|
HIV-1 inhibitor-10 is a nanomolar HIV-1 maturation inhibitor.
|
-
- HY-139630
-
-
- HY-48958
-
|
|
Bacterial
|
Infection
|
|
Protein kinase G inhibitor-1 (Compound 270) is a mycobacterial protein kinase G inhibitor, with an IC50 of 0.9 μM. Protein kinase G inhibitor-1 can be used for mycobacterial infection research .
|
-
- HY-149260
-
-
- HY-152560
-
|
|
HIV
|
Infection
|
|
HIV-1 inhibitor-55 (compound 4d) inhibits WT HIV-1 with an EC50 value of 8.6 nM. HIV-1 inhibitor-55 also shows inhibitory potency against single and double HIV-1 mutants. HIV-1 inhibitor-55 can be used for the research of virus infection .
|
-
- HY-146308
-
|
|
HIV
|
Infection
|
|
HIV-1 inhibitor-26 (compound 9a) is a potent HIV-1 reverse transcriptase (RT) inhibitor with an IC50 value of 1.4 μM. HIV-1 inhibitor-26 has low cytotoxicity with a CC50 of 1486 μM in PBMCs. HIV-1 inhibitor-26 can be used for researching AIDS .
|
-
- HY-143294
-
|
|
Epoxide Hydrolase
|
Cardiovascular Disease
|
|
sEH inhibitor-2 (compound 5l) is an orally active (predicted percentage absorption: 71.2-88.4%) soluble epoxide hydrolase (sEH) inhibitor, with an IC50 of 0.9 nM. sEH inhibitor-2 can maintain epoxyeicosatrienoic acids (EETs) serum level in high concentrations. sEH inhibitor-2 can be used in study of cardiovascular protection .
|
-
- HY-111370
-
|
|
mTOR
|
Cancer
|
|
mTOR inhibitor-2 is a highlt potent, selective and oral mTOR inhibitor with an IC50 of 7 nM. mTOR inhibitor-2 inhibits cellular phosphorylation of mTORC1 (pS6 and p4E-BP1) and mTORC2 (pAKT (S473)) substrates .
|
-
- HY-145822
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
Tubulin inhibitor 16 is a potent tubulin inhibitor. Tubulin inhibitor 16 shows antiproliferative activity. Tubulin inhibitor 16 shows cytotoxicity in HepG2 cells .
|
-
- HY-145821
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
Tubulin inhibitor 15 is a potent tubulin inhibitor. Tubulin inhibitor 15 shows antiproliferative activity. Tubulin inhibitor 15 shows cytotoxicity in HepG2 cells .
|
-
- HY-153745A
-
|
|
Trk Receptor
|
Cancer
|
|
Protein kinase inhibitor 5 sulfate hydrate is a potent TRK-A inhibitor with an IC50 value of 1.8 nM. Protein kinase inhibitor 5 sulfate hydrate inhibits cell viability .
|
-
- HY-168849
-
|
|
Topoisomerase
Bacterial
|
Infection
|
|
Topoisomerase inhibitor 5 (compound 158) is a Bacterial Topoisomerase Inhibitor inhibitor with the lowest inhibitory concentration of 0.125 μg/mL. Topoisomerase inhibitor has antituberculous activity .
|
-
- HY-128403
-
|
|
Btk
|
Inflammation/Immunology
|
|
BTK inhibitor 8 (Compound 27) is a Btk inhibitor with an IC50 of 0.11 nM. BTK inhibitor 8 inhibits B cell activation in hWB with an IC50 of 2 nM .
|
-
- HY-103271
-
|
|
Bcl-2 Family
|
Cancer
|
|
Bax inhibitor peptide, negative control is a inhibitor of Bax. Bax inhibitor peptide, negative control inhibits Bax translocation to mitochondria and Bax-mediated apoptosis in vitro .
|
-
- HY-156876
-
|
|
Cytochrome P450
|
Metabolic Disease
|
|
20-HETE inhibitor-2 is an orally active 20-HETE inhibitor. 20-HETE inhibitor-2 can inhibit the activities of CYP4F2 and CYP4A11, thereby suppressing the production of 20-HETE. 20-HETE inhibitor-2 has the effect of improving blood glucose and can be used for the research of various diseases related to 20-HETE such as obesity .
|
-
- HY-168861
-
|
|
Beta-lactamase
Bacterial
|
Infection
|
|
NDM-1 inhibitor-8 (Compound 18b) is the covalent inhibitor for new delhi metallo-β-lactamase-1 (NDM-1) with an IC50 of 7.03 μM. NDM-1 inhibitor-8 inhibits the drug resistant strains, exhibits synergistic antibacterial effect with the use of Meropenem (HY-13678). NDM-1 inhibitor-8 exhibits anti-infectious activity in mouse models .
|
-
- HY-155054
-
|
|
Parasite
|
Infection
|
|
Cysteine protease inhibitor-3 (Compound 15) is a Cysteine protease inhibitor. Cysteine protease inhibitor-3 inhibits Pf3D7, PfW2, PfFP2 and PfFP3 with IC50s of 0.74 μM, 1.05 μM, 3.5 μM, and 4.9 μM, respectively. Cysteine protease inhibitor-3 has anti-plasmodial efficacy against both drug-sensitive and drug-resistant parasites .
|
-
- HY-149268
-
|
|
JNK
|
Neurological Disease
|
|
JNK3 inhibitor-6 (Compound A53) is a selective JNK3 Inhibitor (IC50=78 nM). JNK3 inhibitor-6 has neuroprotective effect, and can used for research of neurodegenerative diseases .
|
-
- HY-148395
-
|
|
Dihydroorotate Dehydrogenase
|
Cancer
|
|
UCK2 Inhibitor-2 is a non-competitive uridine-cytidine kinase 2 (UCK2) inhibitor with an IC50 value of 3.8 µM. UCK2 Inhibitor-2 can suppress uridine salvage in cells .
|
-
- HY-147388
-
|
|
Cholinesterase (ChE)
|
Metabolic Disease
|
|
hiCE inhibitor-1, a sulfonamide derivative, is a selective human intestinal enzyme (hiCE) inhibitor with a Ki value of 53.3 nM. hiCE inhibitor-1 can be used to improve Irinotecan (HY-16562)-induced diarrhoea .
|
-
- HY-172618
-
|
|
FGFR
|
Cancer
|
|
FGFR1 inhibitor-18 (compound 16) is a potent FGFR1 inhibitor with an IC50 value of 1.31 nM. FGFR1 inhibitor-18 can occupy within the ATP-binding pocket of the target FGFR1 .
|
-
- HY-138284
-
|
|
NF-κB
|
Inflammation/Immunology
|
|
Avenanthramide-C methyl ester is an anti-inflammatory agent and NF-κB inhibitor that inhibits the secretion of pro-inflammatory factors. Avenanthramide-C methyl ester inhibits NF-κB activation by inhibiting IKK and IκB phosphorylation and inhibiting proteasome activity .
|
-
- HY-153754
-
|
|
Others
|
Metabolic Disease
|
|
Phosphatidylcholine transfer protein inhibitor-1 (Answer 37 in Patent) is a phosphatidylcholine transfer protein (PC-TP) inhibitor. Phosphatidylcholine transfer protein inhibitor-1 can be used for research of PC-TP related disease such as obesity .
|
-
- HY-146739
-
|
|
Epigenetic Reader Domain
|
Cancer
|
|
BRD4 Inhibitor-19 is a BET inhibitor with an IC50 of 55 nM for BRD4-BD1. BRD4 Inhibitor-19 can be used for multiple myeloma research .
|
-
- HY-112722
-
-
- HY-155032
-
|
|
P-glycoprotein
|
Cancer
|
|
P-gp inhibitor 15 (compound 7a) is a nonsubstrate inhibitor of P-glycoprotein (Pgp). P-gp inhibitor 15 inhibits Pgp-ATPase activity，and interfers Pgp-mediated Rhodamine123 efflux. P-gp inhibitor 15 also enhances the inhibitory efficacy of Paclitaxel (HY-B0015)，inhibits tumor progress in nude mice KBV xenograft tumors model .
|
-
- HY-18953
-
|
|
mTOR
|
Cancer
|
|
mTOR inhibitor-23 (compound DHM25) is a selective, competitive, irreversible and covalent inhibitor of mTOR. mTOR inhibitor-23 has the mechanism of inhibition occurs mainly through its capacity to covalently interact with a nucleophilic amino acid inside the ATP pocket. mTOR inhibitor-23 exerts potent antitumor activity against triple-negative breast tumor cell lines .
|
-
- HY-149991
-
|
|
HIV
|
Infection
|
|
HIV-1 inhibitor-56 (compound 12126065) is a potent HIV-1 non-nucleoside reverse transcriptase inhibitor. HIV-1 inhibitor-56 has antiviral activity against wild-type HIV-1 in TZM cells with an EC50 value of 0.24 nM. HIV-1 inhibitor-56 penetrates the blood-brain barrier .
|
-
- HY-149279
-
|
|
JNK
|
Neurological Disease
|
|
JNK3 inhibitor-7 is a potent, orally active and cross the blood-brain barrier JNK3 inhibitor with IC50 values of 53, 973, 1039 nM for JNK3, JNK2, JNK1, respectively. JNK3 inhibitor-7 shows significant neuroprotective effects. JNK3 inhibitor-7 has the potential for the research of Alzheimer’s disease (AD) .
|
-
- HY-152539
-
|
|
HIV
|
Infection
|
|
HIV-1 inhibitor-54 is a potent HIV-1 inhibitor. HIV-1 inhibitor-54 has anti-HIV activity in MT-4 cells against WT HIV-1 (strain IIIB) with an EC50 value of 0.032 μM. HIV-1 inhibitor-54 can be used for the research of virus infection .
|
-
- HY-101275
-
-
- HY-119369
-
|
|
Bacterial
|
Infection
|
|
FadD32 Inhibitor-1 is a potent FadD32 inhibitor with anti-tubercular activity .
|
-
- HY-144685
-
|
|
ATM/ATR
|
Cancer
|
|
ATM Inhibitor-2 (compound 7) is a potent and selective ATM inhibitor, with an IC50 of <1 nM .
|
-
- HY-155473
-
-
- HY-P4030
-
|
|
HIV Protease
|
Infection
|
|
Herpes virus inhibitor 2 is a herpes virus inhibitor and disrupts herpes virus ribonucleotide reductase quaternary structure. Herpes virus inhibitor 2 inhibits viral replication .
|
-
- HY-13278A
-
|
|
IRAK
|
Inflammation/Immunology
|
|
IRAK inhibitor 4 (trans) is the trans form of IRAK inhibitor 4. IRAK inhibitor 4 is an interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor.
|
-
- HY-P4028
-
|
|
Virus Protease
|
Infection
|
|
Herpes virus inhibitor 1 is a herpes virus inhibitor and disrupts herpes virus ribonucleotide reductase quaternary structure. Herpes virus inhibitor 1 inhibits viral replication .
|
-
- HY-148374
-
|
|
Epigenetic Reader Domain
|
Cancer
|
|
BRM/BRG1 ATP Inhibitor-4 is a BRG1/BRM inhibitor. BRM/BRG1 ATP Inhibitor-4 can be used for the research of cancers and BAF complex-related disorders .
|
-
- HY-139376
-
|
|
FGFR
|
Cancer
|
|
FGFR1 inhibitor-2 is a FGFR1 inhibitor (IC50 is 4.55 μM in MDA-MB-231 cells). FGFR1 inhibitor-2 can be used for the research of metastatic triple-negative breast cancer .
|
-
- HY-171648
-
|
|
Bacterial
Antibiotic
DNA/RNA Synthesis
|
Infection
|
|
RNAP-σ interaction inhibitor-2 (compound 7d) is an inhibitor of RNA polymerase-sigma factors interaction. RNAP-σ interaction inhibitor-2 exhibits the activity against S. aureus with MIC values of 2 µg/mL .
|
-
- HY-148839
-
|
|
c-Myc
|
Cancer
|
|
c-Myc inhibitor 9 (compound 332) is a c-Myc inhibitor with an logEC50 of ≥6. c-Myc inhibitor 9 inhibits tumor growth in nude mouse models. c-Myc inhibitor 9 can be used for cancer research .
|
-
- HY-149252
-
|
|
Apoptosis
Microtubule/Tubulin
|
Cancer
|
|
Tubulin inhibitor 32 is a potent and orally active tubulin inhibitor. Tubulin inhibitor 32 shows anti-proliferative activity and inhibits microtubule polymerization. Tubulin inhibitor 32 induces Apoptosis and cell cycle arrest at G2/M phase. Tubulin inhibitor 32 shows anti-tumor activity .
|
-
- HY-151928
-
|
|
JNK
|
Neurological Disease
|
|
JNK3 inhibitor-3 (compound 15g) is a selective, BBB permeable and orally active c-Jun N-terminal kinase 3 (JNK3) inhibitor. JNK3 inhibitor-3 has inhibitory activities to JNK1, JNK2 and JNK3 with IC50 values of 147.8, 44.0 and 4.1 nM, respectively. JNK3 inhibitor-3 significantly improves the memory in mouse dementia model. JNK3 inhibitor-3 can be used for the research of Alzheimer’s disease .
|
-
- HY-170835
-
|
|
Beta-lactamase
Bacterial
|
Infection
Inflammation/Immunology
|
|
NDM-1 inhibitor-7 (Compound A8) is a NDM-1 inhibitor, with IC50 of 10.284 μM. NDM-1 inhibitor-7 restores the ability of MEM to penetrate the cell wall of gram-negative bacteria. NDM-1 inhibitor-7 effectively restores the antibacterial activity of MEM against NDM-1-positive Escherichia coli. NDM-1 inhibitor-7 demonstrates strong efficacy in both the Galleria mellonella infection model and murine peritonitis infection model .
|
-
- HY-151972
-
|
|
Epigenetic Reader Domain
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
BRD4 Inhibitor-25 is a BRD4 inhibitor with IC50s of 0.82 μM, 1.94 μM for BD1 and BD2 domains of BRD4. BRD4 Inhibitor-25 induces apoptotic and autophagy cell death in ovarian cancer cells. BRD4 Inhibitor-25 can be used in the research of cancers, cardiovascular, neuromuscular and inflammatory disorders.
|
-
- HY-122573
-
|
|
Epigenetic Reader Domain
|
Cancer
|
|
Bromodomain inhibitor-13 (Compound 1) is an analog of PFI-3 (HY-12409). Bromodomain inhibitor-13 is a bromodomain-containing protein (BCP) inhibitor. Bromodomain inhibitor-13 targets SMARCA2, SMARCA4, PB1(5), and second bromodomain of PB1 (PB1(2)) with KD values of 37, 53, 30, and 190 nM, respectively .
|
-
- HY-149280
-
|
|
JNK
|
Neurological Disease
|
|
JNK3 inhibitor-8 is a potent, delective, orally active and cross the blood-brain barrier JNK3 inhibitor with IC50 values of 21, 2203, >10000 nM for JNK3, JNK2, JNK1, respectively. JNK3 inhibitor-8 shows significant neuroprotective effects. JNK3 inhibitor-8 has the potential for the research of Alzheimer’s disease (AD) .
|
-
- HY-149291
-
|
|
ATM/ATR
Apoptosis
|
Cancer
|
|
ATM Inhibitor-7 is a potent and selective ataxia-telangiectasia mutated (ATM) inhibitor with an IC50 value of 1.0 nM. ATM Inhibitor-7 induces Apoptosis and cell cycle arrest at G2/M phase when combinanted with CPT-11 (HY-16562). ATM Inhibitor-7 combines with CPT-11 shows antitumor activity .
|
-
- HY-150759
-
|
|
HIV
|
Infection
|
|
HIV-1 inhibitor-45 is a potent HIV-1 RNase H inhibitor with an IC50 value of 0.067 μM. HIV-1 inhibitor-45 shows an antiviral activity. HIV-1 inhibitor-45 shows poor cell permeability (with an apparent permeability coefficient (Papp) lower than 0.48 × 10 −6 cm/s) .
|
-
- HY-151933
-
|
|
HIV
Reverse Transcriptase
|
Infection
|
|
HIV-1 inhibitor-49 is an orally active HIV-1 inhibitor, is a HEPT analog. HIV-1 inhibitor-49 possesses great pharmacokinetics profiles and potent non-nucleoside reverse transcriptase inhibitory activity (IC50=30 nM). HIV-1 inhibitor-49 exerts potential safety without acute toxicity in mouse model .
|
-
- HY-138295
-
|
|
Ras
|
Cancer
|
|
KRAS inhibitor-10 selectively and effectively inhibit RAS proteins, and particularly KRAS proteins. KRAS inhibitor-10 is an orally active anti-cancer agent and can be used for cancer research, such as pancreatic cancer, breast cancer, multiple myeloma, leukemia and lung cancer. KRAS inhibitor-10 is a tetrahydroisoquinoline compound (compound 11) extracted from patent WO2021005165 A1 .
|
-
- HY-163191
-
|
|
Beta-lactamase
Bacterial
|
Infection
|
|
NDM-1 inhibitor-5 (compound 57) is a potent NDM-1 inhibitor, with a Ki of 2.5 μM. NDM-1 inhibitor-5 also shows antibacterial synergistic activity with meropenem (HY-13678) .
|
-
- HY-146089
-
|
|
HIV
|
Infection
|
|
HIV-1 inhibitor-32 (compound 3c) is a potent HIV-1 inhibitor with an IC50 value of 34 nM for WT HIV-1. HIV-1 inhibitor-32 can be used for researching AIDS .
|
-
- HY-112412
-
|
PDGF Receptor Tyrosine Kinase Inhibitor III
|
PDGFR
|
Neurological Disease
|
|
PDGFR Tyrosine Kinase Inhibitor III (PDGF Receptor Tyrosine Kinase Inhibitor III), a multikinase inhibitor, inhibits PDGFR, EGFR, FGFR, PKA, and PKC, respectively. PDGFR Tyrosine Kinase Inhibitor III can be used for the research of amyotrophic lateral sclerosis .
|
-
- HY-168189
-
|
|
HIV
|
Infection
|
|
HIV-1 inhibitor-76 (compound 9t-2) is a non-nucleoside reverse transcriptase inhibitor of HIV-1. HIV-1 inhibitor-76 can be used in anti-HIV research .
|
-
- HY-173302
-
|
|
Epoxide Hydrolase
|
Neurological Disease
|
|
sEH inhibitor-20 is an orally active and metabolically stable sEH inhibitor (IC50: 0.2 nM). sEH inhibitor-20 has significant analgesic and anti-inflammatory activities and is expected to become a potential candidate compound for the study of neuropathic pain .
|
-
- HY-163852
-
-
- HY-170969
-
|
|
HIV
HIV Protease
|
Infection
|
|
HIV-1 inhibitor-81 (Compound 14g) is an HIV-1 protease inhibitor with a Ki of 1.6 nM. HIV-1 inhibitor-81 exhibits certain antiviral activity, with an EC50 of 250 nM for HIV-1 .
|
-
- HY-155209
-
|
|
Stearoyl-CoA Desaturase (SCD)
|
Cancer
|
|
SCD1 inhibitor-5 (compound 51) is a SCD1 inhibitor,with the IC50 values of 0.13 μM and 31 μM for H2122 and H1819, respectively. SCD1 inhibitor-5 can be used in cancer research .
|
-
- HY-153017
-
|
|
HIF/HIF Prolyl-Hydroxylase
|
Cancer
|
|
HIF-1 inhibitor-4 is a HIF-1 inhibitor (IC50: 560 nM). HIF-1 inhibitor-4 reduces the HIF-1α protein level without affecting its mRNA level .
|
-
- HY-160548
-
-
- HY-118371
-
|
|
Arginase
|
Cancer
|
|
Arginase inhibitor 2 is an Arginase inhibitor (Page 130 in reference patent). Arginase inhibitor 2 synergizes with adoptively transferred antigen- specific T cells to inhibit tumor growth .
|
-
- HY-170916
-
|
|
ERK
|
Inflammation/Immunology
Cancer
|
|
Angiogenesis inhibitor 7 (compound BT2) ia a potent inhibitor of angiogenesis. Angiogenesis inhibitor 7 inhibits ERK phosphorylation, FosB/ΔFosB and VCAM-1 expression .
|
-
- HY-115956
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
Tubulin inhibitor 18 (compound 5j) is a potent inhibitor of tubulin. Tubulin inhibitor 18 is a chalcone compound. Tubulin inhibitor 18 has the potential for the research of cancer diseases .
|
-
- HY-P34013
-
|
|
Ser/Thr Protease
|
Cancer
|
|
Urinary Trypsin Inhibitor Fragment is a fragment derived from urinary trypsin inhibitor by proteolysis. Urinary Trypsin Inhibitor Fragment can inhibit tumor cell invasion by limited proteolysis .
|
-
- HY-168187
-
|
|
Src
|
Cancer
|
|
Src Inhibitor 3 (Compound 7d) is a Src inhibitor with an IC50 of 285 nM. Src Inhibitor 3 inhibits HepG2 cells proliferative with an IC50 of 1.55 μM .
|
-
- HY-156875
-
-
- HY-111412
-
-
- HY-160499
-
-
- HY-139648
-
-
- HY-162983
-
|
|
Ras
|
Cancer
|
|
KRAS inhibitor-36 (compund Abd2) directly inhibits KRAS Q61H .
|
-
- HY-W192171
-
-
- HY-130260
-
|
|
Ras
|
Cancer
|
|
KRAS inhibitor-4 (compound F12) is a potent KRAS inhibitor and developed as anticancer agents .
|
-
- HY-153159
-
|
|
Others
|
Cancer
|
|
Angiogenesis inhibitor 4 is a potent angiogenesis inhibitor. Angiogenesis inhibitor 4 can be used in research of cancer .
|
-
- HY-128703
-
-
- HY-156130
-
|
|
Epigenetic Reader Domain
|
Cancer
|
|
Menin-MLL inhibitor 29 (Compound C1) is a Menin-MLL PPI inhibitor. Menin-MLL inhibitor 29 binds to Menin with a KD value of 138 nM, and inhibits the binding of Menin to MBM1 (Menin-binding motif 1) with an IC50 value of 46 nM. Menin-MLL inhibitor 29 inhibits HepG2 and Hep3B hepatoma cell proliferation (IC50s: 0.31 μM and 0.71 μM). Menin-MLL inhibitor 29 inhibits tumor growth .
|
-
- HY-118013
-
|
|
Bacterial
|
Infection
|
|
NDM-1 inhibitor-2 is an inhibitor of New Delhi metallo-β-lactamase-1 (NDM-1) and has the ability to inhibit NDM-1 activity. NDM-1 inhibitor-2 exhibits a good inhibitory effect on drug-resistant bacterial strains that overexpress NDM-1. When NDM-1 inhibitor-2 is used in combination with the carbapenem antibiotic meropenem, a favorable synergistic effect can be produced .
|
-
- HY-173141
-
|
|
mTOR
|
Cancer
|
|
mTOR inhibitor-26 (Compound HPT-11) is an inhibitor of mTOR with an IC50 of 0.7 nM. It effectively inhibits the proliferation of AML cell lines Molm-13 and MV-4-11. mTOR inhibitor-26 exhibits antitumor activity and favorable metabolic stability, making it a promising candidate for cancer research .
|
-
- HY-154987
-
|
|
MARK
|
Cancer
|
|
MAPK4 inhibitor 3 (compound 23b) is an inhibitor of MAPK4 with an IC50 value of 1.01 μM. MAPK4 inhibitor 3 inhibits cancer cells growth. MAPK4 inhibitor 3 can be used for research on cancer and tauopathies .
|
-
- HY-139605
-
|
|
GLUT
|
Inflammation/Immunology
Cancer
|
|
GLUT inhibitor-1 is a potent and orally active inhibitor of glucose transporters, targeting both GLUT1 and GLUT3, with IC50s of 242 nM and 179 nM, respectively. GLUT inhibitor-1 has the potential for the reaesrch of cancers and autoimmune diseases .
|
-
- HY-169572
-
|
|
IGF-1R
|
Cancer
|
|
IGF-1R inhibitor-5 (compound 19) is a potent inhibitor of IGF-1R, with the IC50 of 6 μM. IGF-1R inhibitor-5 has the potential for the research of cancer .
|
-
- HY-172093
-
|
|
HIV
|
Infection
|
|
HIV-1 inhibitor-80 (compound M44) is an HIV-1 inhibitor with an EC50 of 5-148 nM. HIV-1 inhibitor-80 shows good metabolic stability and cytotoxicity in human plasma and human liver microsomes .
|
-
- HY-144818
-
|
|
Apoptosis
Microtubule/Tubulin
|
Cancer
|
|
Tubulin inhibitor 23 is a potent Tubulin inhibitor with an IC50 of 4.8 µM. Tubulin inhibitor 23 induces cell apoptosis. Tubulin inhibitor 23 shows antiangiogenic activity in a dose-dependent manner. Tubulin inhibitor 23 has the potential for the research of leukaemia .
|
-
- HY-139077
-
|
|
Stearoyl-CoA Desaturase (SCD)
|
Metabolic Disease
Cancer
|
|
SCD1 inhibitor-3 is a safe, potent and orally active SCD1 inhibitor. SCD1 inhibitor-3 can be used for the research of metabolic diseases such as obesity, type II diabetes and dyslipidemia, as well as skin diseases, acne and cancer .
|
-
- HY-146543
-
|
|
Ras
|
Cancer
|
|
KRAS inhibitor-13 (compound 5-6) is a potent KRAS G12C inhibitor with an IC50 of 0.883 µM. KRAS inhibitor-13 shows p-ERK inhibition activities with IC50s of 5.9, >100 µM in MIA PaCA-2, A549 cells, respectively. KRAS inhibitor-13 has the potential for the research of pancreatic, colorectal, and lung cancers .
|
-
- HY-122714
-
|
|
PAI-1
|
Cancer
|
|
SK-216 is a plasminogen activator inhibitor-1 (PAI-1) inhibitor that acts as an anti-metastatic agent for human osteosarcoma and inhibits lung metastasis of human osteosarcoma .
|
-
- HY-115957
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
Tubulin inhibitor 19 (compound 9b) is a potent inhibitor of tubulin. Tubulin inhibitor 19 is an indole chalcone compound. Tubulin inhibitor 19 has the potential for the research of cancer diseases .
|
-
- HY-160549
-
|
|
c-Myc
|
Cancer
|
|
c-Myc inhibitor 14 (Compound 13A) is a c-Myc protein inhibitor. The IC50 value of HL60 inhibitor is <100 nM. c-Myc inhibitor 14 shows antitumor activity .
|
-
- HY-152156
-
|
|
Microtubule/Tubulin
Apoptosis
|
Cancer
|
|
Tubulin inhibitor 11 is a potent and orally active tubulin inhibitor. Tubulin inhibitor 11 targets the Colchicine binding site on tubulin, inhibits tubulin polymerization, promotes mitotic blockade and apoptosis .
|
-
- HY-145828
-
|
|
Microtubule/Tubulin
Ferroptosis
|
Cancer
|
|
Microtubule inhibitor 2 is a potent and selective, orally active microtubule inhibitor. Microtubule inhibitor 2 triggers cell death through ferroptosis . Microtubule inhibitor 2 shows antitumor activity .
|
-
- HY-112807
-
|
|
SGLT
|
Metabolic Disease
|
|
SGLT inhibitor-1 is a potent dual inhibitor of sodium glucose co-transporter proteins (SGLTs), inhibits hSGLT1 and hSGLT2 with IC50s of 43 nM and 9 nM, respectively .
|
-
- HY-153692
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
WRN inhibitor 1 is a Wemer Syndrome ATP dependent helicase enzyme (WRN) inhibitor that inhibits WRN helicase domain activity. WRN inhibitor 1 can be used in the study of cancer .
|
-
- HY-128722
-
|
|
HIV
|
Infection
|
|
HIV-1 inhibitor-3 is a HIV infection inhibitor extracted from patent US2018360927 .
|
-
- HY-139638
-
|
|
MEK
|
Cancer
|
|
MEK4 inhibitor-1 is a novel MEK4 inhibitor against pancreatic adenocarcinoma with an IC50 value of 61 nM.
|
-
- HY-139639
-
|
|
MEK
|
Cancer
|
|
MEK4 inhibitor-2 is a novel MEK4 inhibitor against pancreatic adenocarcinoma with an IC50 value of 83 nM.
|
-
- HY-W801893
-
|
|
FGFR
|
Cancer
|
|
FGFR1 inhibitor-13 (compound 1) is an FGFR1 inhibitor with an IC50 of 4.2 μM .
|
-
- HY-151983
-
|
|
Thrombin
|
Cardiovascular Disease
|
|
Thrombin inhibitor 6 is a potent thrombin inhibitor (IC50: 1 nM). Thrombin inhibitor 6 has the function as an anticoagulant .
|
-
- HY-114199
-
-
- HY-153668
-
-
- HY-108255
-
|
|
HIV
|
Infection
|
|
HIV-1 inhibitor-60 (compound 45) is an HIV inhibitor with the potential for the research of infection diseases .
|
-
- HY-147370
-
|
|
HIV
|
Infection
|
|
HIV-1 inhibitor-46 (compound 13d) is a potent HIV-1 non-nucleoside reverse transcriptase inhibitor with an EC50 value of 1.425 μM. HIV-1 inhibitor-46 can be used for the research of AIDS .
|
-
- HY-162461
-
|
|
Reverse Transcriptase
HIV
|
Infection
|
|
HIV-1 inhibitor-66 is an orally active non-nucleoside reverse transcription inhibitor (NNRTI). HIV-1 inhibitor-66 shows inhibitory activity against wild-type HIV-1 reverse transcriptase with an IC50 of 40 nM .
|
-
- HY-122848
-
-
- HY-32015
-
|
|
MAP3K
|
Inflammation/Immunology
|
|
Cot inhibitor-1 (compound 28) is a selective tumor progression loci-2 (Tpl2) kinase inhibitor with an IC50 of 28 nM. Cot inhibitor-1 shows an inhibition of TNF-alpha production in human whole blood with an IC50 of 5.7 nM .
|
-
- HY-170818
-
|
|
HSP
|
Cancer
|
|
Grp94 Inhibitor-3 (Compound C6) is a selective glucose regulated protein 94 (Grp94) inhibitor with an affinity of 5.52 μM. Grp94 Inhibitor-3 is promising for research of primary open-angle glaucoma and metastatic cancer .
|
-
- HY-115514A
-
|
|
BRK
|
Cancer
|
|
BRK inhibitor P21d hydrochloride is a potent breast tumor kinase (BRK/PTK6) inhibitor with an IC50 of 30 nM. BRK inhibitor P21d hydrochloride inhibits p-SAM68 with an IC50 of 52 nM. BRK inhibitor P21d hydrochloride can be used to evaluate the in vivo activity of BRK inhibitors in xenograft breast tumor models .
|
-
- HY-147903
-
|
|
HIV
|
Infection
|
|
HIV-1 inhibitor-42 (compound 5b) is a potent HIV-1 inhibitor, with an IC50 of 0.06 μM. HIV-1 inhibitor-42 inhibits HIV-1 RT RNA-dependent DNA polymerase and DNA-dependent DNA polymerase, with IC50 values of 0.518 and 0.072 μM .
|
-
- HY-162341
-
|
|
Topoisomerase
|
Cancer
|
|
Topoisomerase I inhibitor 15 (compound 4b) is an inhibitor of topoisomerase I with anticancer activity. Topoisomerase I inhibitor 15 inhibits A549 cells with an IC50 of 7.34 μM .
|
-
- HY-111079
-
|
|
HIV
Reverse Transcriptase
|
Others
|
|
HIV-1 inhibitor-70 (compound 20) is a bifunctional inhibitor that inhibits both wild-type (WT) and K103N mutant reverse transcriptases (RTs) of HIV-1.
|
-
- HY-146476
-
|
|
Ras
|
Cancer
|
|
KRAS inhibitor-18 (compound 3-10) is a potent KRAS G12C inhibitor with an IC50 of 4.74 µM. KRAS inhibitor-18 shows p-ERK inhibition activities with IC50s of 66.4, 11.1 µM in MIA PaCA-2, A549 cells, respectively. KRAS inhibitor-18 has the potential for the research of pancreatic, colorectal, and lung cancers .
|
-
- HY-146533
-
|
|
Ras
|
Cancer
|
|
KRAS inhibitor-12 (compound 6-1) is a potent KRAS G12C inhibitor with an IC50 of 0.537 µM. KRAS inhibitor-12 shows p-ERK inhibition activities with IC50s of 1.3, 3.7 µM in MIA PaCA-2, A549 cells, respectively. KRAS inhibitor-12 has the potential for the research of pancreatic, colorectal, and lung cancers .
|
-
- HY-146545
-
|
|
Ras
|
Cancer
|
|
KRAS inhibitor-15 (compound 3-19) is a potent KRAS G12C inhibitor with an IC50 of 0.954 µM. KRAS inhibitor-15 shows p-ERK inhibition activities with IC50s of 2.03, >33.3 µM in MIA PaCA-2, A549 cells, respectively. KRAS inhibitor-15 has the potential for the research of pancreatic, colorectal, and lung cancers .
|
-
- HY-147723
-
|
|
HIV
|
Infection
|
|
HIV-1 inhibitor-39 (compound 3c) is a potent HIV-1 inhibitor with an EC50 of >112.88 µM. HIV-1 inhibitor-39 shows anti-RT (HIV-1 reverse transcriptase) activities with an IC50 of 15.75 µM. HIV-1 inhibitor-39 shows cytotoxicity for MT-4 cells with an CC50 of 112.9 µM .
|
-
- HY-146546
-
|
|
Ras
|
Cancer
|
|
KRAS inhibitor-16 (compound 3-11) is a potent KRAS G12C inhibitor with an IC50 of 0.457 µM. KRAS inhibitor-16 shows p-ERK inhibition activities with IC50s of 3.06, 11.1 µM in MIA PaCA-2, A549 cells, respectively. KRAS inhibitor-16 has the potential for the research of pancreatic, colorectal, and lung cancers .
|
-
- HY-146475
-
|
|
Ras
|
Cancer
|
|
KRAS inhibitor-17 (compound 3-9) is a potent KRAS G12C inhibitor with an IC50 of 3.37 µM. KRAS inhibitor-17 shows p-ERK inhibition activities with IC50s of 9.25, >33.3 µM in MIA PaCA-2, A549 cells, respectively. KRAS inhibitor-17 has the potential for the research of pancreatic, colorectal, and lung cancers .
|
-
- HY-146544
-
|
|
Ras
|
Cancer
|
|
KRAS inhibitor-14 (compound 3-22) is a potent KRAS G12C inhibitor with an IC50 of 0.249 µM. KRAS inhibitor-14 shows p-ERK inhibition activities with IC50s of 1.12, >33.3 µM in MIA PaCA-2, A549 cells, respectively. KRAS inhibitor-14 has the potential for the research of pancreatic, colorectal, and lung cancers .
|
-
- HY-138131
-
|
|
SOD
|
Neurological Disease
|
|
SOD1-Derlin-1 inhibitor-1 (compound 56-20) is an inhibitor of SOD1-Derlin-1 interaction. SOD1-Derlin-1 inhibitor-1 inhibits SOD1 G93A-Derlin-1 complex with an IC50 value of 7.11 μM. SOD1-Derlin-1 inhibitor-1 can be used for the research of amyotrophic lateral sclerosis .
|
-
- HY-155029
-
|
|
Epoxide Hydrolase
|
Inflammation/Immunology
|
|
sEH inhibitor-16 is a soluble epoxide hydrolase (sEH) inhibitors with an IC50 of 2 nM. sEH inhibitor-16 reduces the inflammatory damage in Cerulein (HY-A0190)-induced acute pancreatitis (AP) in mice and can be used for inflammation/immunology research .
|
-
- HY-155078
-
|
|
Epigenetic Reader Domain
|
Cancer
|
|
BRD4 Inhibitor-27 (compound 6) is a BRD4 inhibitor with IC50 of 9.6 and 11.3 μM for BRD4 BD1 and BRD4 BD2, respectively. BRD4 Inhibitor-27 has the potential to study cancer .
|
-
- HY-49066
-
-
- HY-17541A
-
|
|
Cathepsin
|
Others
|
|
Cysteine Protease inhibitor hydrochloride is an inhibitor of cysteine protease.
|
-
- HY-17541
-
|
|
Cathepsin
|
Others
|
|
Cysteine Protease inhibitor is an inhibitor of cysteine protease.
|
-
- HY-156969
-
|
|
Topoisomerase
Btk
|
Cancer
|
|
Topoisomerase I inhibitor 11 is a potent inhibitor of Topoisomerase I. Topoisomerase I inhibitor 11 can bind to BTK .
|
-
- HY-148000
-
-
- HY-153668A
-
-
- HY-164201
-
|
|
HIV
|
Infection
|
|
HIV-1 inhibitor-69 (compound Test set 1) is a HIV-1 RT inhibitor .
|
-
- HY-156639
-
|
|
EGFR
|
Cancer
|
|
EGFR/ErbB-2 inhibitor-1 is a ErbB2/HER2 inhibitor .
|
-
- HY-112335
-
|
|
Src
Interleukin Related
|
Cancer
|
|
Lck Inhibitor III (compound 12h) is a potent Lck inhibitor, with an IC50 of 867 nM. Lck Inhibitor III inhibits IL-2 synthesis in Jurkat cells, with an IC50 of 1.270 μM .
|
-
- HY-160854
-
|
|
Microtubule/Tubulin
Apoptosis
|
Cancer
|
|
Tubulin inhibitor 43 (Compound 29) has significant antitumor activity. Tubulin inhibitor 43 inhibits the proliferation and growth of cancer cells by inhibiting the activity of β-microtubulin, and finally induces apoptosis .
|
-
- HY-P10045
-
|
|
Integrin
|
Cardiovascular Disease
|
|
Integrin signaling inhibitor, mP13 is an inhibitor of integrin signaling. Integrin signaling inhibitor, mP13 inhibits inside-out and outside-in signaling, including fibrinogen binding, platelet adhesion, and clot retraction .
|
-
- HY-136279
-
|
|
Apoptosis
|
Cancer
|
|
TrxR inhibitor D9 is a potent and selective inhibitor of thioredoxin reductase (TrxR), with an EC50 of 2.8 nM. TrxR inhibitor D9 has the capability to inhibit tumor proliferation both in vitro and in vivo .
|
-
- HY-125218
-
|
ITK7
|
PARP
|
Cancer
|
|
PARP11 inhibitor ITK7 (ITK7) is a potent and selective PARP11 inhibitor. PARP11 inhibitor ITK7 can potently inhibit PARP11 with an IC50 value of 14 nM. PARP11 inhibitor ITK7 can be used for the research of cellular localization .
|
-
- HY-159984
-
|
|
HIV
|
Infection
|
|
HIV-1 inhibitor-78 (compound 15f) is a potent and broad-spectrum non-nucleoside reverse transcriptase inhibitor, with an EC50 of 3 nM for wild-type HIV-1. HIV-1 inhibitor-78 can be used for the research of HIV infection .
|
-
- HY-150697
-
|
|
HIV
|
Others
|
|
HIV-1 inhibitor-44 (compound 11l) is a HIV-1 reverse transcriptase inhibitor. HIV-1 inhibitor-44 shows inhibitory activity against wild-type HIV-1 strain with an EC50 value of 0.209 μM .
|
-
- HY-156552
-
-
- HY-164662
-
|
|
mTOR
PI3K
|
Cancer
|
|
mTOR inhibitor-24 (comounp 9d) is a mTOR inhibitor, with IC50s of 0.34 nM (mTOR) and 324 nM (PI3K-α) respectively. mTOR inhibitor-24 inhibtis LNCaP cell proliferation (IC50: 180 nM) .
|
-
- HY-146387
-
|
|
Sirtuin
|
Neurological Disease
Cancer
|
|
SIRT5 inhibitor 3 (compound 46) is a potent and competitive SIRT5 inhibitor with an IC50 value of 5.9 μM. SIRT5 inhibitor 3 can inhibit SIRT5 desuccinylation. SIRT5 inhibitor 3 can be used for researching cancer and neurodegenerative diseases .
|
-
- HY-149989
-
|
|
Ack1
Akt
|
Cancer
|
|
Ack1 inhibitor 1 is a potent, selective, and orally active inhibitor of ACK1 kinase with an IC50 value of 2.1 nM. Ack1 inhibitor 1 inhibits the phosphorylation of ACK1 and activation of downstream AKT. Ack1 inhibitor 1 has anti-tumor activity .
|
-
- HY-161386
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
WRN inhibitor 7 (Compound h6) is a WRN inhibitor. WRN inhibitor 7 effectively inhibits WRN's helicase and ATPase activity (IC50: 9.8 μM and 15.8 μM respectively). WRN inhibitor 7 can be used for research of microsatellite instable (MSI) cancers .
|
-
- HY-169600
-
|
|
IGF-1R
|
Cancer
|
|
IGF-1R inhibitor-4 (compound 22) is a potent inhibitor of IGF-1R, with the inhibitiron rate of 63% at 10 μM. IGF-1R inhibitor-4 plays an important role in cancer research .
|
-
- HY-163797
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
WRN inhibitor 10 (Compound P24) is an inhibitor for the Werner helicase WRN with an IC50 of 1.1 nM. WRN inhibitor 10 inhibits the proliferation of cancer cell SW48 with IC50 of 39 nM. WRN inhibitor 10 exhibits good liver microsomal stability and film permeability. WRN inhibitor 10 exhibits good pharmacokinetic characteristics in CD-1 mice .
|
-
- HY-170492
-
|
|
Epoxide Hydrolase
Interleukin Related
TNF Receptor
|
Inflammation/Immunology
|
|
sEH inhibitor-19 (Compound (R)-14i) is an orally active inhibitor for soluble epoxide hydrolase (sEH) with an IC50 of 1.2 nM. sEH inhibitor-19 inhibits the expression of TNF-α and IL-6, exhibits anti-inflammatory activity in mouse acute pancreatitis or Carrageenan (HY-125474)-induced edema models .
|
-
- HY-148042
-
|
|
HIV
|
Infection
|
|
HIV-1 inhibitor-47 is an inhibitor of HIV-1, and inhibits vif-dependent degradation of human APOBEC3G, with an IC50 value of 14.33 μM. HIV-1 inhibitor-47 also involves in derivatives of 1-(2-pyrimidinyl)piperazine synthesis, with potential antianxiety, antidepressant, and antipsychotic effect .
|
-
- HY-173509
-
|
|
Phosphodiesterase (PDE)
LPL Receptor
|
Infection
Cardiovascular Disease
Neurological Disease
Cancer
|
|
ATX inhibitor 27 (Compound 31) is an ATX inhibitor. The IC50 values of ATX inhibitor 27 against human autotaxin (hATX) and lysophosphatidylcholine (LPC) are 13 nM and 23 nM, respectively. ATX inhibitor 27 reduces LPA levels in vivo by inhibiting ATX enzyme. ATX inhibitor 27 can be used in the study of ATX-LPA-related diseases such as inflammation, neurodegenerative diseases and cancer .
|
-
- HY-153970
-
|
|
URAT1
|
Inflammation/Immunology
|
|
URAT1 inhibitor 7 (compound 10f) is a potent URAT1 inhibitor, with an IC50 of 12 nM. URAT1 inhibitor 7 exhibits microsomal stability (HLM <13 µL/min/mg). URAT1 inhibitor 7 also inhibits CYP2C9, with an IC50 of 4.2 μM. URAT1 inhibitor 7 can be used for gout research .
|
-
- HY-128859
-
|
|
Cytochrome P450
|
Metabolic Disease
|
|
EMT inhibitor-2 (Compound 1) inhibits epithelial-mesenchymal transition (EMT) induced by substances such as IL-1β and TGF-β released from the immunocytes. EMT inhibitor-2 inhibits CYP3A4 testosteron and CYP2C9 with IC50s of 49.72 and 5.54 μM, respectively .
|
-
- HY-118054
-
|
|
Orphan Receptor
|
Cancer
|
|
LRH-1 Inhibitor-3 is a small molecule that inhibits LRH-1 transcriptional activity, thereby decreasing the expression of target genes associated with cell growth and proliferation. LRH-1 Inhibitor-3 has shown potential in reducing cancer cell proliferation in human pancreatic, colon, and breast adenocarcinoma cell lines. LRH-1 Inhibitor-3 serves as a molecular probe for investigating the role of LRH-1 in various malignancies.
|
-
- HY-147552
-
|
|
HIV
|
Infection
|
|
HIV-1 inhibitor-35 (compound 74) is a potent HIV-1 inhibitor with EC50s of 80 nM and 70 nM for LTR and CMV in HEK293 cells, respectively. HIV-1 inhibitor-35 has inhibitory activity against liver cancer cell HepG2 with a CC50 of 40 nM. HIV-1 inhibitor-35 can be used as HIV-1 latency reversing agent .
|
-
- HY-123982
-
|
|
SOD
|
Neurological Disease
|
|
SOD1-Derlin-1 inhibitor-2 (compound 56-59) is an inhibitor of SOD1-Derlin-1 interaction. SOD1-Derlin-1 inhibitor-2 attenuates the interactions between Derlin-1 and SOD1 mut. SOD1-Derlin-1 inhibitor-2 can be used for the research of amyotrophic lateral sclerosis (ALS) .
|
-
- HY-167952
-
|
|
PI3K
|
Cancer
|
|
mTOR inhibitor-25 is an enzyme inhibitor that is more selective than PI3K and has good anticancer activity. mTOR inhibitor-25 shows strong inhibitory effects on mTOR and may be used to study leukemia, skin cancer, breast cancer, lung cancer and colon cancer. mTOR inhibitor-25 showed excellent activity in cell proliferation experiments, but its inhibitory ability on PI3K was relatively weak .
|
-
- HY-149350
-
|
|
HIV
|
Infection
|
|
HIV-1 inhibitor-57 (Compound 12g) is a HIV inhibitor. HIV-1 inhibitor-57 is active against wild-type and five prevalent NNRTI-resistant HIV-1 strains with EC50 values ranging from 0.024 to 0.0010 μM. HIV-1 inhibitor-57 forms additional interactions with residues around the binding site in HIV-1 RT .
|
-
- HY-122912
-
|
ALDH1Ai 673A
|
Aldehyde Dehydrogenase (ALDH)
Necroptosis
|
Cancer
|
|
ALDH1A inhibitor 673A is an ALDH1A inhibitor. ALDH1A inhibitor 673A inhibits all three ALDH1A family members (IC50: 246 nM, 230 nM, 348 nM for ALDH1A1, ALDH1A2, ALDH1A3 respectively. ALDH1A inhibitor 673A induces necroptotic cell death preferentially in CD133+ ovarian CSCs. ALDH1A inhibitor 673A also inhibits chemotherapy-resistant tumor growth .
|
-
- HY-168560
-
|
|
MMP
|
Cancer
|
|
MMP Inhibitor 4 (compound 4 B) is a potent MMP inhibitor. MMP Inhibitor 4 shows antiproliferative activity. MMP Inhibitor 4 induces cell cycle arrest at subG1 phase. MMP Inhibitor 4 decreases the mRNA expression of MMP2, MMP9 and VEGFA .
|
-
- HY-120777
-
|
|
Bacterial
|
Others
|
|
GSK729 is a THPP inhibitor with the activity of inhibiting EchA6 and inhibiting Mycobacterium tuberculosis. GSK729 can selectively pull down EchA6 in a stereospecific manner, inhibit its activity, inhibit fatty acid synthesis of Mycobacterium tuberculosis, and has a bactericidal effect in a mouse chronic tuberculosis infection model.
|
-
- HY-172603
-
|
|
HIV
|
Infection
|
|
HIV-1 inhibitor-82 (Compound L14) is an orally active small-molecule entry inhibitor for HIV-1 with an IC50 value of 0.39 μM. HIV-1 inhibitor-82 is promising for research of anti-HIV-1 infection .
|
-
- HY-147553
-
|
|
HIV
|
Infection
|
|
HIV-1 inhibitor-36 (Compound 2) is a potent HIV-1. HIV-1 inhibitor-36 has the potential for further development as novel latency reversing agents .
|
-
- HY-147555
-
|
|
HIV
|
Infection
|
|
HIV-1 inhibitor-38 (Compound 91) is a potent HIV-1. HIV-1 inhibitor-38 has the potential for further development as novel latency reversing agents .
|
-
- HY-152214
-
|
|
Sirtuin
|
Cancer
|
|
SIRT5 inhibitor 5 is a potent SIRT5 inhibitor with an IC50 value of 0.21 µM. SIRT5 inhibitor 5 does not occupy the NNAD + -binding pocket and acts as a substrate-competitive inhibitor .
|
-
- HY-162625
-
|
|
Microtubule/Tubulin
Apoptosis
|
Cancer
|
|
Tubulin inhibitor 47 (compound C11) is a potent tubulin inhibitor. Tubulin inhibitor 47 induces apoptosis and cell cycle arrest at the M phase. Tubulin inhibitor 47 shows anti-tumor activity .
|
-
- HY-163195
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
Tubulin inhibitor 40 (compound 45) is a tubulin inhibitor with IC50 of 1.2 μM. Tubulin inhibitor 40 shows selective cytotoxicity towards cancer cells. Tubulin inhibitor 40 processes antitumor activity .
|
-
- HY-147554
-
|
|
HIV
|
Infection
|
|
HIV-1 inhibitor-37 (Compound 83) is a potent HIV-1. HIV-1 inhibitor-37 has the potential for further development as novel latency reversing agents .
|
-
- HY-149694
-
|
|
Aurora Kinase
|
Cancer
|
|
Aurora kinase inhibitor-12 (Compound 1a ) is the inhibitor of aurora kinase which is a key enzyme that is implicated in tumor growth .
|
-
- HY-P0017
-
-
- HY-160220S
-
|
|
Ras
|
Cancer
|
|
KRAS inhibitor-23 (Isomer 2 of compound i) is a potent inhibitor of KRAS that plays an important role in cancer research .
|
-
- HY-163161
-
|
|
HIV
|
Infection
|
|
HIV-1 inhibitor-62 (compound 6) is an HIV-1 inhibitor that can be used in antiviral research .
|
-
- HY-115958
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
Tubulin inhibitor 20 (compound 1) is a potent inhibitor of tubulin. Tubulin inhibitor 20 has the potential for the research of cancer diseases .
|
-
- HY-119372
-
-
- HY-151621
-
-
- HY-162101
-
|
|
Topoisomerase
|
Cancer
|
|
Topoisomerase inhibitor 3 (compound 9) is a potent Topoisomerase inhibitor. Topoisomerase inhibitor 3 shows antiproliferative and anti-tumor activity .
|
-
- HY-112843
-
|
|
Nucleoside Transporters
|
Others
|
|
CNT2 inhibitor-1 is a potent concentrative nucleoside transporter 2 Inhibitor (CNT2), with an IC50 of 640 nM for hCNT2.
|
-
- HY-155091
-
|
|
ATM/ATR
|
Cancer
|
|
ATM Inhibitor-9 (Compd 7a) is a potent ATM inhibitor with IC505 nM for ATM kinase, useful in cancer research .
|
-
- HY-P2166
-
|
|
MMP
|
Cancer
|
|
MMP3 inhibitor 3 is an inhibitor of MMP3. MMP3 inhibitor 3 can used to study breast cancer .
|
-
- HY-169623
-
|
|
FGFR
|
Cancer
|
|
FGFR1 inhibitor-14 (compound 28) is a FGFR1 inhibitor, which can be used in anti-cancer research .
|
-
- HY-169728
-
-
- HY-157886
-
-
- HY-169311
-
|
|
Ras
|
Cancer
|
|
KRAS inhibitor-37 (compound 2) is a potent KRAS inhibitor with KDs of 0.004 nM, 0.041 nM, 0.019 nM and 0.144 nM for KRAS wild type, KRAS G12D, KRAS G12C and KRAS G12V by SPR binding assay, respectively. KRAS inhibitor-37 inhibits cell proliferation with IC50s of <2 nM-14 nM for H358, SW620, PANC08.13 cells, respectively. KRAS inhibitor-37 has the potential for cancer research .
|
-
- HY-12202
-
|
|
MEK
|
Cancer
|
|
MEK inhibitor is a potent MEK inhibitor with antitumor potency.
|
-
- HY-47026
-
-
- HY-10421
-
|
|
c-Met/HGFR
|
Cancer
|
|
Tyrosine kinase inhibitor is a potent tyrosine kinase inhibitor.
|
-
- HY-141476
-
|
|
PI3K
mTOR
|
Cancer
|
|
PI3K/mTOR Inhibitor-3 (compound 12), an imidazoline, is a potent PI3K and mTOR dual inhibitor. PI3K/mTOR Inhibitor-3 has anti-cancer activity .
|
-
- HY-152193
-
|
|
Apoptosis
|
Cancer
|
|
ChoKα inhibitor-4 is a bioisosteric inhibitor of HChoK α1 (IC50=0.66 μM), with inhibitory and antiproliferative effect on cancer cells. ChoKα inhibitor-4 induces apoptosis via mitochondrial pathway, and reduces anti-apoptotic proteins expression .
|
-
- HY-P4133
-
|
|
ERK
MEK
|
Cancer
|
|
MEK1 Derived Peptide Inhibitor 1 is a peptide inhibitor. MEK1 Derived Peptide Inhibitor 1 can inhibit the in vitro activation of ERK2 by MEK1 with an IC50 value of 30 μM. MEK1 Derived Peptide Inhibitor 1 can be used for the research of cell-permeable .
|
-
- HY-156863
-
-
- HY-169423
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
WRN inhibitor 17 (Compound 250) is an orally active Werner Syndrome ATP dependent helicase enzyme (WRN) inhibitor, in particular inhibit WRN helicase domain activity. WRN inhibitor 17 is promising for research of cancers .
|
-
- HY-151372
-
|
|
PKD
|
Cancer
|
|
Protein kinase D inhibitor 1 (compound 17m) is a pan-PKD inhibitor, with IC50 values ranging from 17 to 35 nM. Protein kinase D inhibitor 1 inhibits PKD-dependent cortactin phosphorylation .
|
-
- HY-163431
-
|
|
URAT1
|
Inflammation/Immunology
|
|
URAT1 inhibitor 10 (Compound 23a) is a URAT1 inhibitor. URAT1 inhibitor 10 has oral efficacy and low cytotoxicity. URAT1 inhibitor 10 has high selectivity for OAT1 .
|
-
- HY-112469
-
|
|
ERK
Insulin Receptor
|
Metabolic Disease
|
|
ERK Inhibitor II (Negative control) is an effective inhibitor of extracellular signal-regulated kinase (ERK). ERK Inhibitor II (Negative control) inhibits the activation of insulin receptor, which can be used in the study of diabetes .
|
-
- HY-163656
-
|
|
Methionine Adenosyltransferase (MAT)
|
Cancer
|
|
MAT2A inhibitor 5(compound 39) is an orally active, selectivity and blood-brain permeability inhibitor of MAT2A with the IC50 of 11 nM. MAT2A inhibitor 5 inhibits tumor cell growth in vivo .
|
-
- HY-W806047
-
|
|
Epigenetic Reader Domain
|
Cancer
|
|
BRD4 Inhibitor-37 is a compound with anticancer activity that has inhibitory activity against BRD4. BRD4 Inhibitor-37 has an IC50 of approximately 0.05-0.1 μM in binding assays and shows a GI50 of 0.1-0.3 μM in cell-based assays. The effect of BRD4 Inhibitor-37 on c-Myc, a downstream protein of BRD4, has been validated, demonstrating its ability to intervene in this signaling pathway. BRD4 Inhibitor-37 exhibits selectivity among five different bromodomain proteins, enhancing its potential as a BET protein inhibitor .
|
-
- HY-147733
-
-
- HY-148535
-
|
|
Proteasome
|
Neurological Disease
|
|
Calpain Inhibitor XI is a reversible covalent inhibitor of calpain-1. Calpain Inhibitor XI can be used for the research of neurodegenerative disorders .
|
-
- HY-139092
-
-
- HY-148394
-
-
- HY-153750
-
|
|
Wnt
|
Cancer
|
|
Wnt pathway inhibitor 3 is a potent wnt inhibitor with an IC50 value of 45 nM. Wnt pathway inhibitor 3 shows antiproliferative activity .
|
-
- HY-135864
-
|
|
Ras
|
Cancer
|
|
KRAS inhibitor-6 is a potent KRAS G12C inhibitor, extracted from patent WO2017087528A1, compound A .
|
-
- HY-128617
-
|
|
Legumain
|
Cancer
|
|
Legumain inhibitor 1 is a potent and selective Legumain inhibitor with an IC50 of 3.6 nM. Legumain inhibitor 1 can be used for cancer research .
|
-
- HY-148138
-
|
|
HIV
|
Infection
|
|
Deaminase inhibitor-1 is a small molecule inhibitor of APOBEC3G DNA Deaminase, with an IC50 value of 18.9 μM .
|
-
- HY-162799
-
|
|
Choline Kinase
|
Cancer
|
|
ChoKα inhibitor-6 (compound Fa22) is a less specific ChoKα1 inhibitor with antitumor activity .
|
-
- HY-149725
-
|
|
MMP
|
Neurological Disease
|
proMMP-9 selective inhibitor-1 (compound 33) is a highly potent and selective inhibitor of proMMP-9 activation .
|
-
- HY-W028145
-
|
|
TGF-β Receptor
|
Cancer
|
|
TGF-βRI inhibitor 2 (compound 13) is a TGF-βRI inhibitor. TGF-βRI inhibitor 2 can be used in cancer research .
|
-
- HY-160215
-
|
|
TGF-β Receptor
|
Cancer
|
|
TGF-βRI inhibitor 1 (compoimd i) is a TGF-βRI inhibitor. TGF-βRI inhibitor 1 can be used for cancer research .
|
-
- HY-15253
-
|
PAI-039; Tiplasinin
|
PAI-1
Apoptosis
|
Metabolic Disease
Cancer
|
|
Tiplaxtinin is a selective and orally efficacious inhibitor of plasminogen activator inhibitor-1 (PAI-1) with IC50 of 2.7 μM .
|
-
- HY-W843265
-
|
|
PIN1
|
Cancer
|
|
PIN1 inhibitor 6 (compound 38) is a Pin1 inhibitor. PIN1 inhibitor 6 can be utilized in cancer research .
|
-
- HY-144766
-
|
|
Apoptosis
|
Cancer
|
|
ATX inhibitor 13 (10c) is an orally active and potent ATX inhibitor, with an IC50 of 3.4 nM. ATX inhibitor 13 inhibits proliferation and migration, and induces apoptosis and G2 phase arrest in RAW264.7 cells. ATX inhibitor 13 suppresses tumor cell colony formation .
|
-
- HY-160634
-
-
- HY-147888
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
Tubulin inhibitor 29 (compound 3c) is a potent tubulin inhibitor with an IC50 value of 1.2 µM. Tubulin inhibitor 29 shows antiproliferative effects with an IC50 value of 7.5 µM for MCF-7 cells. Tubulin inhibitor 29 inhibits tubulin assembly and bounds in the colchicine site .
|
-
- HY-128062
-
|
|
LIM Kinase (LIMK)
|
Cancer
|
|
LIMK1 inhibitor BMS-4 is a LIM Kinase (LIMK) inhibitor targeting to LIMK1/2. LIMK1 inhibitor BMS-4 inhibits phosphorylation of cofilin, the LIMK substrate. However, LIMK1 inhibitor BMS-4 is noncytotoxic on A549 cells .
|
-
- HY-112390C
-
|
|
5-HT Receptor
Syk
|
Inflammation/Immunology
|
|
Syk Inhibitor II hydrochloride is a potent, high selective and ATP-competitive Syk inhibitor with an IC50 of 41 nM. Syk Inhibitor II hydrochloride inhibits 5-HT release from RBL-cells with an IC50 of 460 nM. Syk Inhibitor II hydrochloride shows less potent against other kinases and has anti-allergic effect .
|
-
- HY-112390A
-
|
|
Syk
5-HT Receptor
|
Inflammation/Immunology
|
|
Syk Inhibitor II is a potent, high selective and ATP-competitive Syk inhibitor with an IC50 of 41 nM. Syk Inhibitor II inhibits 5-HT release from RBL-cells with an IC50 of 460 nM. Syk Inhibitor II shows less potent against other kinases and has anti-allergic effect .
|
-
- HY-112390
-
|
|
5-HT Receptor
Syk
|
Inflammation/Immunology
|
|
Syk Inhibitor II dihydrochloride is a potent, high selective and ATP-competitive Syk inhibitor with an IC50 of 41 nM. Syk Inhibitor II dihydrochloride inhibits 5-HT release from RBL-cells with an IC50 of 460 nM. Syk Inhibitor II dihydrochloride shows less potent against other kinases and has anti-allergic effect .
|
-
- HY-147703
-
|
|
Aurora Kinase
|
Cancer
|
|
Aurora kinase inhibitor-9 (compound 9d) is a potent AURKA/B dual aurora kinase inhibitor with IC50s of 0.093, 0.09 µM for Aurora A, Aurora B, respectively. Aurora kinase inhibitor-9 shows broad spectrum anti-proliferative activity .
|
-
- HY-146194
-
|
|
Reactive Oxygen Species
|
Cancer
|
|
NHEJ inhibitor-1 (Compound C2) is a trifunctional Pt(II) complex, alleviates the non-homologous end connection (NHEJ)/homologous recombination (HR)-related double strand breaks (DSBs) repairs to evade Cisplatin-resistance in non-small cell lung cancer (NSCLC). NHEJ inhibitor-1 inhibits the damage repair proteins Ku70 and Rad51 to make tumors re-sensitive to Cisplatin. NHEJ inhibitor-1 also induces ROS generation and MMP deduction .
|
-
- HY-170604
-
|
|
MMP
|
Cardiovascular Disease
Cancer
|
|
MMP-2 Inhibitor-4 (Compound 5g) is an MMP-2 inhibitor with an IC50 of 152.62 nM. MMP-2 Inhibitor-4 can reduce the levels of MMP-2 in the K562 cell line through stable binding at the MMP-2 active site, and it demonstrates strong antiangiogenic effects in the ACHN cell line. MMP-2 Inhibitor-4 holds promise for research in chronic myeloid leukemia (CML) .
|
-
- HY-172455
-
|
|
Potassium Channel
|
Neurological Disease
|
|
TREK inhibitor-3 (Cpd8l) is a selective and BBB-permeable TREK-1 inhibitor with an IC50 of 0.81 μM. TREK inhibitor-3 has neuroprotective effects, which can significantly reduce the death of cortical neurons induced by oxygen-glucose deprivation/reoxygenation (OGD/R) and improve brain injury in mice models of middle cerebral artery occlusion/reperfusion (MCAO/R). TREK inhibitor-3 can be used in the research of ischemic stroke .
|
-
- HY-147807
-
|
|
HIV
Cytochrome P450
|
Infection
|
|
HIV-1 inhibitor-40 (Compound 4ab) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV-1 with an EC50 of 1.9 nM. HIV-1 inhibitor-40 displays weak CYP sensitivity with IC50 values of 5.16 μM and 4.51 μM against CYP2C9 and CYP2C19, respectively. HIV-1 inhibitor-40 has no apparent in vivo acute toxicity .
|
-
- HY-169064
-
|
|
HIV
Reverse Transcriptase
|
Infection
|
HIV-1 inhibitor-75 is a human immunodeficiency virus 1 (HIV-1) inhibitor, with an EC50 value ranging from 0.0039 to 0.338 μM. The binding target of HIV-1 inhibitor-75 is reverse transcriptase, with an IC50 value of 0.055 μM. HIV-1 inhibitor-75 shows good in vitro metabolic stability, exhibiting moderate clearance rates and a longer half-life in human plasma and liver microsomes .
|
-
- HY-132291
-
|
|
HIV
|
Infection
|
|
HIV-1 inhibitor-8 is an orally active, low-toxicity and potent HIV‑1 non-nucleoside reverse transcriptase inhibitor (NNRTI). HIV-1 inhibitor-8 yields exceptionally potent antiviral activities (EC50=4.44~54.5 nM) against various HIV‑1 strains. The IC50 of HIV-1 inhibitor-8 against WT HIV-1 reverse transcriptase is 0.081 μM .
|
-
- HY-149976
-
|
|
Pim
|
Cancer
|
|
Pim-1 kinase inhibitor 4 (Compound 10f) is a Pim-1 kinase inhibitor (IC50: 17.01 nM). Pim-1 kinase inhibitor 4 also has antioxidant activity and inhibits DPPH. Pim-1 kinase inhibitor 4 induces apoptosis in PC-3 cell, and inhibits PC-3 cell growth with an IC50 of 16 nM. Pim-1 kinase inhibitor 4 can be used for research of prostate cancer .
|
-
- HY-170686
-
-
- HY-115926
-
|
|
Epigenetic Reader Domain
|
Cancer
|
|
BRD4 Inhibitor-16 (Compound 4) is a potent inhibitor of bromodomain 4 (BRD4). Overexpression of bromodomain 4 (BRD4) is closely correlated with a variety of human cancers by regulating the histone post-translational modifications. BRD4 Inhibitor-16 represents a useful tool for explorative studies of BRD4 inhibition, such as an improved understanding of BRD4 inhibitor release-related information .
|
-
- HY-144774
-
|
|
Topoisomerase
DNA/RNA Synthesis
Apoptosis
|
Cancer
|
|
Topoisomerase I inhibitor 5 is an effective topoisomerase inhibitor with IC50 value of. Topoisomerase I inhibitor 5 can interfere with DNA and significantly inhibit the activity of Topoisomerase I. Topoisomerase I inhibitor 5 can arrest cell cycle at the G1 phase and induce MCF-7 cells apoptosis. Topoisomerase I inhibitor 5 has potency in reversing P-gp-mediated resistance to Adriamycin .
|
-
- HY-161075
-
|
|
Microtubule/Tubulin
Ferroptosis
|
Cancer
|
|
Microtubule inhibitor 8 (MP-HJ-1b) is a potent inhibitor of microtubule. Microtubule inhibitor 8 triggers cell death through ferroptosis. Microtubule inhibitor 8 has anti-tumor effect .
|
-
- HY-129199
-
|
|
PGE synthase
|
Cardiovascular Disease
|
|
U-51605 is a platelet aggregation inhibitor and inhibits thromboxane synthesis. U-51605 is also a prostaglandin I2 synthase inhibitor and can inhibit the retinal vasodilation response induced by NO donors (such as NOR3) .
|
-
- HY-145020
-
|
|
Ras
|
Cancer
|
|
KRAS G12C inhibitor 23 is a KRAS G12C inhibitor. KRAS G12C inhibitor 23 inhibits H358 cells with an IC50 of 491 nM (WO2021218939A1, compound 1) .
|
-
- HY-N2117
-
-
- HY-131901
-
|
Oxophenylarsine; PhAsO; Arsenosobenzene
|
Phosphatase
|
Others
|
|
Phenylarsine oxide (PAO), an inhibitor of endocytosis, inhibits PTPε with an IC50 of 18 μM. Phenylarsine oxide (PAO) inhibits oxygen consumption and decreases cellular ATP content overlap with those used to inhibit protein internalization .
|
-
- HY-153401
-
|
|
Topoisomerase
|
Cancer
|
|
Topoisomerase II inhibitor 13 is a topoisomerase II (Topo II) inhibitor. Topoisomerase II inhibitor 13 shows antiproliferative activity against several cancer cells. Topoisomerase II inhibitor 13 induces cancer cells apoptosis .
|
-
- HY-149883
-
|
|
Others
|
Others
|
|
IZS-L is a amino acid-derived corrosion inhibitor. IZS-L exhibits corrosion inhibition performance for metal at longer immersion. IZSs, the series of corrosion inhibitors, inhibit mild steel corrosion through the formation of an inhibitor film on the metal surface .
|
-
- HY-153412
-
|
|
Ras
|
Cancer
|
|
KRAS inhibitor-22 (compound FB9/6B9) is a potent inhibitor of K-Ras. KRAS inhibitor-22 targets to Kras 4B(G12D) and (G12C), which can be used for cancer research .
|
-
- HY-146091
-
|
|
HIV
|
Infection
|
|
HIV-1 inhibitor-34 (compound 5q) is a potent and selective HIV-1 inhibitor with an EC50 of 6.4 nM for HIV-1 and a CC50 of 16 μM in MT-4 cells. HIV-1 inhibitor-34 can be used for researching AIDS .
|
-
- HY-149002
-
|
|
Topoisomerase
Apoptosis
|
Cancer
|
|
Topoisomerase I/II inhibitor 4 (compound F16) is a potent topoisomerase I (Topo I) and II (Topo II) dual inhibitor. Topoisomerase I/II inhibitor 4 inhibits cell proliferation, invasion and migration and induces apoptosis. Topoisomerase I/II inhibitor 4 can be used for liver cancer research .
|
-
- HY-112505
-
|
|
BCRP
|
Cancer
|
|
Efflux inhibitor-1 (compound 2) is a pyrazolo[1,5-a]pyrimidine efflux inhibitor. Efflux inhibitor-1 selectively targets toward ABCG2/BCRP over ABCB1 with IC50s of 0.45 μM and 2.17 μM, respectively .
|
-
- HY-148035
-
|
|
Parasite
|
Infection
|
|
Plm IV inhibitor-2 (compound 3) is a potent digestive vacuole plasmepsins IV (Plm IV) inhibitor with IC50 values of 24 nM, 70 nM and 0.3 μM for Plm IV, II and I, respectively. Plm IV inhibitor-2 can be used to research malaria caused by Plasmodium parasites .
|
-
- HY-147202
-
|
|
Epigenetic Reader Domain
|
Cancer
|
|
BRD4 Inhibitor-24 (compound 3U) is a potent BRD4 inhibitor, BRD4 Inhibitor-24 shows antitumor activity against MCF7 and K652 cells, with IC50 values of 33.7 and 45.9 μM, respectively (extracted from patent CN107721975A) .
|
-
- HY-122650
-
|
|
Autophagy
|
Cancer
|
|
PHY34 is an inhibitor that inhibits ATP6V0A2 and CAS thereby inhibiting autophagy, and has a nanomolar effect. PHY34 inhibits cancer cell growth by inducing apoptosis and inhibits tumor growth in xenograft models. PHY34 can be used for research on high grade serous ovarian cancer .
|
-
- HY-173483
-
|
|
Phosphodiesterase (PDE)
ERK
JNK
p38 MAPK
|
Inflammation/Immunology
|
|
ATX inhibitor 26 is an Autotaxin (ATX) inhibitor with an IC50 of 57 nM in human plasma. ATX inhibitor 26 inhibits cell migration and collagen gel contraction. ATX inhibitor 26 has significant anti-fibrotic effects, reducing collagen deposition in a Bleomycin (BLM) (HY-108345)-induced pulmonary fibrosis model .
|
-
- HY-144366
-
|
|
P-glycoprotein
|
Cancer
|
|
P-gp inhibitor 3 is an effective P-glycoprotein (P-gp) inhibitor. P-gp inhibitor 3 inhibits the efflux function of P-gp by activating P-gp ATPase. P-gp inhibitor 3 has relatively stronger multidrug resistance (MDR) reversal ability and enhances the anti-tumor activity of Paclitaxel .
|
-
- HY-112812
-
|
|
Stearoyl-CoA Desaturase (SCD)
|
Metabolic Disease
|
|
SCD1 inhibitor-1 (Compound 48) is an orally active and liver-selective inhibitor of stearoyl-CoA desaturase 1 (SCD1) with an IC50 of 8.8 nM for recombinant human SCD1 enzyme. SCD1 inhibitor-1 can be used in the study of diseases such as diabetes, hepatic steatosis and obesity .
|
-
- HY-146090
-
|
|
HIV
|
Infection
|
|
HIV-1 inhibitor-33 (compound 5n) is a potent and selective HIV-1 inhibitor with an EC50 of 8.6 nM for HIV-1 and a CC50 of 18 μM in MT-4 cells. HIV-1 inhibitor-33 can be used for researching AIDS .
|
-
- HY-145820
-
|
|
Apoptosis
Microtubule/Tubulin
|
Cancer
|
|
Tubulin inhibitor 14 is a potent NQO2 (quinone oxidoreductase 2) inhibitor with an IC50 of 1.0 μM. Tubulin inhibitor 14 also inhibits tubulin polymerization and the formation of endothelial cell capillary-like tubes. Tubulin inhibitor 14 is a microtubule-destabilizing agent with potential tumor-selectivity and antiangiogenic and vascular disrupting features .
|
-
- HY-150552
-
-
- HY-153594
-
-
- HY-15182
-
|
|
MMP
|
Cancer
|
|
Collagen proline hydroxylase inhibitor-1 is an antifibroproliferative agents.
|
-
- HY-126388
-
-
- HY-162854
-
|
|
Acyltransferase
|
Metabolic Disease
|
|
Diacylglycerol acyltransferase inhibitor-2 (Example 8) is an inhibitor of Diacylglycerol Acyl Transferase 2 (DGAT2) with an IC50 value of 3.7 nM .
|
-
- HY-161695
-
|
|
VEGFR
|
Cancer
|
|
Angiogenesis inhibitor 6 (Compound 8) is a non-tyrosine kinase inhibitor with effective antiangiogenic properties. Angiogenesis inhibitor 6 has antitumor activity .
|
-
- HY-W275048
-
-
- HY-169605
-
|
|
LIM Kinase (LIMK)
|
Cancer
|
|
LIMK1 inhibitor 1 (compound 24) is a LIMK1 inhibitor. LIMK1 inhibitor 1 can be used in anti-cancer research .
|
-
- HY-169505
-
|
|
Aurora Kinase
|
Cancer
|
|
Aurora kinase inhibitor-13 (Compound 2) is an inhibitor of Aurora kinase, with an IC50 value of 2.3 μM against Aurora kinase A .
|
-
- HY-135866
-
|
|
Ras
|
Cancer
|
|
KRAS inhibitor-8 is a potent KRAS G12C inhibitor, extracted from patent WO2017087528A1, compound C .
|
-
- HY-145946
-
-
- HY-173620
-
|
|
Carbonic Anhydrase
|
Infection
|
|
Carbonic anhydrase inhibitor 31 is a mtCA2 inhibitor (Ki: 5.2 nM). Carbonic anhydrase inhibitor 31 can be used in the research of anti-tuberculosis .
|
-
- HY-146643
-
-
- HY-151879
-
-
- HY-P2166A
-
|
|
MMP
|
Cancer
|
|
MMP3 inhibitor 3 (TFA) is an inhibitor of MMP3. MMP3 inhibitor 3 (TFA) can used to study breast cancer .
|
-
- HY-160859
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
WRN inhibitor 8 (Example 224) is a WRN helicase inhibitor with IC50 value of 48 nM. WRN inhibitor 8 can be used in cancer research .
|
-
- HY-135865
-
|
|
Ras
|
Cancer
|
|
KRAS inhibitor-7 is a potent KRAS G12C inhibitor, extracted from patent WO2017087528A1, compound B .
|
-
- HY-153706
-
-
- HY-147613
-
|
|
PI3K
mTOR
|
Cancer
|
|
PI3K/mTOR Inhibitor-6 (Compound 19c) is a potent and dual inhibitor of PI3K/mTOR. PI3K/mTOR Inhibitor-6 displays better stability in artificial gastric fluids than gedatolisib. PI3K/mTOR Inhibitor-6 significantly suppresses the PI3K/Akt/mTOR signaling pathway at 10 μM. PI3K/mTOR Inhibitor-6 has the potential for the research of cancer diseases .
|
-
- HY-169218
-
|
|
BCL6
|
Cancer
|
|
WK692 is a BCL6 inhibitor that inhibits the BCL6 BTB/SMRT interaction. WK692 can effectively inhibit the growth of diffuse large B-cell lymphoma cells and synergize with EZH2 and PRMT5 inhibitors. .
|
-
- HY-171647
-
|
|
Bacterial
Antibiotic
DNA/RNA Synthesis
|
Infection
|
|
RNAP-σ interaction inhibitor1 (compound 5d) is an inhibitor of RNA polymerase-sigma factors interaction. RNAP-σ interaction inhibitor-1 exhibits the activity against Streptococci with MIC values of 1-2 µg/mL .
|
-
- HY-149856
-
|
|
Microtubule/Tubulin
Apoptosis
|
Cancer
|
|
Tubulin inhibitor 33, a tubulin polymerization inhibitor, inhibits tubulin polymerization in a dose-dependent manner with an IC50 of 9.05 μM. Tubulin inhibitor 33 has antitumor effects and induces cell apoptosis that can be used for antitumor research .
|
-
- HY-143251
-
|
|
Microtubule/Tubulin
Apoptosis
|
Cancer
|
|
Tubulin inhibitor 13 (E27) is a potent tubulin inhibitor with an IC50 value of 16.1 μM for the tubulin polymerization inhibition. Tubulin inhibitor 13 inhibits migration and invasion of cancer cells, induces apoptosis and has anticancer activity .
|
-
- HY-17542
-
|
|
SARS-CoV
|
Infection
|
|
PLpro inhibitor is a potent inhibitor of papain-like protease (PLpro) with an IC50 of 2.6 µM . PLpro inhibitor inhibits SARS-CoV-2 PLpro with an IC50 of 5.0 µM and an EC50 of 21.0 µM .
|
-
- HY-157483
-
|
|
P-glycoprotein
|
Cancer
|
|
P-gp inhibitor 18 (compound 6G) is a potent inhibitor of P-gp. P-gp inhibitor 18 inhibits rhodamine 123 efflux in the P-gp overexpressed leukemia cells, K562/Dox .
|
-
- HY-112607
-
|
|
Microtubule/Tubulin
Apoptosis
|
Cancer
|
|
Tubulin inhibitor 1 is a tubulin inhibitor, inhibits tubulin polymerization. Tubulin inhibitor 1 shows potent anti-tumor activity, casues cellular mitotic arrest in the G2/M phase, and induces cellular apoptosis .
|
-
- HY-114317
-
|
|
MARK
AMPK
Apoptosis
|
Cancer
|
|
MARK4 inhibitor 1 is a potent and selective microtubule affinity-regulating kinase 4 (MARK4) inhibitor, with an IC50 of 1.54 μM. MARK4 inhibitor 1 inhibits cancer cell proliferation, metastasis and induces apoptosis .
|
-
- HY-150238S
-
|
|
Isocitrate Dehydrogenase (IDH)
|
Cancer
|
|
IDH1 Inhibitor 7-d2 is the deuterium labeled IDH1 Inhibitor 7 (HY-150238). IDH1 Inhibitor 7 is an IDH1 inhibitor with an IC50 of less than 100 nM .
|
-
- HY-170656
-
|
|
PI3K
mTOR
|
Cancer
|
|
PI3K/mTOR Inhibitor-17 (compound 5nh) is a potent inhibitor of PI3K/mTOR, with the inhibitor of 0.45 and 2.9 nM for PI3Kα and mTOR, respectively. PI3K/mTOR Inhibitor-17 plays an important role in cancer research .
|
-
- HY-146504
-
|
|
Topoisomerase
PI3K
Apoptosis
Reactive Oxygen Species
|
Cancer
|
|
Topoisomerase I/II inhibitor 3 (compound 7) is a potent topoisomerase I (Topo I) and II (Topo II) dual inhibitor. Topoisomerase I/II inhibitor 3 can inhibit cell proliferation, invasion and migration, and induce apoptosis by inhibiting PI3K/Akt/mTOR signaling pathway. Topoisomerase I/II inhibitor 3 can be used for liver cancer research .
|
-
- HY-158618
-
|
|
Aurora Kinase
Apoptosis
|
Cancer
|
|
Aurora kinase inhibitor-14 (Compound 79) is an orally active and highly selective inhibitor of Aurora kinases with IC50 values of 0.5 nM and 1.2 nM for Aurora A and Aurora B, respectively. Aurora kinase inhibitor-14 binds to the ATP-binding site of Aurora kinases to block chromosome segregation during mitosis and induce apoptosis in tumor cells. Aurora kinase inhibitor-14 is promising for research of various solid tumors and hematological malignancies, such as non-small cell lung cancer, breast cancer, and acute myeloid leukemia .
|
-
- HY-152238
-
|
|
PI3K
mTOR
|
Cancer
|
|
PI3K/mTOR Inhibitor-12 is a potent, orally active and selective PI3K/mTOR inhibitor with IC50 values of 0.06 nM and 3.12 nM for PI3Kα and mTOR, respectively. PI3K/mTOR Inhibitor-12 has antitumor activity. PI3K/mTOR Inhibitor-12 has lower liver toxicity .
|
-
- HY-146352
-
|
|
HIV
|
Infection
Inflammation/Immunology
|
|
HIV-1 inhibitor-28 (compound 14j2) is a highly potent and selective HIV-1 inhibitor with an EC50 of 58 nM for WT HIV-1 strain and an IC50 of 3.37 μM for HIV-1 WT reverse transcription (RT). HIV-1 inhibitor-28 exhibits relatively low cytotoxicity in MT-4 cells (CC50 = 38.6 μM). HIV-1 inhibitor-28 can be used for researching AIDS .
|
-
- HY-146339
-
|
|
HIV
|
Infection
Inflammation/Immunology
|
|
HIV-1 inhibitor-27 (compound 5) is a potent HIV-1 inhibitor with IC50s of 16 μM, 0.5 μM and 0.39 μM for HIV-1 YU2, NL4-3 and 89.6 strain, respectively. HIV-1 inhibitor-27 has low cytotoxicity with a CC50 of 128 μM in TZM-bl cells. HIV-1 inhibitor-27 can be used for researching AIDS .
|
-
- HY-32018
-
|
|
MAP3K
|
Cancer
|
|
Cot inhibitor-2 is a potent, selective and orally active cot (Tpl2/MAP3K8) inhibitor with an IC50 of 1.6 nM. Cot inhibitor-2 inhibts TNF-α production in LPS-stimulated human whole blood with an IC50 of 0.3 μM .
|
-
- HY-160656
-
|
|
5-HT Receptor
|
Neurological Disease
|
|
5-HT/NA Reuptake inhibitor-1 (compound 9) is a selective dual 5-HT and NA reuptake inhibitor with IC50 of 660 nM and 70 nM respectively. . 5-HT/NA Reuptake inhibitor-1 has good in vitro human metabolic stability, hERG selectivity and passive membrane permeability .
|
-
- HY-137918
-
|
|
Src
TGF-β Receptor
Anaplastic lymphoma kinase (ALK)
|
Others
|
|
TGF-βRI inhibitor 3 (Compound 9ac) is a selective TGF-β inhibitor. TGF-βRI inhibitor 3 can effectively inhibit the TGF-β signaling pathway. TGF-βRI inhibitor 3 has IC50 values of 13 μM and 0.63 μM for c-Src kinase and ALK5 kinase, respectively .
|
-
- HY-151421
-
|
|
Fungal
|
Infection
Cancer
|
|
Chitin synthase inhibitor 11 is a chitin synthase inhibitor. Chitin synthase inhibitor 11 shows excellent chitin synthase inhibitory activity with an IC50 value of 0.10 mM. Chitin synthase inhibitor 11 has broad-spectrum antifungal activity in vitro. Chitin synthase inhibitor 11 can be used for the research of invasive fungal infections (IFIs) .
|
-
- HY-143420
-
|
|
Phosphodiesterase (PDE)
|
Inflammation/Immunology
|
|
ATX inhibitor 15 (compound 30), a indole-based carbamate derivative, is a potent autotaxin (ATX) inhibitor with an IC50 of 2.17 nM. ATX inhibitor 15 inhibits in vivo ATX and the gene expression of pro-fibrotic factors. ATX inhibitor 15 has lung protection effects in Bleomycin challenged mice lung fibrosis model .
|
-
- HY-162380
-
|
|
Topoisomerase
|
Cancer
|
|
Topoisomerase II inhibitor 18 (Compound IV) is a Quinoxaline derivative, which inhibits topoisomerase II with IC50 of 7.5 μM. Topoisomerase II inhibitor 18 inhibits proliferation, cell cycle at S phase and induces apoptosis in PC-3 cells. Topoisomerase II inhibitor 18 reveals antitumor activity against cancer .
|
-
- HY-160030
-
|
|
IAP
|
Cancer
|
|
XIAP BIR2/BIR2-3 inhibitor-3 is a dual inhibitor of BIR2 and BIR2-3 with IC50s less than 1 nM. XIAP BIR2/BIR2-3 inhibitor-3 can used in study cancers .
|
-
- HY-147734
-
|
|
Calcium Channel
|
Cancer
|
|
Calpain Inhibitor-2 (compound 5) is a peptide inhibitor of μ-calpain (Ki=9 nM). Calpain Inhibitor-2 exhibits antiproliferative activity against melanoma cell lines (A-375 and B-16F1) and PC-3 prostate cancer cells in vitro .
|
-
- HY-112390B
-
|
|
Syk
5-HT Receptor
|
Inflammation/Immunology
|
|
Syk Inhibitor II dihydrochloride dihydrate is a potent, high selective and ATP-competitive Syk inhibitor with an IC50 of 41 nM. Syk Inhibitor II dihydrochloride dihydrate inhibits 5-HT release from RBL-cells with an IC50 of 460 nM. Syk Inhibitor II dihydrochloride dihydrate shows less potent against other kinases and has anti-allergic effect .
|
-
- HY-147727
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
Microtubule inhibitor 6 (compound 17o) is a potent microtubule inhibitor. Microtubule inhibitor 6 shows cytotoxicity with IC50s of 14.0, 6.6, 7.0 nM for NCI-H460, BxPC-3, HT-29 cells, respectively. Microtubule inhibitor 6 efficiently inhibits microtubule polymerization .
|
-
- HY-126328
-
|
|
PKC
|
Inflammation/Immunology
|
|
PKC-theta inhibitor 1 is the PKCθ inhibitor with an Ki value of 6 nM, inhibits IL-2 production in vivo with an IC50 of 0.19 μM. PKC-theta inhibitor 1 demonstrates a reduction of symptoms in a mouse model of multiple sclerosis .
|
-
- HY-150983
-
|
|
ATP Synthase
Bacterial
|
Infection
|
|
ATP synthase inhibitor 2 is a Pseudomonas aeruginosa (PA) ATP synthase inhibitor (IC50=10 μg/mL). ATP synthase inhibitor 2 can inhibit Pseudomonas aeruginosa (PA) ATP synthesis activity completely at 128 μg/mL .
|
-
- HY-143461
-
|
|
Casein Kinase
|
Cancer
|
|
CK2 inhibitor 3 is a potent CK2 inhibitor with IC50 value of 280 nM. CK2 inhibitor 3 inhibits endocellular CK2, significantly affects viability of tumour cells and shows remarkable selectivity on a panel of 320 kinases .
|
-
- HY-147726
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
Microtubule inhibitor 5 (compound 17f) is a potent microtubule inhibitor. Microtubule inhibitor 5 shows cytotoxicity with an IC50 value of 154.5 nM for NCI-H460 cells. Microtubule inhibitor 5 shows good cell permeability .
|
-
- HY-171295
-
|
|
p38 MAPK
|
Inflammation/Immunology
|
|
p38 Kinase inhibitor 7 (Comp:XXXIX) is the inhibitor for p38α with an IC50 of 5.25 nM. p38 Kinase inhibitor 7 inhibits TNFα production in cell THP-1 with an IC50 of 5.88 nM .
|
-
- HY-146205
-
|
|
Phosphodiesterase (PDE)
|
Cardiovascular Disease
|
|
ATX inhibitor 18 is a potent ATX inhibitor with an IC50 value of 24.2 nM. ATX inhibitor 18 shows antiproliferative activity and anti-fibrosis activity. ATX inhibitor 18 suppresses collagen deposition in TGF-β-mediated cardiac fibrosis .
|
-
- HY-153752
-
|
|
Ser/Thr Protease
|
Cancer
|
|
TAO Kinase inhibitor 2 (Example 49) is a TAO Kinase inhibitor (IC50=between 50 and 500 nM). TAO Kinase inhibitor 2 also inhibits KIAA1361 and JIK with IC50s of 50-500 nM .
|
-
- HY-153593
-
|
|
Epigenetic Reader Domain
|
Cancer
|
BET bromodomain inhibitor 3 is BET bromodomain inhibitor. BET bromodomain inhibitor 3 has inhibitory effect against BrdT with Ki value of > 40 µM. BET bromodomain inhibitor 3 can be used for the research of contraception, cancer, and heart disease .
|
-
- HY-162294
-
|
|
c-Myc
|
Cancer
|
|
c-Myc inhibitor 13 (compound A6) is a c-MYC transcription inhibitor. c-Myc inhibitor 13 selectively stabilizes c-MYC G4 and inhibits G4-associated c-MYC transcription .
|
-
- HY-109023
-
|
|
Others
|
Others
|
|
Azeloprazole is a compound used to inhibit acid-related diseases. It is a proton pump inhibitor that inhibits H +,K --ATPase in pig gastric vesicles. It can effectively inhibit gastric acid secretion in the dog's gastric fistula model. The effect is long-lasting and superior to esomeprazole.
|
-
- HY-160636
-
|
|
Epigenetic Reader Domain
|
Others
|
|
BRD4 Inhibitor-32 (example 15) is a BRD4 inhibitor that can be used in acute kidney disease and chronic kidney disease research .
|
-
- HY-160215A
-
|
|
TGF-β Receptor
|
Cancer
|
|
TGF-βRI inhibitor 1 (compoimd i) methylbenzenesulfonate is a TGF-βRI inhibitor. TGF-βRI inhibitor 1 methylbenzenesulfonate can be used for cancer research .
|
-
- HY-15002
-
AST 487
5 Publications Verification
NVP-AST 487
|
RET
FLT3
VEGFR
c-Kit
Bcr-Abl
|
Cancer
|
|
AST 487 is a RET kinase inhibitor with IC50 of 880 nM, inhibits RET autophosphorylation and activation of downstream effectors, also inhibits Flt-3 with IC50 of 520 nM.
|
-
- HY-W100403
-
|
Choline p-toluenesulfonate
|
Phospholipase
|
Cancer
|
|
Choline tosylate is a nucleophilic compound that inhibits phospholipase A2 and phospholipase C. Choline tosylate inhibits tumor growth in mice by inhibiting the formation of diacylglycerol (DAG) .
|
-
- HY-128133
-
|
MMP8-I
|
MMP
|
Cancer
|
|
MMP-8 inhibitor-1 (compound 21), a hydroxamic acid derivative, is a potent MMP-8 inhibitor without significant oral bioavailability .
|
-
- HY-109151
-
|
E6007
|
Others
|
Inflammation/Immunology
|
|
Milategrast is useful as cell adhesion inhibitor or cell infiltration inhibitor. Milategrast in vitro inhibites the adhesion of Jurkat cells to human fibronectin with an IC50 of ＜5 μM .
|
-
- HY-132196
-
|
|
Btk
|
Inflammation/Immunology
|
|
BTK inhibitor 18 is a potent, selective,orally active and covalent Btk inhibitor with a IC50 of 142 nM. BTK inhibitor 18 has anti-inflammatory activities .
|
-
- HY-111408
-
|
|
Deubiquitinase
|
Cancer
|
|
EOAI3402143 is a deubiquitinase (DUB) inhibitor, which inhibits dose-dependently inhibits Usp9x/Usp24 and Usp5.
|
-
- HY-160660
-
|
|
Epigenetic Reader Domain
|
Others
|
|
BRD4 Inhibitor-33 (example 13) is a BRD4 inhibitor that can be used in acute kidney disease and chronic kidney disease research .
|
-
- HY-112914
-
|
|
mTOR
Autophagy
|
Cancer
|
|
mTOR inhibitor-1 (Compound C-4) is an ATP-Competitive mTOR inhibitor which can suppress cells proliferation and inducing autophagy .
|
-
- HY-N2033
-
-
- HY-122098
-
|
PAI-749
|
PAI-1
|
Cardiovascular Disease
|
|
Diaplasinin (PAI-749) is a plasminogen activator inhibitor-1 (PAI-1) inhibitor with IC50 of 295 nM. Diaplasinin has antithrombotic efficacy .
|
-
- HY-100463
-
-
- HY-136717
-
|
|
FBPase
|
Metabolic Disease
|
|
FBPase-1 inhibitor-1 (compound 1) is a allosteric inhibitor of fructose-1,6-bisphosphatase (FBPase-1) .
|
-
- HY-41648
-
-
- HY-176139
-
|
|
URAT1
|
Inflammation/Immunology
|
|
URAT1 inhibitor 13 (compound 22k) is a potent URAT1 inhibitor. URAT1 inhibitor 13 can be used in the study of gout .
|
-
- HY-136813
-
|
|
Beta-secretase
Amyloid-β
Cholinesterase (ChE)
|
Neurological Disease
|
Multitarget AD inhibitor-1 is a selective and reversible butyrylcholinesterase (BuChE) inhibitor with IC50s of 7.22 μM and 1.55 μM for hBuChE and eqBuChE (BuChE from equine serum), respectively. Multitarget AD inhibitor-1 inhibits β-secretase (IC50hBACE-1=41.60 μM), amyloid β aggregation (IC50Aβ=3.09 μM), tau aggregation. Multitarget AD inhibitor-1, a diphenylpropylamine derivative, has the potential for multifunctional disease-modifying anti-Alzheimer’s research .
|
-
- HY-142644
-
-
- HY-104051
-
-
- HY-168592
-
-
- HY-P10117
-
-
- HY-143730
-
|
|
Btk
|
Cancer
|
|
BTK inhibitor 20 is a potent BTK inhibitor with an IC50 of 8 nM .
|
-
- HY-U00065
-
-
- HY-110243
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
CAIX Inhibitor S4 is a potent and selective inhibitor of carbonic anhydrase IX/XII (CA IX/XII), with a Ki of 7 nM and 2 nM, respectively. CAIX Inhibitor S4 also inhibits CA II and CA I (Ki=546 and 5600 nM, respectively). CAIX Inhibitor S4 can inhibit the number of lung metastasis in orthotopic MDA-MB-231 mouse model without affecting primary tumor growth .
|
-
- HY-162447
-
|
|
P-glycoprotein
Apoptosis
|
Cancer
|
|
P-gp inhibitor 22 is a P-glycoprotein (P-gp) inhibitor that effectively inhibits P-pg and efflux function. P-gp inhibitor 22 induces apoptosis and accumulation of MCF-7/ADR cells processed in the S phase .
|
-
- HY-124871
-
|
|
Arenavirus
|
Infection
|
|
LASV inhibitor 3.3 is a Lassa fever virus (LASV) inhibitor. LASV inhibitor 3.3 binds with LASV glycoprotein (GP) and promotes virus membrane fusion and infection. LASV inhibitor 3.3 can be used for LASV infection research .
|
-
- HY-104032
-
|
|
RSV
|
Infection
Metabolic Disease
|
|
Ac-CoA Synthase Inhibitor1 is a potent, reversible acetate-dependent acetyl-CoA synthetase 2 (ACSS2) inhibitor with an IC50 of 0.6 µM . Ac-CoA Synthase Inhibitor1 inhibits the respiratory syncytial virus (RSV) .
|
-
- HY-157954
-
|
|
DNA/RNA Synthesis
Apoptosis
|
Cancer
|
|
WRN inhibitor 6 (compound 3ci) is a potent WRN inhibitor. WRN inhibitor 6 induces apoptosis. WRN inhibitor 6 increases the expression of p-p53, P-Chk2, γH2AX expression .
|
-
- HY-10172
-
|
IKK2 Inhibitor V
|
IKK
|
Cancer
|
|
IMD-0354 (IKK2 Inhibitor V) is a selective IKKβ inhibitor which inhibits NF-κB activity . IMD0354 inhibits TNF-α induced NF-κB transcription activity with an IC50 of 1.2 uM .
|
-
- HY-125257
-
|
LY6
|
SHP2
Phosphatase
|
Cancer
|
|
SHP2 inhibitor LY6 (LY6) is potent and selective inhibitor of SHP2, with an IC50 of 9.8 µM. SHP2 inhibitor LY6 can inhibits SHP2-mediated cell signaling and proliferation .
|
-
- HY-163720
-
|
|
Ras
Apoptosis
|
Cancer
|
|
KRAS G12C inhibitor 63 (K45) is a KRAS G12C inhibitor. KRAS G12C inhibitor 63 can induce Apoptosis. KRAS G12C inhibitor 63 has antitumor activity .
|
-
- HY-N1504
-
|
|
PAI-1
Potassium Channel
ERK
JNK
|
Metabolic Disease
|
|
Loureirin B, a flavonoid extracted from Dracaena cochinchinensis, is an inhibitor of plasminogen activator inhibitor-1 (PAI-1), with an IC50 of 26.10 μM; Loureirin B also inhibits KATP, the phosphorylation of ERK and JNK, and has anti-diabetic activity.
|
-
- HY-112355
-
|
|
Aurora Kinase
|
Cancer
|
|
Aurora kinase inhibitor-2 is a selective and ATP-competitive Aurora kinase inhibitor with IC50s of 310 nM and 240 nM for Aurora A and Aurora B, respectively .
|
-
- HY-152150
-
|
|
Ser/Thr Protease
|
Metabolic Disease
|
|
Thrombin inhibitor 7 is a potent FXIIa inhibitor with IC50 values of 28 nM, >132 µM for FXIIa and FXIa, respectively. Thrombin inhibitor 7 shows low cytotoxicity .
|
-
- HY-142853
-
|
|
Carbonic Anhydrase
|
Endocrinology
|
|
Carbonic anhydrase inhibitor 3 (compound 11g) is a carbonic anhydrase II inhibitor. Carbonic anhydrase inhibitor 3 reduces the intraocular pressure in glaucomatous rabbits .
|
-
- HY-142849
-
|
|
Carbonic Anhydrase
|
Endocrinology
|
|
Carbonic anhydrase inhibitor 1 (compound 7c) is a carbonic anhydrase II inhibitor. Carbonic anhydrase inhibitor 3 reduces the intraocular pressure in glaucomatous rabbits .
|
-
- HY-131705
-
|
|
Btk
|
Inflammation/Immunology
|
|
BTK inhibitor 17 is a potent and orally active irreversible BTK inhibitor with an IC50 of 2.1 nM. BTK inhibitor 17 can be used for rheumatoid arthritis research .
|
-
- HY-149498
-
-
- HY-P1026
-
-
- HY-153743
-
|
|
ROS Kinase
Trk Receptor
|
Cancer
|
|
Protein kinase inhibitor 4 (Compound 3) is a protein kinase inhibitor that inhibits TRK-A and ROS1 (IC50=3.0 nM and 104 nM respectively) .
|
-
- HY-101959A
-
|
|
Ser/Thr Protease
|
Cancer
|
|
Tyrphostin 47 is a nonspecific inhibitor of WNK1. Tyrphostin 47 is a protein tyrosine kinase inhibitor. Tyrphostin 47 inhibits smooth-muscle cell proliferation
|
-
- HY-114509
-
|
|
Bacterial
|
Infection
Metabolic Disease
|
|
Anilazine is a fungicide and inhibit the growth of Rhizobium sp. and E. coli. Anilazine inhibits glucose oxidation and succinate oxidation and also inhibits in vitro succinic dehydrogenase activity .
|
-
- HY-19990
-
-
- HY-10217
-
|
|
Thrombin
|
Cardiovascular Disease
|
|
Thrombin Inhibitor 2 is a small molecule direct thrombin inhibitor, extracted from US8541580B2.
Thrombin Inhibitor 2 has antithrombotic activity .
|
-
- HY-123955
-
|
|
Casein Kinase
CDK
Apoptosis
|
Cancer
|
|
Casein Kinase inhibitor A86 is a potent and orally active casein kinase 1α (CK1α) inhibitor. Casein Kinase inhibitor A86 also inhibits of CDK7 (TFIIH) and CDK9 (P-TEFb). Casein Kinase inhibitor A861 induces leukemia cell apoptosis, and has potent anti-leukemic activities .
|
-
- HY-146672
-
|
|
Itk
|
Cancer
|
|
ITK inhibitor 6 (compound 43) is a potent and selective ITK inhibitor with IC50s of 4 nM, 133 nM, 320 nM, 2360 nM, 155 nM for ITK, BTK, JAK3, EGFR, LCK, respectively. ITK inhibitor 6 inhibits phosphorylation of PLCγ1 and ERK1/2. ITK inhibitor 6 shows antiproliferative activities .
|
-
- HY-151985
-
|
|
Apoptosis
|
Cancer
|
|
TACC3 inhibitor 1 is a potent and cross the blood-brain barrier TACC3 inhibitor. TACC3 inhibitor 1 induces Apoptosis and cell cycle arrest at G2/M phase. TACC3 inhibitor 1 induces the generation of intracellular ROS. TACC3 inhibitor 1 shows antiproliferative and anti-tumor activity .
|
-
- HY-139606
-
|
|
p97
|
Cancer
|
|
VCP/p97 inhibitor-1 is a potent inhibitor of VCP/p97 (also called Cdc48, CDC-. 48, or Ter94) with an IC50 of 54.7 nM. VCP/p97 inhibitor-1 causes the dysregulation of protein homeostasis and disturbs the degradation of misfolded polypeptides by the ubiquitin-proteasome system (UPS) .
|
-
- HY-128729
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
DNA2 inhibitor C5 is a potent, competitive, and specific DNA2 nuclease inhibitor with an IC50 of 20 μM. DNA2 inhibitor C5 inhibits the nuclease, DNA-dependent ATPase, helicase, and DNA-binding activities of DNA2. DNA2 inhibitor C5 can be used in breast cancer and colorectal cancer research .
|
-
- HY-143265
-
|
|
Topoisomerase
Apoptosis
Caspase
|
Cancer
|
|
Topoisomerase I inhibitor 2 (ZML-8) is a highly selective inhibitor of DNA topoisomerase I (Top1). Topoisomerase I inhibitor 2 inhibits Top1 activity and results DNA damage. Topoisomerase I inhibitor 2 blocks G2/M phase and induces apoptosis, exhibits anti-tumor effect .
|
-
- HY-151434
-
|
|
Glutaminase
Apoptosis
|
Cancer
|
|
GLS1 Inhibitor-6 (Compound 24y) is an orally active, potent and selective glutaminase 1 (GLS1) inhibitor (IC50=68 nM), shows 220-fold selectivity for GLS2. GLS1 Inhibitor-6 shows good anti-tumor activity, antitumor cell proliferation activity and induces apoptosis .
|
-
- HY-107662
-
|
|
Apoptosis
|
Infection
Cancer
|
|
TCS PrP Inhibitor 13, an antiprion agent, is a cellular prion protein (PrP C) inhibitor. TCS PrP Inhibitor 13, as a protease-resistant form of prion protein (PrP-res) accumulation inhibitor, shows an IC50 value of 3 nM in both ScN2a and F3 cell lines. TCS PrP Inhibitor 13 induces Schwannoma cells apoptosis .
|
-
- HY-163119
-
|
|
Pim
|
Cancer
|
|
Pim-1 kinase inhibitor 9 (compound 8b) is a selective inhibitor against Pim-1 kinase with IC50 value of 0.24 µM. Pim-1 kinase inhibitor 9 inhibits cell cycle of T47D at S phase. Pim-1 kinase inhibitor 9 reveals antitumor activity .
|
-
- HY-148396
-
|
|
DNA/RNA Synthesis
|
Infection
Cancer
|
|
UCK2 Inhibitor-3 is a non-competitive inhibitor of uridine-cytidine kinase 2 (UCK2, a pyrimidine salvage enzyme) with an IC50 value of 16.6 μM. UCK2 can replace dihydroorotate dehydrogenase (DHODH), in a certain extent, in infected or rapidly dividing cells to continue efficient uridine salvage. UCK2 Inhibitor-3 also inhibits DNA polymerase eta and kappa with IC50s of 56 μM and 16 μM .
|
-
- HY-151595
-
|
|
Epigenetic Reader Domain
|
Cancer
|
|
Menin-MLL inhibitor-22 (compound C20) is an orally active inhibitor of the interaction between menin and mixed lineage leukemia (MLL) (IC50=7 nM). Menin-MLL inhibitor-22 binds menin protein and inhibits cancer cell growth (MV4 cells, IC50=0.3 μM). Menin is a putative tumor suppressor associated with multiple endocrine neoplasia type 1 (MEN-1 syndrome) .
|
-
- HY-119621
-
|
|
β-glucuronidase
DNA/RNA Synthesis
Apoptosis
|
Cancer
|
|
Aceglatone, an antineoplastic agent, is a β-glucuronidase inhibitor. Aceglatone is a compound that inhibits colon carcinogenesis and prevents the induction of colon cancer by inhibiting the hydrolysis of glucuronides. Aceglatone reduces cell proliferation, induces apoptosis and inhibits DNA synthesis in human colon cancer cells .
|
-
- HY-151432
-
|
|
URAT1
|
Inflammation/Immunology
|
|
URAT1 inhibitor 3 is a potent, orally active, selective URAT1 inhibitor with an IC50 value of 0.8 nM. URAT1 inhibitor 3 has urate-lowering efficacy. URAT1 inhibitor 3 can be used in research of gout and hyperuricemi .
|
-
- HY-169730
-
|
|
Wnt
|
Cancer
|
|
Wnt pathway inhibitor 5 (Compound 28) is wnt pathway inhibitor, with an IC50 value of < 0.003 μΜ. Wnt pathway inhibitor 5 inhibits many cancers, including ovarian teratocarcinoma cancer, breast cancer, osteosarcoma, head and neck squamous carcinoma .
|
-
- HY-168008
-
|
|
P-glycoprotein
|
Cancer
|
|
P-gp inhibitor 25 (compound 16c) is a P-gp inhibitor. P-gp inhibitor 25 can enhance the oral absorption of paclitaxel (HY-B0015). P-gp inhibitor 25 can be used in anti-cancer research .
|
-
- HY-112475
-
|
|
Tie
FLT3
|
Cancer
|
|
Flt-3 Inhibitor III is a potent and selective FLT3 kinase inhibitor with an 50 of 50 nM. Flt-3 Inhibitor III shows less active against other kinases. Flt-3 Inhibitor III has anticancer effects .
|
-
- HY-122709
-
|
|
Glutaminase
|
Cancer
|
|
hTG2 inhibitor VA4 (compound VA4) is an irreversible Type 2 transglutaminase (TG2) inhibitor. hTG2 inhibitor VA4 reacts exclusively at the TG2 transamidase site, inhibits both transamidase and GTP-binding activities .
|
-
- HY-118168
-
|
Galosfen
|
Topoisomerase
|
Others
|
|
A9387 is an inhibitor of the Tn3 Resolvase, which promotes site-specific recombination reactions between two directly repeated recombination sites. Several inhibitors have been isolated that inhibit this event. A9387 inhibits the binding of resolvase to the res site .
|
-
- HY-P3199
-
|
|
PKC
|
Inflammation/Immunology
|
|
PKCβII Peptide Inhibitor I is a PKCβII inhibitor. PKCβII Peptide Inhibitor I shows cardioprotective effects in rat cardiac Ischemia/reperfusion injury model. PKCβII Peptide Inhibitor I also prevents vascular endothelial dysfunction .
|
-
- HY-149364
-
|
|
Microtubule/Tubulin
Apoptosis
|
Cancer
|
|
Tubulin inhibitor 34 (compound b5) is a potent anticancer agent. Tubulin inhibitor 34 can inhibit tubulin polymerization and induce G2/M arrest and apoptosis. Tubulin inhibitor 34 exhibits significant antivascular and antitumor activity .
|
-
- HY-168036
-
|
|
PIN1
Ligands for Target Protein for PROTAC
|
Cancer
|
|
PIN1 inhibitor 3 (Compound A0) is a PIN1 inhibitor, with a KD of 25 nM and an IC50 of 150 nM. PIN1 inhibitor 3 can be used as a target protein ligand for the synthesis of PROTAC. PIN1 inhibitor 3 can be utilized in cancer research .
|
-
- HY-169106
-
|
|
Topoisomerase
Apoptosis
|
Cancer
|
|
Topoisomerase inhibitor 4 (compound 45) is a potent Topoisomerase1/2 inhibitor. Topoisomerase inhibitor 4 causes cell cycle arrest in the G2/M phase by inducing Apoptosis. Topoisomerase inhibitor 4 has antitumor activity .
|
-
- HY-146353
-
|
|
HIV
|
Infection
Inflammation/Immunology
|
|
HIV-1 inhibitor-29 (compound 14d2) is a potent HIV-1 inhibitor with an EC50 of 2.18 μM for HIV-1 IIIB. HIV-1 inhibitor-29 has high anti-resistance profile toward F227L/V106A strain (EC50 = 0.974 μM), and exhibits low cytotoxicity in MT-4 cells (CC50 = 211 μM). HIV-1 inhibitor-29 can be used for researching AIDS .
|
-
- HY-149509
-
|
|
α-synuclein
|
Neurological Disease
|
|
α-Synuclein inhibitor 9 (Compound 20C) is an α-Synuclein inhibitor. α-Synuclein inhibitor 9 binds to cavities in mature α-synuclein fibrils and reduces the β-sheet structure. α-Synuclein inhibitor 9 inhibits A53T α-Syn aggregation. α-Synuclein inhibitor 9 has neuroprotective effect, improves brain functional connection and relieves motor dysfunction.α-Synuclein inhibitor 9 can be used for Parkinson’s disease (PD) research. .
|
-
- HY-144122
-
|
|
HIV
|
Infection
|
|
HIV-1 inhibitor-15 (compound 9d) is a highly potent and broad-spectrum HIV-1 inhibitor. HIV-1 inhibitor-15 has inhibitory activity against HIV-1 WT, L100I, K103N, Y181C, E138K with EC50s of 1.7 nM, 4 nM, 2 nM, 6 nM and 9 nM, respectively. HIV-1 inhibitor-15 has good solubility, safety profiles and favorable oral bioavailability .
|
-
- HY-44153
-
|
|
Potassium Channel
|
Neurological Disease
|
|
KV2 channel inhibitor-1 is a selective KV2 channel inhibitor with IC50s of 0.2 μM and 0.41 μM for KV2.1 and KV2.2, respectively. KV2 channel inhibitor-1 possesses good selectivity over KV1.2 (IC50>10 μM). KV2 channel inhibitor-1 is >10-fold selective over NaV channels and other KV channels and displays weak activity on CaV channels .
|
-
- HY-172807
-
|
|
p38 MAPK
MAPKAPK2 (MK2)
CDK
Wee1
|
Cancer
|
|
p38α inhibitor 9 (Compound 2015) is a p38α inhibitor and blocks p38α’s enzymatic activity with an IC50 lower than 20 nM. p38α inhibitor 9 inhibits MK2 T334 phosphorylation. p38α inhibitor 9 activates Cdc25b and Cdc25c and simultaneously inactivates Wee1, leading to mitotic catastrophe, aneuploidy or polyploidy and DNA damage. p38α inhibitor 9 Inhibits colorectal cancer (CRC) metastasis .
|
-
- HY-131473
-
-
- HY-122127
-
|
|
Others
|
Others
|
|
Acetobixan is a potent cellulose biosynthesis inhibitor. Acetobixan inhibits cellulose biosynthesis .
|
-
- HY-119692
-
-
- HY-10249A
-
|
|
Akt
|
Cancer
|
|
AKT Kinase Inhibitor is an Akt kinase inhibitor with anti-tumor activity .
|
-
- HY-145151
-
|
|
TRP Channel
|
Others
|
|
The compound inhibits TRPC proteins, and more specifically inhibits the TRPC6 protein.
|
-
- HY-B0884
-
-
- HY-B0884A
-
-
- HY-131005
-
-
- HY-B0552A
-
|
Cinchocaine hydrochloride
|
Sodium Channel
|
Neurological Disease
|
|
Dibucaine hydrochloride (Cinchocaine hydrochloride) is a sodium channel inhibitor. Dibucaine hydrochloride is a potent SChE inhibitor .
|
-
- HY-156648A
-
-
- HY-142655
-
-
- HY-N5048
-
|
6'-O-Galloyl paeoniflorin
|
NF-κB
|
Others
|
|
Galloylpaeoniflorin is a NF-κB inhibitor . And Galloylpaeoniflorin is a inhibitor of DNA cleavage .
|
-
- HY-156648
-
|
|
Others
|
Metabolic Disease
|
|
Vamagloxistat is glycolate oxidase inhibitor, used to inhibit hyperoxaluria and kidney stones .
|
-
- HY-U00410
-
-
- HY-B0552
-
-
- HY-134851
-
|
|
HIV
|
Infection
|
|
HIV-1 inhibitor-6 (compound 9), a diheteroarylamide-based compound, is a potent HIV-1 pre-mRNA alternative splicing inhibitor. HIV-1 inhibitor-6 blocks HIV replication. HIV-1 inhibitor-6 is active against wild-type HIV-1IIIB (subtype B, X4-tropic) and HIV-1 97USSN54 (subtype A, R5-tropic) with EC50s of 0.6 μM and 0.9 μM, respectively. HIV-1 inhibitor-6 inhibits HIV strains resistant to agents targeting HIV reverse transcriptase, protease, integrase, and coreceptor CCR5 with EC50s ranging from 0.9 to 1.5 μM .
|
-
- HY-19510
-
-
- HY-157330
-
|
|
P-glycoprotein
Apoptosis
|
Cancer
|
|
P-gp inhibitor 16 (compound 14) is a p-glycoprotein inhibitor. P-gp inhibitor 16 significantly increases Doxorubicin-induced apoptosis and shows anticancer effects .
|
-
- HY-P1029
-
|
|
Myosin
CaMK
Autophagy
|
Others
|
|
MLCK inhibitor peptide 18 is a myosin light chain kinase (MLCK) inhibitor with an IC50 of 50 nM, and inhibits CaM kinase II only at 4000-fold higher concentrations.
|
-
- HY-151419
-
|
|
Fungal
|
Infection
|
|
Chitin synthase inhibitor 9 is a chitin synthase (CHS) inhibitor with broad-spectrum antifungal activity. Chitin synthase inhibitor 9 can be used in the research of fungi infection .
|
-
- HY-151418
-
|
|
Fungal
|
Infection
|
|
Chitin synthase inhibitor 8 is a chitin synthase (CHS) inhibitor with broad-spectrum antifungal activity. Chitin synthase inhibitor 8 can be used in the research of fungi infection .
|
-
- HY-144817
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
Tubulin inhibitor 27 (DYT-1) is a tubulin polymerisation inhibitor with an IC50 of 25.6 μM. Tubulin inhibitor 27 shows anti-angiogenesis and antitumor activities .
|
-
- HY-155472
-
|
|
Bcl-2 Family
|
Cancer
|
|
Mcl-1 inhibitor 17 is a Mcl-1 protein inhibitor. Mcl-1 inhibitor 17 can be used for the research of cancer and other diseases .
|
-
- HY-146889
-
|
|
Phosphodiesterase (PDE)
|
Cancer
|
|
ATX inhibitor 16 is a potent ATX inhibitor with an IC50 of 0.0021 μM. ATX inhibitor 16 shows excellent anti-proliferative activities in breast cancer cells .
|
-
- HY-148058
-
|
|
Topoisomerase
|
Cancer
|
|
Topoisomerase I inhibitor 8 is a potent topoisomerase I inhibitor. Topoisomerase I inhibitor 8 is a hexacyclic analogue of camptothecin, and displays cytotoxic effect against tumor cells .
|
-
- HY-163842
-
|
|
Cathepsin
|
Inflammation/Immunology
|
|
Cathepsin K inhibitor 7 (compound 7) is a Cathepsin K inhibitor with the pKi of 7.3 aganist CatK. Cathepsin K inhibitor 7 can be used for study of osteoporosis .
|
-
- HY-150758
-
-
- HY-112569
-
-
- HY-161061
-
|
|
Arginase
|
Cancer
|
|
Arginase inhibitor 7 (compound A17) is an arginase (ARG1) inhibitor, with an IC50 of 0.16 μM. Arginase inhibitor 7 has high oral bioavailability .
|
-
- HY-P4243
-
|
|
Ser/Thr Protease
|
Others
|
|
Dansyl-Glu-Gly-Arg-Chloromethylketone is a protease inhibitor, and inhibits serine/threonine proteases. Dansyl-Glu-Gly-Arg-Chloromethylketone inhibits activated porcine factor IX .
|
-
- HY-15503
-
|
|
Caspase
CDK
Flavivirus
|
Infection
|
|
PHA-690509 is an anti-ZikV compound that inhibits ZikV replication. PHA-690509 is also a CDK inhibitor, and inhibits caspase-3 activity .
|
-
- HY-14679
-
|
|
GSK-3
|
Neurological Disease
|
|
GSK3β inhibitor II is an inhibitor of GSK3β. GSK3β inhibitor II can be used for research of Alzheimer’s disease (AD) .
|
-
- HY-163637
-
|
|
Sodium Channel
|
Cardiovascular Disease
|
|
Sodium Channel inhibitor 5 (compound 7d) is a potent inhibitor of sodium channel, with the IC50 of 2.7 μM. Sodium Channel inhibitor 5 plays an important role in antiarrhythmic research .
|
-
- HY-18327
-
|
|
E1/E2/E3 Enzyme
MDM-2/p53
|
Cancer
|
|
HLI98C is a ubiquitin ligase inhibitor. HLI98C inhibits p53 ubiquitylation. HLI98C inhibits HDM2 auto-ubiquitylation .
|
-
- HY-121259
-
|
Adriamycinol; DXR-OL
|
Endogenous Metabolite
|
Cardiovascular Disease
|
|
Doxorubicinol, a potent inhibitor of the cardiac sarcoplasmic reticulum calcium pump, inhibits systolic myocardial function in isolated heart muscle. Doxorubicinol inhibits tumor cell growth and has cardiotoxicity.
|
-
- HY-163753
-
|
|
Carbonic Anhydrase
|
Others
|
|
Carbonic anhydrase inhibitor 25 (compound 6a) is a potent carbonic anhydrase inhibitor. Carbonic anhydrase inhibitor 25 shows inhibition for hCA I and hCA II receptor .
|
-
- HY-169254
-
|
|
Phospholipase
|
Metabolic Disease
|
|
sPLA2 inhibitor 2 (compound 6a) is a sPLA2 inhibitor, with IC50 of 0.0475 μM. sPLA2 inhibitor 2 can be used in diabetes research .
|
-
- HY-169316
-
|
|
YAP
|
Cancer
|
|
YAP/TAZ inhibitor-4 (Compound 45) is an inhibitor of YAP/TAZ, exhibiting TEAD transcriptional activation inhibitory activity by suppressing the binding of YAP or TAZ to TEAD .
|
-
- HY-146890
-
|
|
Phosphodiesterase (PDE)
|
Cancer
|
|
ATX inhibitor 17 is a potent ATX inhibitor with an IC50 of 0.019 μM. ATX inhibitor 17 shows excellent anti-proliferative activities in breast cancer cells .
|
-
- HY-123751
-
|
AGF 94
|
Antifolate
|
Cancer
|
|
Antifolate C1 (AGF 94) is a GARFTase inhibitor. Antifolate C1 inhibits de novo purine biosynthesis. Antifolate C1 inhibits cell proliferation .
|
-
- HY-163519
-
|
|
α-synuclein
|
Neurological Disease
|
|
α-Synuclein inhibitor 13 is an inhibitor of α-synuclein (α-Syn). α-Synuclein inhibitor 13 inhibits the aggregation of α-Syn proteins and is able to break down formed fibers. It is mainly used in Parkinson's disease research .
|
-
- HY-147785
-
|
|
Pim
Apoptosis
|
Cancer
|
|
Pim-1 kinase inhibitor 2 (Compound 13) is a potent inhibitor of Pim-1 kinase. Pim-1 kinase inhibitor 2 induces apoptosis. Pim-1 kinase inhibitor 2 has the potential for the research of cancer diseases .
|
-
- HY-154986
-
|
|
MARK
AMPK
|
Cancer
|
|
MARK4 inhibitor 2 is an inhibitor of microtubule affinity-regulating kinase 4 (MARK4) with an Km of 6.3×10 7 and an IC50 of 0.82 μM. MARK4 inhibitor 2 inhibits the growth of human cells and can be used for cancer research .
|
-
- HY-170960
-
|
|
Microtubule/Tubulin
Apoptosis
|
Cancer
|
|
TACC3 inhibitor 2 (Compound 13b) is a TACC3 inhibitor with an IC50 of 200 nM. TACC3 inhibitor 2 can induce mitotic arrest, cell apoptosis (Apoptosis), and DNA damage. TACC3 inhibitor 2 can be used for cancer research .
|
-
- HY-172815
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
IDB-001 is an inhibitor of ribosome PTC that inhibits protein synthesis in a sequence-selective manner. IDB-001 inhibits HCC-1143 with EC50 value of 0.84 μM. IDB-001 inhibits MYC-dependent cancer cell viability .
|
-
- HY-161747
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
Tubulin inhibitor 46 (Compound 21) is a potent tubulin assembly inhibitor. Tubulin inhibitor 46 has antiproliferative activities, with GI50 values of 0.0095-33 μM for cancer and non-cancerous cells. Tubulin inhibitor 46 can be used for the reserch of cancer .
|
-
- HY-122968
-
|
NSD-1065
|
Endogenous Metabolite
|
Neurological Disease
|
|
Brocresine (NSD-1065) is an orally active histidine decarboxylase inhibitor and inhibits the formation of histamine from histidine. Brocresine is also a L-amino acid decarboxylase inhibitor with both a peripheral and central action. Brocresine inhibits gastric secretory response to administration of exogenous gastrin .
|
-
- HY-147710
-
|
|
MicroRNA
|
Cancer
|
|
PIN1 inhibitor 2 (compound 12) is a potent PIN1 inhibitor. PIN1 inhibitor 2 shows antitumor activity with an IC50 of 9.55 µM for MCF7 cells. PIN1 inhibitor 2 has the potential for the research of breast cancer .
|
-
- HY-149375
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
Tubulin inhibitor 37 (Compound 12) is a Tubulin inhibitor that can effectively inhibit Tubulin aggregation (IC50=1.3 µM). Tubulin inhibitor 37 exhibits antiproliferative activity against human tumor cell lines and has potential for studying cancer .
|
-
- HY-112464
-
|
|
Pyruvate Kinase
|
Neurological Disease
|
|
PKR Inhibitor, negative control is an inactive structural analog of RNA-dependent protein kinase (PKR) inhibitor, which can be used as a negative control. PKR Inhibitor, negative control can also inhibit LK-induced neuronal death, exhibiting significant neuroprotective effects .
|
-
- HY-170763A
-
|
|
Apoptosis
Bcl-2 Family
|
Cancer
|
|
(+)-Mcl-1 inhibitor 22 (Example 37) is a myeloid cell leukemia-1 (MCL-1) inhibitor which inhibits the antiapoptotoic activity of MCL-1 by inhibiting its interaction with proapototic proteins. (+)-Mcl-1 inhibitor 22 exhibits anti-proliferation activities against various cancer cell lines and can be utilized in cancer research .
|
-
- HY-143301
-
|
|
Topoisomerase
|
Cancer
|
|
Topoisomerase I inhibitor 4 (compound 7a) is a topoisomerase I inhibitor. Topoisomerase I inhibitor 4 inhibits HepG2, A549, MCF-7 and HeLa cancer cells proliferation with IC50s of 1.20, 2.09, 1.56 and 1.92 μM, respectively. Topoisomerase I inhibitor 4 can be used for the research of cancer .
|
-
- HY-121693
-
|
MDL101114ZA free base
|
VDAC
RAD51
|
Cancer
|
|
DIDS is a dual inhibitor of ABCA1 and VDAC1. DIDS also inhibits RAD51, inhibiting RAD51-mediated homologous pairing and strand exchange reactions. DIDS inhibits anion exchange and binding to red blood cell membranes, inhibits the activation of caspase-3 and -9, and can be used in cancer research .
|
-
- HY-170763
-
|
|
Apoptosis
Bcl-2 Family
|
Cancer
|
|
Mcl-1 inhibitor 22 (Example 36) is a myeloid cell leukemia-1 (MCL-1) inhibitor which inhibits the antiapoptotoic activity of MCL-1 by inhibiting its interaction with proapototic proteins. Mcl-1 inhibitor 22 exhibits anti-proliferation activities against various cancer cell lines and can be utilized in cancer research .
|
-
- HY-15681
-
|
|
CDK
|
Cancer
|
|
Senexin A is an inhibitor of CDK8/19 (IC50: 280 nM, CDK8) and an inhibitor downstream of p21 transcription. It only inhibits p21-induced transcription but does not inhibit other biological effects of p21. Senexin A inhibits CMV-GFP induction as well as the p21 stimulatory activity of the consensus NF-κB-dependent promoters .
|
-
- HY-150044
-
|
|
DNA/RNA Synthesis
Topoisomerase
Bacterial
|
Infection
|
|
Type II topoisomerase inhibitor 1 is a potent and selective E. coli DNA gyrase inhibitor (IC50: 1.7 nM), and forms hydrogen bonds with Asp73 residue. Type II topoisomerase inhibitor 1 inhibits topoisomerase IV activity (IC50: 0.98 μM). Type II topoisomerase inhibitor 1 can be used in the research of antibacterial area .
|
-
- HY-160022
-
|
|
IAP
|
Cancer
|
|
XIAP BIR2/BIR2-3 inhibitor-1 (compound 3) is a dual inhibitor of BIR2 and BIR2-3 with IC50s of 1.9 and 0.8 nM, respectively. XIAP BIR2/BIR2-3 inhibitor-1 can used in study cancers .
|
-
- HY-156445
-
|
|
PI3K
mTOR
|
Cancer
|
|
PI3K/mTOR Inhibitor-14 (compound Y-2) is a potent PI3K and mTOR dual inhibitor with IC50s of 171.4 nM and 10.1 nM, respectively. PI3K/mTOR Inhibitor-14 has antitumor activities .
|
-
- HY-15681A
-
|
|
CDK
|
Cancer
|
|
Senexin A hydrochloride is an inhibitor of CDK8/19 (IC50: 280 nM, CDK8) and an inhibitor downstream of p21 transcription. It only inhibits p21-induced transcription but does not inhibit other biological effects of p21. Senexin A hydrochloride inhibits CMV-GFP induction as well as the p21 stimulatory activity of the consensus NF-κB-dependent promoters .
|
-
- HY-146497
-
|
|
Topoisomerase
|
Cancer
|
|
Topoisomerase I inhibitor 7 (Compound 8) is a potent inhibitor of Topoisomerase I. Topoisomerase I inhibitor 7 significantly inhibits tumor growth (up to 79%) and increases the lifespan (153%) of mice bearing P388 lymphoma transplants. Topoisomerase I inhibitor 7 indicates prospects for further search of new antitumor agent candidates among the heteroarene-fused anthraquinones .
|
-
- HY-N10109A
-
|
|
SARS-CoV
Parasite
Cathepsin
|
Infection
|
|
Gallinamide A TFA is a linearly depositing peptide and a potent inhibitor of cathepsin L (CatL) (IC50: 17.6 pM). Gallinamide A TFA inhibits SARS-CoV-2 infection by inhibiting CatL (EC50: 28 nM). Gallinamide A TFA also inhibits Plasmodium falciparum (IC50: 50 nM) .
|
-
- HY-169306
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
IL-17A inhibitor 4 (Example 449) is a potent IL-17A inhibitor. IL-17A inhibitor 4 inhibits HTRF and NHK cells viability with IC50s of 0.028 and 0.0047 μM, respectively .
|
-
- HY-150983A
-
|
|
ATP Synthase
Bacterial
|
Infection
|
|
ATP synthase inhibitor 2 (Compound 22) TFA is a Pseudomonas aeruginosa (PA) ATP synthase inhibitor (IC50=10 μg/mL). ATP synthase inhibitor 2 TFA can inhibit Pseudomonas aeruginosa (PA) ATP synthesis activity completely at 128 μg/mL .
|
-
- HY-119160
-
|
|
PAI-1
|
Inflammation/Immunology
Cancer
|
|
TM5007 is a poent and orally active inhibitor of plasminogen activator inhibitor-1 (PAI-1) with an IC50 of 29 μM. TM5007 enhance fibrinolysis activity and inhibits coagulation. TM5007 also prevents the fibrotic process initiated by bleomycin in mouse lung .
|
-
- HY-13624A
-
|
4'-Epidoxorubicin hydrochloride
|
DNA/RNA Synthesis
Topoisomerase
Apoptosis
Antibiotic
|
Cancer
|
|
Epirubicin hydrochloride (4'-Epidoxorubicin hydrochloride), a semisynthetic L-arabino derivative of doxorubicin, has an antineoplastic agent by inhibiting Topoisomerase . Epirubicin hydrochloride inhibits DNA and RNA synthesis. Epirubicin hydrochloride is a Forkhead box protein p3 (Foxp3) inhibitor and inhibits regulatory T cell activity .
|
-
- HY-15358
-
|
|
Anaplastic lymphoma kinase (ALK)
FAK
|
Cancer
|
|
ALK inhibitor 2 (compound 18) is a potent pyrimidin ALK inhibitor. ALK inhibitor 2 is a potent inhibitor of testis-specific serine/threonine kinase 2 (TSSK2; IC50=37 nM) and focal adhesion kinase (FAK; IC50=5 nM) .
|
-
- HY-122856
-
|
|
TGF-β Receptor
|
Cancer
|
|
AZ12601011 is an orally active, selective TGFBR1 kinase inhibitor with an IC50 of 18 nM and a Kd of 2.9 nM. AZ12601011 inhibits phosphorylation of SMAD2 via selectively inhibiting ALK4, TGFBR1, and ALK7. AZ12601011 inhibits mammary tumor growth .
|
-
- HY-15357
-
|
|
Anaplastic lymphoma kinase (ALK)
FAK
|
Cancer
|
|
ALK inhibitor 1 (compound 17) is a potent pyrimidin ALK inhibitor. ALK inhibitor 1 is a potent inhibitor of testis-specific serine/threonine kinase 2 (TSSK2; IC50=31 nM) and focal adhesion kinase (FAK; IC50=2 nM) .
|
-
- HY-P4136
-
|
|
ERK
|
Cancer
|
|
Myristoyl-MEK1 Derived Peptide Inhibitor 1 is the myristoylated form of the MEK1 Derived Peptide Inhibitor 1 (HY-P4133). Myristoyl-MEK1 Derived Peptide Inhibitor 1 inhibits ERK activation with an IC50 of 10 μM .
|
-
- HY-13624
-
|
4'-Epidoxorubicin
|
DNA/RNA Synthesis
Topoisomerase
Apoptosis
Antibiotic
|
Cancer
|
|
Epirubicin (4'-Epidoxorubicin), a semisynthetic L-arabino derivative of doxorubicin, has an antineoplastic agent by inhibiting Topoisomerase . Epirubicin inhibits DNA and RNA synthesis. Epirubicin is a Forkhead box protein p3 (Foxp3) inhibitor and inhibits regulatory T cell activity .
|
-
- HY-155460
-
|
|
Bacterial
|
Infection
|
|
Pks13-TE inhibitor 4 (compound 44) is an oxadiazole series Pks13 inhibitor that effectively inhibits tuberculosis (TB) and resolves its drug resistance .
|
-
- HY-153423A
-
|
|
Bcl-2 Family
|
Cancer
|
|
Mcl-1 inhibitor 13 (Example 9) is a MCL-1 inhibitor (Ki: 8.2 nM). Mcl-1 inhibitor 13 can be used for the research of cancers .
|
-
- HY-153423
-
|
|
Bcl-2 Family
|
Cancer
|
|
Mcl-1 inhibitor 12 (Example 10) is a MCL-1 inhibitor (Ki: 0.22 nM). Mcl-1 inhibitor 12 can be used for the research of cancers .
|
-
- HY-142467
-
|
|
HIV
|
Infection
|
|
HIV-1 inhibitor-11, a fused pyridine ring derivative, is a HIV-1 inhibitor. WO2021104413A1 ( compound 1-1b) .
|
-
- HY-154988
-
|
|
MARK
|
Neurological Disease
Cancer
|
|
MARK4 inhibitor 4 is a MARK4 inhibitor with an IC50 of 1.49 μM. MARK4 inhibitor 4 can be used in cancer and tau lesion-related research .
|
-
- HY-159474
-
|
|
Ras
|
Cancer
|
|
KRAS inhibitor-24 (compound 115c) is a pyridopyrimidine KRAS inhibitor, with an IC50 of < 100 nM for KRas G12V, KRas WT and KRas G12R .
|
-
- HY-146753
-
|
|
HIV
|
Infection
|
|
HIV-1 inhibitor-20 is a potent HIV-1 inhibitor by non-classical isosteric replacement of amide to 1,2,4-oxadiazoles .
|
-
- HY-163798
-
|
|
Epigenetic Reader Domain
|
Cancer
|
|
Menin-MLL inhibitor 33 (compound 15-a) is a potent Menin-MLL inhibitor with an IC50 value of 3.6 nM. Menin-MLL inhibitor 33 shows antiproliferative activity .
|
-
- HY-N0518
-
|
|
PAI-1
|
Cardiovascular Disease
|
|
Toddalolactone, a main component of Toddalia asiatica, inhibits the activity of recombinant human plasminogen activator inhibitor-1 (PAI-1), with an IC50 value of 37.31 μM .
|
-
- HY-103192
-
|
RMI12330A
|
Adenylate Cyclase
Phosphodiesterase (PDE)
|
Others
|
|
MDL12330A (RMI12330A) is an adenyl cyclase inhibitor. MDL12330A inhibits the vasopressin action on the short-circuit current (SCC). MDL12330A is also an inhibitor of cAMP phosphodiesterase .
|
-
- HY-W325699
-
|
|
HIV
Reverse Transcriptase
|
Infection
|
|
HIV-1 inhibitor-48 (compound 13o) is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) and exhibits anti-HIV-1 activity .
|
-
- HY-N2384
-
|
|
Parasite
DNA/RNA Synthesis
Apoptosis
|
Infection
Cancer
|
|
Febrifugine is a quinazolinone alkaloid that inhibits P. falciparum and has antimalarial activity. Febrifugine inhibits bladder cancer by inhibiting DNA synthesis, inducing apoptosis, and reducing steroids .
|
-
- HY-48187
-
|
|
Drug Intermediate
|
Cancer
|
|
KRAS inhibitor-39 (Example 46) is an intermediate of BI-0474 (HY-148278). BI-0474 is a robust KRAS G12C inhibitor .
|
-
- HY-172797
-
-
- HY-164451
-
|
|
γ-secretase
Notch
|
Cancer
|
|
GSI-18 is a γ-secretase inhibitor with anticancer activity. GSI-18 inhibits the attachment-free growth of pancreatic cancer cells by inhibiting Notch signaling .
|
-
- HY-144376
-
|
|
Carbonic Anhydrase
|
Cancer
|
|
Carbonic anhydrase inhibitor 4 is carbonic anhydrase photoprobe/inhibitor. Carbonic anhydrase inhibitor 4 is against human carbonic anhydrases (hCA I-XIV) with Ki values of 640-1166 nM .
|
-
- HY-139536
-
-
- HY-19144
-
|
|
5 alpha Reductase
|
Others
|
|
ONO-3805 is an early lead compound of a non-steroidal 5α-reductase inhibitor, used to inhibit the conversion of testosterone to dihydrotestosterone, with potential effects in inhibiting benign prostatic hyperplasia.
|
-
- HY-144748
-
|
|
Microtubule/Tubulin
Apoptosis
|
Cancer
|
|
Tubulin inhibitor 17 (Compound 3b) is a tubulin polymerization inhibitor with an IC50 of 12.38 µM. Tubulin inhibitor 17 has anticancer activities and induces cell apoptosis .
|
-
- HY-153971
-
|
|
URAT1
|
Metabolic Disease
|
|
URAT1 inhibitor 8 (example 247) is a potent URAT1 inhibitor, with an IC50 of 0.001 μM. URAT1 inhibitor 8 can be used for gout research .
|
-
- HY-150686
-
|
|
Fungal
|
Infection
|
|
Chitin synthase inhibitor 4 (compound 4fh) is a chitin synthase inhibitor with fungicidal effect. Chitin synthase inhibitor 4 is a potential chitin synthase-based fungicide in agriculture .
|
-
- HY-N2384A
-
|
|
Parasite
DNA/RNA Synthesis
Apoptosis
|
Infection
Cancer
|
|
Febrifugine dihydrochloride is a quinazolinone alkaloid that inhibits P. falciparum and has antimalarial activity. Febrifugine dihydrochloride inhibits bladder cancer by inhibiting DNA synthesis, inducing apoptosis, and reducing steroids .
|
-
- HY-159475
-
|
|
Ras
|
Cancer
|
|
KRAS inhibitor-25 (compound 151a) is a pyridopyrimidine KRAS inhibitor, with an IC50 of < 100 nM against KRas G12V, KRas WT and KRas G12R .
|
-
- HY-173062
-
|
|
Epigenetic Reader Domain
c-Myc
|
Others
|
|
BRD4 Inhibitor-40 (Compound 23) is the inhibitor for BRD that inhibits BRD4-BD1, BRD4-BD2, BRD2-BD1 and BRD2-BD2 with IC50s of 16.1, 142.18, 29.35 and 302.35 nM, respectively. BRD4 Inhibitor-40 modulates the expression of c-Myc and p21, arrests cell cycle at G1 phase, inhibits Pkd1-null (PN) renal cystic epithelial cells, and blocks the renal cysts formation in Madin-Darby canine kidney and embryonic kidney vesicle models. BRD4 Inhibitor-40 exhibits renal cysts inhibitory activity in mouse models .
|
-
- HY-123905A
-
|
|
Drug Isomer
MicroRNA
Parasite
|
Infection
Cancer
|
|
LIN28 inhibitor LI71 enantiomer is the less active enantiomer of LIN28 inhibitor LI71 (HY-123905). LIN28 inhibitor LI71 is a LIN28 inhibitor that effectively inhibits LIN28:let-7 binding (IC50: 7 μM). LIN28 inhibitor LI71 can abolish LIN28-mediated oligouridylation of let-7 precursor (IC50: 27 μM). LIN28 inhibitor LI71 has potential application value in LIN28-driven cancer research. LIN28 inhibitor LI71 inhibits the interaction of cold shock protein of Plasmodium falciparum (PfCoSP) with DNA and α/β tubulin and has an inhibitory effect on Plasmodium falciparum .
|
-
- HY-147614
-
|
|
PI3K
mTOR
|
Cancer
|
|
PI3K/mTOR Inhibitor-7 (Compound 19i) is a potent and dual inhibitor of PI3K/mTOR. PI3K/mTOR Inhibitor-7 shows 4.7-fold higher potency than the positive control gedatolisib (0.3 vs. 1.4 μM, IC50 values). PI3K/mTOR Inhibitor-7 significantly suppresses the PI3K/Akt/mTOR signaling pathway at 10 μM. PI3K/mTOR Inhibitor-7 has the potential for the research of cancer diseases .
|
-
- HY-151622
-
|
|
PI3K
mTOR
|
Cancer
|
|
PI3K/mTOR Inhibitor-11 is an orally active PI3K/mTOR inhibitor (IC50: 3.5, 4.6, and 21.3 nM for PI3Kα, PI3Kδ, and mTOR). PI3K/mTOR Inhibitor-11 regulates the PI3K/AKT/mTOR signaling pathway by inhibiting the phosphorylation of AKT and S6 proteins. PI3K/mTOR Inhibitor-11 can be used in the research of cancers .
|
-
- HY-139881
-
|
|
Btk
|
Cancer
|
|
BTK inhibitor 19 is a highly selective, covalent BTK inhibitor (IC50 = 2.7 nM).
|
-
- HY-103338
-
-
- HY-144375
-
|
|
MAGL
|
Others
|
|
Monoacylglycerol lipase inhibitor 1 is a potent monoacylglycerol lipase inhibitor (compound 13) .
|
-
- HY-164852
-
-
- HY-15183
-
|
|
MMP
|
Cancer
|
|
Collagen proline hydroxylase inhibitor is a collagen proline hydroxylase inhibitor; useful for antifibroproliferative agents.
|
-
- HY-U00387
-
-
- HY-108322
-
|
|
Others
|
Cardiovascular Disease
|
|
NBTGR (p-Nitrobenzylthioguanosine) is a potent inhibitor of nucleoside transport; inhibits adenosine uptake with a Ki of 70 nM.
|
-
- HY-112270
-
-
- HY-N12485
-
-
- HY-101932
-
-
- HY-U00319
-
-
- HY-P5388
-
|
|
Renin
|
Others
|
|
Renin inhibitor peptide,rat is a biological active peptide. (A specific rat renin inhibitor.)
|
-
- HY-112269
-
-
- HY-157393
-
-
- HY-142296
-
-
- HY-124798
-
|
|
mTOR
|
Neurological Disease
Inflammation/Immunology
Cancer
|
Rheb inhibitor NR1 is a Rheb inhibitor with an IC50 of 2.1 µM in the Rheb-IVK assay. Rheb inhibitor NR1 can directly bind Rheb in the switch II domain and selectively inhibit the activation of mechanistic target of rapamycin complex 1 (mTORC1). Rheb inhibitor NR1 inhibits the phosphorylation of mTORC1 driven T389pS6K1 and increases the phosphorylation of S473pAKT in a dose-dependent manner. Rheb inhibitor NR1 does not influence mTORC2 activity .
(Rheb-IVK: Rheb-dependent mTORC1 kinase activity)
|
-
- HY-151929
-
|
|
JNK
|
Neurological Disease
|
|
JNK3 inhibitor-4 is a potent inhibitor of JNK3 (IC50=1.0 nM) based on 2-aryl-1-pyrimidinyl-1H-imidazole-5-yl acetonitrile. JNK3 inhibitor-4 shows excellent selectivity over other protein kinases including isoforms JNK1 (IC50=143.9 nM) and JNK2 (IC50=298.2 nM) . JNK3 inhibitor-4 has neuroprotective effect and predicated blood-brain barrier permeability .
|
-
- HY-176456
-
|
|
PARP
|
Inflammation/Immunology
Cancer
|
|
PARP14 inhibitor 2 (Compound 3) is an orally active and highly selective PARP14 inhibitor with an IC50 value of <30 nM. PARP14 inhibitor 2 inhibits the mono-ADP-ribosyltransferase activity of PARP14 and regulates IFN-γ and IL-4 signaling, reversing protumor macrophage polarization and inhibiting anti-tumor inflammatory responses. PARP14 inhibitor 2 is promising for research of PARP14-related diseases such as tumors, atopic dermatitis and autoimmune diseases .
|
-
- HY-170550
-
|
|
Ras
ERK
|
Cancer
|
|
KRAS G12C inhibitor 69 (Compound K09) is the inhibitor for mutant RAS protein KRASG12C with an IC50 of 4.36 nM. KRAS G12C inhibitor 69 inhibits the ERK phosphorylation in NCI-H358 and MIA-PACA-2 with an IC50 of 12 nM and 7 nM. KRAS G12C inhibitor 69 inhibits the proliferation of cancer cell NCI-H358 and MIA-PACA-2 with IC50 of 3.15 nM and 2.33 nM .
|
-
- HY-100983R
-
|
|
Reference Standards
PKC
|
Cancer
|
|
Protein kinase inhibitor H-7 (dihydrochloride) (Standard) is the analytical standard of Protein kinase inhibitor H-7 (dihydrochloride). This product is intended for research and analytical applications. Protein kinase inhibitor H-7 dihydrochloride is a potent PKC (protein kinase C) inhibitor. At 100 μM, Protein kinase inhibitor H-7 dihydrochloride completely inhibits both TPA (skin tumour promoter, 12-O-tetradecanoylphorbol-13-acetate) and phospholipase C-induced ODC (ornithine decarboxylase) .
|
-
- HY-118717
-
|
|
mTOR
|
Cancer
|
|
mTOR inhibitor WYE-28 (compound 28) is a selective inhibitor of mTOR>/b< (IC50)=0.08 nM. mTOR inhibitor WYE-28 inhibits PI3Kα with an IC50 value of 6 nM. mTOR inhibitor WYE-28 shows a metabolic time (T1/2) in nude mouse microsomes of 13 min .
|
-
- HY-122720
-
|
KL-1
|
Apoptosis
|
Cancer
|
|
SEC inhibitor KL-1 (KL-1) is a peptide-like lead compound that is an effective selective SEC inhibitor. SEC inhibitor KL-1 promotes apoptosis and has anti-tumor activity. SEC inhibitor KL-1 doses dependently inhibits the AFF4-CCNT1 interaction, with a Ki value of 3.48 μM .
|
-
- HY-153120A
-
|
|
PI3K
mTOR
|
Cancer
|
|
PI3K/mTOR Inhibitor-13 sodium is an orally active dual inhibitor of phosphoinositol 3-kinase (PI3K) and mTOR kinase. PI3K/mTOR Inhibitor-13 sodium has potential applications in sexual diseases, solid tumor and idiopathic pulmonary fibrosis (IPF) .
|
-
- HY-138989
-
|
|
Lipoxygenase
|
Inflammation/Immunology
|
|
15-LOX-1 inhibitor 1 is a potent inhibitor of 15-LOX-1 (15-lipoxygenase-1) with an IC50 value of 0.19 μM. 15-LOX-1 inhibitor 1 protects macrophages from lipopolysaccharide-induced cytotoxicity. 15-LOX-1 inhibitor 1 inhibits NO formation and lipid peroxidation .
|
-
- HY-D0086
-
|
MDL101114ZA
|
VDAC
RAD51
|
Cancer
|
|
DIDS sodium salt (MDL101114ZA) is a dual inhibitor of ABCA1 and VDAC1. DIDS also inhibits RAD51, inhibiting RAD51-mediated homologous pairing and strand exchange reactions. DIDS inhibits anion exchange and binding to red blood cell membranes, inhibits the activation of caspase-3 and -9, and can be used in cancer research .
|
-
- HY-146316
-
|
|
Topoisomerase
|
Cancer
|
|
Topoisomerase II inhibitor 6 (Compound 5), a tryptanthrin derivative, is a potent and selective inhibitor of topoisomerase II. Topoisomerase II inhibitor 6 exhibits antiproliferative activity on different tumor cell lines. Topoisomerase II inhibitor 6 blocks the cell cycle of CCRF-CEM in the G2 phase and induces DNA DSB. Topoisomerase II inhibitor 6 has the potential for the research of cancer diseases .
|
-
- HY-100932
-
ML-9
4 Publications Verification
|
Myosin
|
Cancer
|
|
ML-9 is a selective and potent inhibitor of Akt kinase, inhibits myosin light-chain kinase (MLCK) and stromal interaction molecule 1 (STIM1) activity . ML-9 inhibits inhibits MLCK, PKA and PKC activity with Ki values of 4, 32 and 54 μM, respectively . ML-9 induces autophagy by stimulating autophagosome formation and inhibiting their degradation .
|
-
- HY-144714
-
|
|
HIV
|
Infection
|
|
HIV-1 inhibitor-18 (compound II-13c) is a potent HIV-1 capsid inhibitor with an EC50 value of 5.14 μM for HIV-1 NL4-3. HIV-1 inhibitor-18 has certain cytotoxicity (MT-4 cells CC50 >9.51) .
|
-
- HY-163390
-
|
|
RIP kinase
Necroptosis
|
Inflammation/Immunology
Cancer
|
|
RIP1 kinase inhibitor 9 (compound SY-1) is a selective RIP kinase inhibitor. RIP1 kinase inhibitor 9 effectively suppresses the central inflammatory response induced by epilepsy. RIP1 kinase inhibitor 9 inhibits Z-VAD-FMK (HY-16658B)-induced necroptosis in HT-29 cells with an EC50 of 7.04 nM .
|
-
- HY-142452
-
|
|
Raf
|
Cancer
|
|
Pan-RAF kinase inhibitor 1 is a potent inhibitor of Pan-RAF kinase. Pan-RAF kinase inhibitor 1 regulates MAPK signaling by inhibiting RAF kinase, thereby exerting an effect on the proliferation of RAS-mutant tumor cells. Pan-RAF kinase inhibitor 1 has the potential for the research of cancer diseases (extracted from patent WO2021110141A1, compound 16B) .
|
-
- HY-12072
-
|
|
Src
|
Inflammation/Immunology
|
|
Lck Inhibitor is a potent, orally active Lck (lymphocyte specific kinase) inhibitor with IC50s of 7, 2.1, 4.2 and 200 nM for Lck, Lyn, Src and Syk kinases, respectively. Lck Inhibitor shows >1000-fold selectivity for Lck over MAPK, CDK and RSK family representatives. Lck Inhibitor inhibits T cell proliferation and in vivo models of arthritis .
|
-
- HY-144715
-
|
|
HIV
|
Infection
|
|
HIV-1 inhibitor-18 (compound V-25i) is a potent HIV-1 capsid inhibitor with an EC50 value of 2.57 μM for HIV-1 NL4-3. HIV-1 inhibitor-18 has certain cytotoxicity (MT-4 cells CC50 >8.55) .
|
-
- HY-170971
-
|
|
Apoptosis
Src
|
Cancer
|
|
Src Inhibitor 4 (Compound 18) is a derivative of KX-01 and an Src inhibitor. Src Inhibitor 4 can inhibit tumor cells, disrupt microtubules, and induce cell cycle arrest, apoptosis, and immunogenic cell death. After the introduction of phenolic or aniline functionality, Src Inhibitor 4 can serve as a payload attachment site for antibody-drug conjugates and has anti-tumor activity .
|
-
- HY-153120
-
|
|
PI3K
mTOR
|
Cancer
|
|
PI3K/mTOR Inhibitor-13 is an orally active dual inhibitor of phosphoinositol 3-kinase (PI3K) and mTOR kinase. PI3K/mTOR Inhibitor-13 has potential applications in sexual diseases, solid tumor and idiopathic pulmonary fibrosis (IPF) .
|
-
- HY-10917
-
|
|
c-Fms
|
Inflammation/Immunology
Cancer
|
|
GW2580 is an orally bioavailable and selective inhibitor of c-Fms kinase which completely inhibits human cFMS kinase in vitro at 0.06 μM. GW2580 acts as a competitive inhibitor of ATP binding to the cFMS kinase and inhibits colony-stimulating-factor-1 signaling .
|
-
- HY-16661
-
|
SKPin C1
|
E1/E2/E3 Enzyme
|
Cancer
|
|
Skp2 Inhibitor C1 (SKPin C1) is an S-phase kinase-related protein 2 (Skp2) inhibitor with an inhibitory effect on metastatic melanoma cells. Skp2 Inhibitor C1 slows the cell cycle, inhibits cell proliferation, and triggers apoptosis .
|
-
- HY-116476
-
|
|
Neprilysin
|
Others
|
|
Risotilide is an inhibitor of enkephalinase B, which has the ability to inhibit enkephalinase B activity (IC50 value is 0.35 microM), and can also effectively inhibit enkephalinase A (IC50 = 0.02 microM) and aminopeptidase activity (IC50 = 13 microM), and can be regarded as a complete inhibitor of enkephalin biodegradation.
|
-
- HY-149981
-
|
|
P-glycoprotein
|
Cancer
|
P-gp inhibitor 13 is a P-gp inhibitor. P-gp inhibitor 13 can reverse P-glycoprotein-mediated paclitaxel resistance in A2780/T cell. P-gp inhibitor 13 can be used for the research of advanced acute myeloid leukemia .
|
-
- HY-124651
-
|
|
NF-κB
MMP
|
Inflammation/Immunology
Cancer
|
|
SEMBL is a potent NF-κB inhibitor. SEMBL can inhibit NF-κB-DNA binding, and also inhibits NF-κB-dependent inflammatory cytokine secretions. SEMBL inhibits cancer cell migration and invasion via decreasing MMP expression. SEMBL can be used for researching anticancer .
|
-
- HY-P10346
-
|
Smooth-Muscle Myosin Light-Chain Kinase (796-815)
|
Myosin
|
Cardiovascular Disease
Inflammation/Immunology
|
|
smMLCK peptide is a specific inhibitor of smooth muscle myosin light chain kinase (smMLCK). The smMLCK peptide mimics the substrate and competitively inhibits the binding of the actual substrate to the enzyme, thereby inhibiting the kinase activity. This inhibition prevents the phosphorylation of the myosin light chain, thus inhibiting muscle contraction .
|
-
- HY-119973
-
|
|
Prostaglandin Receptor
|
Others
|
|
CAY10397 is a 15-hydroxyprostaglandin dehydrogenase inhibitor. It has the activity of inhibiting endothelial cell proliferation. CAY10397 can inhibit 15-hydroxyprostaglandin dehydrogenase, thereby affecting the metabolism of 11-oxoeicosatetraenoic acid (11-oxoeicosatetraenoic acid), which can inhibit endothelial cell proliferation.
|
-
- HY-160699
-
|
|
ULK
Ras
Autophagy
|
Cancer
|
|
DCC-3116 is an orally active ULK1/2 inhibitor. DCC-3116 can inhibit autophagy in lung cancer cells by inhibiting KRAS G12C signaling, thereby inhibiting the proliferation of lung cancer cells and exerting anti-cancer effects .
|
-
- HY-146227
-
|
|
Topoisomerase
Apoptosis
|
Cancer
|
|
DNA topoisomerase II inhibitor 1 (compound 8ed) is a potent DNA topoisomerase II inhibitor. DNA topoisomerase II inhibitor 1 shows anti-proliferative activity. DNA topoisomerase II inhibitor 1 induces apoptosis and cell cycle arrest at sub G1 phase .
|
-
- HY-10255A
-
|
SU 11248
|
VEGFR
PDGFR
IRE1
Mitophagy
Autophagy
Apoptosis
|
Cancer
|
|
Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively . Sunitinib, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation .
|
-
- HY-163666
-
|
|
HIV
PKC
|
Infection
|
|
HIV-1 inhibitor-68 (compound 26) is a protein kinase C (PKC) activator derivative with reversal activity in HIV-1 latency. HIV-1 inhibitor-68 may be able to eliminate cells latently infected with HIV-1, .
|
-
- HY-P4243A
-
|
|
Ser/Thr Protease
|
Others
|
|
Dansyl-Glu-Gly-Arg-Chloromethylketone TFA is a protease inhibitor, and inhibits serine/threonine proteases. Dansyl-Glu-Gly-Arg-Chloromethylketone TFA inhibits activated porcine factor IX .
|
-
- HY-147649
-
|
|
Glyoxalase (GLO)
|
Cancer
|
|
Glyoxalase I inhibitor 7 (Compound 6) is a glyoxalase I (Glo-I) inhibitor with an IC50 of 3.65 μM. Glyoxalase I inhibitor 7 can be used as anticancer agent .
|
-
- HY-135890
-
-
- HY-155645
-
|
|
Topoisomerase
Apoptosis
|
Cancer
|
|
Topoisomerase II inhibitor 15 (compound 2g) is a Topoisomerase II inhibitor. Topoisomerase II inhibitor 15 potently is an apoptotic inducer with greater selectivity against head and neck tumors .
|
-
- HY-156800
-
|
|
Phospholipase
|
Others
|
|
PDDC is a compound used to inhibit Alzheimer's disease. It is a nSMase2 inhibitor that can inhibit tau-induced nSMase2 activity and ceramide elevation, and slow the spread of tau in mouse models.
|
-
- HY-159150
-
|
|
HIV
|
Infection
|
|
HIV-1 inhibitor-71 (compound 2a) blocks the transport of endocytosed HIV-1 particles into nuclear envelope invagination (NEIs) that can inhibit productive infection .
|
-
- HY-N7563
-
|
|
EBV
|
Infection
Cancer
|
|
α-Toxicarol is a potent inhibitor of EBV.α-Toxicarol significantly inhibits mouse skin tumor in vivo. α-Toxicarol inhibits the TPA-induced EBV-EA activation .
|
-
- HY-132808
-
|
SAR 444727; PRN473
|
Btk
|
Inflammation/Immunology
|
|
Atuzabrutinib (SAR 444727) is a potent, selective reversible inhibitor of Btk (Bruton's tyrosine kinase) inhibitor. Atuzabrutinib inhibits neutrophil recruitment via inhibition of macrophage antigen-1 signalling .
|
-
- HY-139631
-
|
|
HIV
|
Infection
|
|
HIV-1 inhibitor-9 is found to be potent inhibitor against the wild-type (WT) HIV-1 strain or multiple NNRTI-resistant strains at low nanomolar levels.
|
-
- HY-157543
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
Tubulin polymerization-IN-59 ((R)-9k) is a potent inhibitor of colchicine binding site inhibitor (CBSI). Tubulin polymerization-IN-59 inhibits tubulin polymerization .
|
-
- HY-113951
-
|
Boc-Pro-prolinal; (Boc)-Prolyl-prolinal
|
Prolyl Endopeptidase (PREP)
|
Neurological Disease
|
|
Prolyl Endopeptidase Inhibitor 1 (Boc-Pro-prolinal) is a potent prolyl endopeptidase (PEP; PE) inhibitor, with a Ki value of 15 nM. Prolyl Endopeptidase Inhibitor 1 has anti-amnesic effect .
|
-
- HY-160445
-
|
|
Ras
|
Cancer
|
|
KRAS G12D inhibitor 19 (Compound 7) is a KRAS G12D inhibitor. KRAS G12D inhibitor 19 can be used for the research of cancer .
|
-
- HY-162366
-
|
|
Ras
|
Cancer
|
|
KRAS G12D inhibitor 20 (Compound 14) is a selective G12D KRAS inhibitor. KRAS G12D inhibitor 20 has antitumor activity .
|
-
- HY-123141
-
|
|
Pim
|
Cancer
|
|
K00135 is a potent and selective inhibitor of PIM kinases. K00135 inhibits survival and clonogenic growth of acute leukemia cells. K00135 inhibits the phosphorylation of PIM downstream targets .
|
-
- HY-19931
-
COH29
4 Publications Verification
RNR Inhibitor COH29
|
DNA/RNA Synthesis
|
Cancer
|
|
COH29 (RNR Inhibitor COH29) is a potent ribonucleotide reductase (RNR) inhibitor with anticancer activity. COH29 inhibits α and β subunit of RNR with IC50s of 16 μM.
|
-
- HY-161734
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
Microtubule inhibitor 11 (compound 33) is a microtubule inhibitor with a mechanism of action similar to colchicine (HY-N0282). Microtubule inhibitor 11 can be used in cancer-related research .
|
-
- HY-147877
-
|
|
Topoisomerase
|
Cancer
|
|
Topoisomerase II inhibitor 12 (Compound 8c) is a topoisomerase II (topo II) inhibitor, working as a DNA non-intercalator. Topoisomerase II inhibitor 12 shows antineoplastic activity .
|
-
- HY-169517
-
|
|
TAM Receptor
FAK
c-Kit
|
Cancer
|
|
Protein kinase inhibitor 10 is a protein kinase inhibitor with IC50 values of 28.9, 13.6, and 2.41 μM for TAM receptor, FAK, and KIT, respectively. Protein kinase inhibitor 10 can inhibit abnormal and excessive cell proliferation, showing promise for research in cancer therapy .
|
-
- HY-149486
-
|
|
FGFR
|
Cancer
|
|
FGFR1 inhibitor 7 (compound 5) is an inhibitor of FGFR1 Tyrosine Kinase with IC50 value of 0.33 nM. FGFR1 inhibitor 7 shows broad-spectrum cytotoxicity agasinst human cancer cell lines, and inhibits MOLT3 cells with IC50 of 2.1 μM .
|
-
- HY-159092
-
|
|
HIV Integrase
|
Infection
|
|
HIV-1 integrase inhibitor 13 (Compound 15) is an inhibitor for HIV-1 integrase with an IC50 of 1.8 nM. HIV-1 integrase inhibitor 13 inhibits the HIV-1 WT and HIV-1 T125A, with IC50 of 21 and 580 nM, respectively .
|
-
- HY-172616
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
Tubulin inhibitor 50 (compound 07) is a tubulin inhibitor that increases the mitochondrial reactive oxygen species level. Tubulin inhibitor 50 has anti-cancer effect in HeLa cells with IC50 value of 0.46 μM. Tubulin inhibitor 50 shows low toxicity in normal cell lines .
|
-
- HY-P2477
-
|
|
PD-1/PD-L1
|
Inflammation/Immunology
|
|
Human PD-L1 inhibitor IV, a polypeptide, is a competitive human PD-1 protein inhibitor with a Kd value of 1.38 μM. Human PD-L1 inhibitor IV inhibits the interaction of hPD-1/hPD-L1 .
|
-
- HY-W844558
-
|
|
Pim
CDK
GSK-3
Src
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Protein kinase inhibitor 11 (Compound I-96) is a protein kinase inhibitor that can inhibit the activity of PIM-1, CDK-2, GSK-3, and SRC. Protein kinase inhibitor 11 holds promise for research in cancer, immune disorders, and neurodegenerative diseases .
|
-
- HY-128034
-
|
|
PIN1
|
Cancer
|
|
PPIase-Parvulin inhibitor (compound B) is a cell-permeable inhibitor targeting PPIase Pin1 and Par14, with IC50s of 1.5 and 1.0 µM, respectively. PPIase-Parvulin inhibitor has anticancer activity and inhibits the growth and proliferation of mouse embryonic fibroblasts (MEFs) .
|
-
- HY-146778
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
Tubulin inhibitor 25 is a potent tubulin inhibitor with an IC50 value of 0.98 μM. Tubulin inhibitor 25 exhibits remarkable activity against cancer cell line HT29. Tubulin inhibitor 25 displays the potent inhibition on cell migration and tube formation that contributes to the anti-angiogenesis .
|
-
- HY-113571
-
|
|
Tie
|
Cardiovascular Disease
|
|
Tie2 kinase inhibitor 2 (compound 7) is a selective Tie2 kinase inhibitor with an IC50 value of 1 μM. Tie2 kinase inhibitor 2 inhibits endothelial cell tube formation, and can be used for Tie2-mediated angiogenic disorders research .
|
-
- HY-149542
-
|
|
Tau Protein
Apoptosis
GSK-3
|
Neurological Disease
|
|
GSK-3β inhibitor 15 (Compound 54) is a GSK-3β inhibitor (IC50: 3.4 nM). GSK-3β inhibitor 15 inhibits Aβ1-42-induced GSK-3β and tau protein phosphorylation. GSK-3β inhibitor 15 inhibits LPS-induced iNOS expression. GSK-3β inhibitor 15 has neuroprotective effects on Aβ1-42-induced neurotoxicity. GSK-3β inhibitor 15 can be used for research of Alzheimer’s disease (AD) .
|
-
- HY-155114
-
|
|
HIV
|
Infection
|
|
HIV-1 inhibitor-59 (Compound I-5b) is a HIV-1 inhibitor, with EC50s of 5.62-171 nM against the wild-type (WT) and mutant HIV-1 strains. HIV-1 inhibitor-59 has moderate RT enzyme inhibitory activity (IC50: 0.094-12.0 μM) .
|
-
- HY-159957
-
|
|
Histone Acetyltransferase
Estrogen Receptor/ERR
|
|
|
BAY-184 is a selective and orally active KAT6A and KAT6B inhibitor. BAY-184 inhibits KAT6A/KAT6B activity with an IC50 of 71 nM and 83 nM. respectively BAY-184 inhibits ERα transcriptional activity. BAY-184 inhibits proliferation of diverse breast cancer subtypes, and inhibits tumor growth .
|
-
- HY-150570
-
|
|
Carbonic Anhydrase
CDK
|
Cancer
|
|
Carbonic anhydrase inhibitor 14 (Compound 8b) is a carbonic anhydrase (CA) inhibitor with Ki values of 1203, 99.7, 9.4 and 27.7 nM against hCA I, hCA II, hCA IX and hCA XII, respectively. Carbonic anhydrase inhibitor 14 can also inhibit CDK2 with an IC50 of 20.3 μM. Carbonic anhydrase inhibitor 14 shows antitumor activity .
|
-
- HY-148133
-
|
|
GSK-3
|
Neurological Disease
|
|
GSK-3β inhibitor 12 (compound 15) is an inhibitor of GSK-3β. GSK-3β inhibitor 12 inhibits 49.11% and 37.11% activity of 25 μM and 50 μM GSK-3β, respectively. GSK-3β inhibitor 12 can be used for the research of neurodegenerative diseases .
|
-
- HY-144112
-
|
|
HIV
|
Infection
|
|
HIV-1 inhibitor-13 (compound 16c) is a orally active and potent HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI), with IC50 of 0.14 μM (HIV-1 RT). HIV-1 inhibitor-13 shows activity against a panel of HIV-1 resistant strains, with EC50 values of 2.85-18.0 nM .
|
-
- HY-143721
-
|
|
Monoamine Oxidase
|
Cardiovascular Disease
Metabolic Disease
Inflammation/Immunology
|
|
SSAO inhibitor-2 (Compound 1) is a semicarbazide-sensitive amine oxidase (SSAO) inhibitor with IC50s of <10 nM, and 10-100 μM for human SSAO and MAO-A, respectively. SSAO inhibitor-3 can be used for the research of atherosclerosis, diabetes and its complications, obesity, stroke, chronic kidney disease, retinopathy, chronic obstructive pulmonary disease (COPD), autoimmune diseases, multiple sclerosis, etc .
|
-
- HY-147841
-
|
|
HIV
Reverse Transcriptase
|
Infection
|
|
HIV-1 inhibitor-41 (Compound B23) is an orally active non-nucleoside HIV-1 reverse transcriptase inhibitor with EC50 values of 20.8 nM and 50 nM against HIV-1 WT and mutant E138K strain, respectively. HIV-1 inhibitor-41 shows low hERG, no apparent CYP enzymatic inhibition and no acute toxicity .
|
-
- HY-162879
-
|
|
FAK
Src
Akt
Autophagy
|
Cancer
|
FAK inhibitor 7 is a type of FAK inhibitor with an IC50 value of 3.58 nM. FAK inhibitor 7 can inhibit the downstream signaling cascades of FAK (like Src and AKT), causing ovarian cancer cells to stall in the G0/G1 phase and induce cytotoxic autophagy. FAK inhibitor 7 can also suppress tumor metastasis and growth in ovarian cancer mice .
|
-
- HY-161153
-
|
|
Apoptosis
|
Cancer
|
|
Microtubule inhibitor 9 (Compound O-7) is a 2-Aryl-1H-benzo [d] imidazole derivative with in vitro anticancer activity. Microtubule inhibitor 9 can induce cell cycle arrest at the G2/M phase and early apoptosis. Microtubule inhibitor 9 inhibits cancer cell migration by inhibiting wound healing and colony formation .
|
-
- HY-163269
-
|
|
Bacterial
|
Others
|
|
MPT is a novel and highly efficient nitrification inhibitor. MPT inhibits ammoniaoxidizing bacteria and archaea .
|
-
- HY-70005
-
|
Carboxypeptidase inhibitor
|
Carboxypeptidase
|
Others
|
|
CPA inhibitor (Compound 5) is a potent carboxypeptidase A (CPA) inhibitor with a Ki of 0.32 μM .
|
-
- HY-161721
-
|
|
Cathepsin
|
Cancer
|
|
Cathepsin Inhibitor 4 (Compound 45) is a selective inhibitor for Cathepsin S with Ki of 0.04 nM .
|
-
- HY-132920
-
|
|
Ras
|
Cancer
|
|
KRAS mutant protein inhibitor 1 is a KRAS mutant protein inhibitor for potential research in cancer.
|
-
- HY-U00439
-
|
|
DYRK
|
Cancer
|
|
Protein kinase inhibitor 1 is a novel inhibitor of HIPK2 with an IC50 of 74 nM and Kd of 9.5 nM.
|
-
- HY-120673
-
-
- HY-153348
-
|
|
p38 MAPK
|
Cancer
|
|
p38 Kinase inhibitor 4 (compound 135) is a potent p38 inhibitor .
|
-
- HY-50900
-
|
Amyloid-β production inhibitor; γ-Secretase Modulators
|
Amyloid-β
|
Neurological Disease
|
|
gamma-Secretase Modulators (Amyloid-β production inhibitor) is a Amyloid-β production inhibitor.
|
-
- HY-10846
-
|
OPC-67683
|
Bacterial
Antibiotic
|
Cancer
|
|
Delamanid, a newer mycobacterial cell wall synthesis inhibitor, inhibits the synthesisi of mucolic acids .
|
-
- HY-W013478
-
|
|
Phosphatase
|
Cancer
|
|
PTP inhibitor 1 is a protein tyrosine phosphatase (PTP) inhibitor, with anti-angiogenic effect .
|
-
- HY-103217
-
-
- HY-146122
-
-
- HY-126112
-
|
|
Others
|
Neurological Disease
|
|
Mephenoxalone inhibits neuron transmission and can relax skeletal muscles by inhibiting the reflex arc .
|
-
- HY-15162A
-
-
- HY-111488
-
|
|
Phosphatase
|
Metabolic Disease
|
|
ML 400 is a potent and selective LMPTP inhibitor with an IC50 value of 1680 nM. ML 400 inhibits adipogenesis .
|
-
- HY-106749
-
-
- HY-146656
-
|
|
Glyoxalase (GLO)
|
Cancer
|
|
Glyoxalase I inhibitor 4 (compound 14) is a potent glyoxalase I inhibitor with an Ki of 10 nM .
|
-
- HY-12277
-
AZ191
5 Publications Verification
|
DYRK
|
Cancer
|
|
AZ191 is a potent inhibitor that selectively inhibits DYRK1B with IC50 of 17 nM .
|
-
- HY-P2021
-
-
- HY-100110
-
KNK437
3 Publications Verification
Heat Shock Protein Inhibitor I
|
HSP
|
Cancer
|
|
KNK437 is a HSP inhibitor, and inhibits the induction of HSP105, HSP70, and HSP40.
|
-
- HY-N12405
-
|
|
Calmodulin
|
Others
|
|
Encecalinol, extracted from aerial parts of Ageratina grandifolia, is a potent inhibitor of calmodulin inhibitor .
|
-
- HY-146124
-
-
- HY-139720
-
-
- HY-101791
-
|
|
P-glycoprotein
|
Cancer
|
|
P-gp inhibitor 1 is a novel inhibitor reversing P-glycoprotein-mediated multidrug resistance.
|
-
- HY-156579
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
WRN inhibitor 3 (example 110), a cyclic vinyl sulfone compound, is a Wemer Syndrome ATP dependent helicase enzyme (WRN) inhibitor. WRN inhibitor 3 can be used for the research of cancer .
|
-
- HY-122394
-
|
|
Antibiotic
Bacterial
|
Infection
|
|
Thiolactomycin is an antibiotic. Thiolactomycin is active against Gram-negative anaerobes. Thiolactomycin also inhibits malaria and trypanosomes. Thiolactomycin is a FabB inhibitor. Thiolactomycin inhibits the synthesis of fatty acids and mycolic acids .
|
-
- HY-156464
-
|
|
Topoisomerase
|
Infection
|
|
Topoisomerase I inhibitor 10 (compound 13) is a leishmanial topoisomerase IB inhibitor. Topoisomerase I inhibitor 10 has antileishmanial activity against L. donovani promastigotes, with the IC50 of 27.91 μM .
|
-
- HY-143250
-
|
|
Microtubule/Tubulin
|
Cancer
|
|
Tubulin inhibitor 12 (Hit 9) is a novel tubulin inhibitor (IC50=25.3 μM). Tubulin inhibitor 12 shows anti-tumor activity and anti-proliferative activity .
|
-
- HY-154962
-
|
|
Bcl-2 Family
|
Cancer
|
|
Mcl-1 inhibitor 15 (Compound (Ra)-15) is a Mcl-1 inhibitor (Ki: 0.02 nM). Mcl-1 inhibitor 15 can be used for research of cancer .
|
-
- HY-105387
-
-
- HY-114309
-
|
|
URAT1
|
Inflammation/Immunology
|
|
URAT1 inhibitor 1 (1g) is a uric acid transporter 1 (URAT1) inhibitor, with an IC50 of 32 nM. URAT1 inhibitor 1 has potential to treat hyperuricemia associated with gout .
|
-
- HY-111429
-
|
|
YAP
|
Cancer
|
|
YAP/TAZ inhibitor-1 is a YAP/TAZ inhibitor extracted from patent WO2017058716A1, Compound 1, has an IC50 of <0.100 μΜ in firefly luciferase assay .
|
-
- HY-136750
-
|
Calpain Inhibitor IV
|
Apoptosis
Proteasome
|
Cancer
|
|
Z-LLY-FMK (Calpain Inhibitor IV) is a calpain inhibitor, involved in apoptosis of many cell systems. Z-LLY-FMK inhibits the intestine apoptosis after common bile duct ligation .
|
-
- HY-138037
-
|
|
Aminopeptidase
|
Cancer
|
|
Aminopeptidase N inhibitor 1 (Compound 19b) is an aminopeptidase N inhibitor with an IC50 of 25 μM. Aminopeptidase N inhibitor 1 can be used in the research of fields related to tumor angiogenesis .
|
-
- HY-120494
-
|
|
Epoxide Hydrolase
|
Inflammation/Immunology
|
|
sEH inhibitor-1 (compound TCPU ) is a potent and oral active inhibitor of sEH (soluble epoxide hydrolase) with IC50s of 0.4 and 5.3 nM in human and murine, respectively .
|
-
- HY-149850
-
|
|
p38 MAPK
|
Inflammation/Immunology
|
p38 Kinase inhibitor 5 (AA6) is a potent p38 kinase inhibitor with an IC50 of 403.57 nM. p38 Kinase inhibitor 5 has anti-inflammatory activity .
|
-
- HY-112910
-
|
|
HSP
|
Inflammation/Immunology
Cancer
|
|
Grp94 Inhibitor-1 is a potent, selective Grp94 inhibitor with an IC50 value of 2 nM, and over 1000-fold selectivity to Grp94 against Hsp90α .
|
-
- HY-169255
-
-
- HY-164143
-
|
|
Topoisomerase
|
Cancer
|
|
T638 is a topoisomerase II (TOP2) inhibitor. T638 inhibits TOP2A activity with a IC50 of 0.7 uM. T638 strongly inhibits cancer cell growth .
|
-
- HY-148676
-
|
Menin-MLL inhibitor 26
|
Epigenetic Reader Domain
|
Cancer
|
|
Emilumenib (Menin-MLL inhibitor 26) is an orally active Menin-MLL inhibitor. Emilumenib also is an active reference. Emilumenib can inhibits cell growth. Emilumenib can be used for the research of leukemia .
|
-
- HY-124718
-
|
M36
|
PKC
|
Cancer
|
|
p32 inhibitor M36 (M36) is a p32 mitochondrial protein inhibitor, which binds directly to p32 and inhibits p32 association with LyP-1 .
|
-
- HY-146064
-
|
|
Osteopontin
|
Cancer
|
|
OPN expression inhibitor 1 is an osteopontin (OPN) expression inhibitor. OPN expression inhibitor 1 has potential anti-breast cancer cell metastasis activity and can be used in the study of cancer .
|
-
- HY-156580
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
WRN inhibitor 4 (example 107), a cyclic vinyl sulfone compound, is a Wemer Syndrome ATP dependent helicase enzyme (WRN) inhibitor. WRN inhibitor 4 can be used for the research of cancer .
|
-
- HY-169629
-
|
|
Casein Kinase
|
Cancer
|
|
CK2 inhibitor 4 (compound 5b) is a protein kinase CK2 inhibitor with IC50 of 3.8 μM. CK2 inhibitor 4 can be used in tumor research .
|
-
- HY-115753
-
|
|
Proteasome
|
Neurological Disease
|
|
Calpain Inhibitor-1 (compound 36) is a potent and selective cysteine protease calpain 1 (Cal1) inhibitor (IC50=100 nM; Ki=2.89 μM) .
|
-
- HY-106508
-
|
HP 129; P 71-0129
|
PAI-1
|
Inflammation/Immunology
|
|
Fendosal (HP 129) is an orally active, potent non-steroidal anti-inflammatory agent. Fendosal (HP 129) is also an inhibitor of Plasminogen activator inhibitor-1 (PAI-1) .
|
-
- HY-118355
-
|
Calpain inhibitor II
|
Proteasome
Cathepsin
|
Neurological Disease
|
|
ALLM (Calpain inhibitor II) is a potent inhibitor of calpain and cathepsin proteases. ALLM inhibits neuronal cell death and improves chronic neurological function after spinal cord injury (SCI) .
|
-
- HY-147647
-
|
|
Glyoxalase (GLO)
|
Cancer
|
|
Glyoxalase I inhibitor 5 (Compound 9h) is a glyoxalase I (Glo-I) inhibitor with an IC50 of 1.28 μM. Glyoxalase I inhibitor 5 can be used as anticancer agent .
|
-
- HY-152177
-
|
|
NF-κB
|
Cancer
|
|
JS6 is a Bcl3 inhibitor, and inhibits Bcl3-NF-kB1 binding. JS6 inhibits tumor cell growth in vitro and in vivo .
|
-
- HY-161082
-
|
|
Topoisomerase
|
Cancer
|
|
Topoisomerase I inhibitor 12 (compound 12), a Camptothecin (HY-16560)-based derivative, is a potent Topoisomerase I inhibitor. Topoisomerase I inhibitor 12 shows anticancer activity .
|
-
- HY-169312
-
|
|
Ras
|
Cancer
|
|
KRAS inhibitor-38 (Example 18) is a KRAS inhibitor that effectively suppresses the activity of KRAS G12C, KRAS G12D, and KRAS G12V in vivo .
|
-
- HY-135130
-
|
(-)-BABX
|
Bacterial
|
Infection
|
|
Bischloroanthrabenzoxocinone is a potent Type II fatty acid synthesis (FASII) inhibitor. Bischloroanthrabenzoxocinone inhibits fatty acid synthesis. Bischloroanthrabenzoxocinone shows antibacterial activities and inhibits phospholipid, DNA, RNA, protein, and cell wall synthesis .
|
-
- HY-162452
-
|
|
Prolyl Endopeptidase (PREP)
|
Neurological Disease
|
|
Prolyl endopeptidase inhibitor 2 (Compound 8) was a proline endopeptidase (PEP) inhibitor with IC50 value 31.11 μM. Prolyl endopeptidase inhibitor 2 can be used in the study of neurodegenerative diseases .
|
-
- HY-RI01066
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4462 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4462 inhibitor
hsa-miR-4462 inhibitor
- HY-RI01977
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-657 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-657 inhibitor
hsa-miR-657 inhibitor
- HY-RI02476
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-8084 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-8084 inhibitor
hsa-miR-8084 inhibitor
- HY-RI00783
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3674 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3674 inhibitor
hsa-miR-3674 inhibitor
- HY-RI00899
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3939 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3939 inhibitor
hsa-miR-3939 inhibitor
- HY-RI04525
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-6314 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-6314 inhibitor
rno-miR-6314 inhibitor
- HY-RI00775
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3666 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3666 inhibitor
hsa-miR-3666 inhibitor
- HY-RI03346
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6340 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6340 inhibitor
mmu-miR-6340 inhibitor
- HY-RI04161
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-8113 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-8113 inhibitor
mmu-miR-8113 inhibitor
- HY-RI01296
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4710 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4710 inhibitor
hsa-miR-4710 inhibitor
- HY-RI04305
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-215 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-215 inhibitor
rno-miR-215 inhibitor
- HY-RI04141
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-8093 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-8093 inhibitor
mmu-miR-8093 inhibitor
- HY-RI00631
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3175 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3175 inhibitor
hsa-miR-3175 inhibitor
- HY-RI01186
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4641 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4641 inhibitor
hsa-miR-4641 inhibitor
- HY-RI01783
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-5701 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-5701 inhibitor
hsa-miR-5701 inhibitor
- HY-RI00626
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3170 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3170 inhibitor
hsa-miR-3170 inhibitor
- HY-RI04155
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-8107 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-8107 inhibitor
mmu-miR-8107 inhibitor
- HY-RI03348
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6342 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6342 inhibitor
mmu-miR-6342 inhibitor
- HY-RI00895
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3935 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3935 inhibitor
hsa-miR-3935 inhibitor
- HY-RI01054
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4448 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4448 inhibitor
hsa-miR-4448 inhibitor
- HY-RI04406
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-3570 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-3570 inhibitor
rno-miR-3570 inhibitor
- HY-RI02453
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-8061 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-8061 inhibitor
hsa-miR-8061 inhibitor
- HY-RI00884
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3924 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3924 inhibitor
hsa-miR-3924 inhibitor
- HY-RI01913
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-639 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-639 inhibitor
hsa-miR-639 inhibitor
- HY-RI00977
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4297 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4297 inhibitor
hsa-miR-4297 inhibitor
- HY-RI00625
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3169 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3169 inhibitor
hsa-miR-3169 inhibitor
- HY-RI00226
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-1297 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-1297 inhibitor
hsa-miR-1297 inhibitor
- HY-RI04383
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-3547 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-3547 inhibitor
rno-miR-3547 inhibitor
- HY-RI02470
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-8078 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-8078 inhibitor
hsa-miR-8078 inhibitor
- HY-RI01978
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-658 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-658 inhibitor
hsa-miR-658 inhibitor
- HY-RI00981
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4301 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4301 inhibitor
hsa-miR-4301 inhibitor
- HY-RI03284
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-5136 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-5136 inhibitor
mmu-miR-5136 inhibitor
- HY-RI01178
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4636 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4636 inhibitor
hsa-miR-4636 inhibitor
- HY-RI01081
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4476 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4476 inhibitor
hsa-miR-4476 inhibitor
- HY-RI01070
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4466 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4466 inhibitor
hsa-miR-4466 inhibitor
- HY-RI01365
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4752 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4752 inhibitor
hsa-miR-4752 inhibitor
- HY-RI04327
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-297 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-297 inhibitor
rno-miR-297 inhibitor
- HY-RI00727
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3611 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3611 inhibitor
hsa-miR-3611 inhibitor
- HY-RI00169
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-1261 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-1261 inhibitor
hsa-miR-1261 inhibitor
- HY-RI01753
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-562 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-562 inhibitor
hsa-miR-562 inhibitor
- HY-RI01577
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-5191 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-5191 inhibitor
hsa-miR-5191 inhibitor
- HY-RI03351
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6345 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6345 inhibitor
mmu-miR-6345 inhibitor
- HY-RI02440
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-7976 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-7976 inhibitor
hsa-miR-7976 inhibitor
- HY-RI00393
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-1973 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-1973 inhibitor
hsa-miR-1973 inhibitor
- HY-RI01074
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4470 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4470 inhibitor
hsa-miR-4470 inhibitor
- HY-RI03369
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6363 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6363 inhibitor
mmu-miR-6363 inhibitor
- HY-RI01777
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-5696 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-5696 inhibitor
hsa-miR-5696 inhibitor
- HY-RI01861
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-6086 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-6086 inhibitor
hsa-miR-6086 inhibitor
- HY-RI03561
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-692 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-692 inhibitor
mmu-miR-692 inhibitor
- HY-RI01099
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4490 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4490 inhibitor
hsa-miR-4490 inhibitor
- HY-RI00178
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-1267 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-1267 inhibitor
hsa-miR-1267 inhibitor
- HY-RI01377
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4759 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4759 inhibitor
hsa-miR-4759 inhibitor
- HY-RI04187
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-882 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-882 inhibitor
mmu-miR-882 inhibitor
- HY-RI00712
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-346 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-346 inhibitor
hsa-miR-346 inhibitor
- HY-RI01087
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4480 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4480 inhibitor
hsa-miR-4480 inhibitor
- HY-RI00245
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-1321 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-1321 inhibitor
hsa-miR-1321 inhibitor
- HY-RI00635
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3178 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3178 inhibitor
hsa-miR-3178 inhibitor
- HY-RI04546
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-6334 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-6334 inhibitor
rno-miR-6334 inhibitor
- HY-RI02802
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-1983 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-1983 inhibitor
mmu-miR-1983 inhibitor
- HY-RI01069
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4465 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4465 inhibitor
hsa-miR-4465 inhibitor
- HY-RI04377
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-352 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-352 inhibitor
rno-miR-352 inhibitor
- HY-RI02442
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-7978 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-7978 inhibitor
hsa-miR-7978 inhibitor
- HY-RI01055
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4449 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4449 inhibitor
hsa-miR-4449 inhibitor
- HY-RI00946
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4267 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4267 inhibitor
hsa-miR-4267 inhibitor
- HY-RI00778
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3668 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3668 inhibitor
hsa-miR-3668 inhibitor
- HY-RI03821
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-704 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-704 inhibitor
mmu-miR-704 inhibitor
- HY-RI00091
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-12115 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-12115 inhibitor
hsa-miR-12115 inhibitor
- HY-RI01036
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4434 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4434 inhibitor
hsa-miR-4434 inhibitor
- HY-RI01914
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-640 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-640 inhibitor
hsa-miR-640 inhibitor
- HY-RI00503
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-2861 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-2861 inhibitor
hsa-miR-2861 inhibitor
- HY-RI03371
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6365 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6365 inhibitor
mmu-miR-6365 inhibitor
- HY-RI00201
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-1283 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-1283 inhibitor
hsa-miR-1283 inhibitor
- HY-RI03428
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6419 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6419 inhibitor
mmu-miR-6419 inhibitor
- HY-RI01758
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-5680 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-5680 inhibitor
hsa-miR-5680 inhibitor
- HY-RI01118
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4504 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4504 inhibitor
hsa-miR-4504 inhibitor
- HY-RI01104
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4495 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4495 inhibitor
hsa-miR-4495 inhibitor
- HY-RI00880
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3921 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3921 inhibitor
hsa-miR-3921 inhibitor
- HY-RI00940
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4261 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4261 inhibitor
hsa-miR-4261 inhibitor
- HY-RI01248
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4679 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4679 inhibitor
hsa-miR-4679 inhibitor
- HY-RI01056
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4450 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4450 inhibitor
hsa-miR-4450 inhibitor
- HY-RI03256
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-5112 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-5112 inhibitor
mmu-miR-5112 inhibitor
- HY-RI02727
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-1902 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-1902 inhibitor
mmu-miR-1902 inhibitor
- HY-RI04539
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-6327 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-6327 inhibitor
rno-miR-6327 inhibitor
- HY-RI00878
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3919 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3919 inhibitor
hsa-miR-3919 inhibitor
- HY-RI01340
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4736 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4736 inhibitor
hsa-miR-4736 inhibitor
- HY-RI00397
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-198 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-198 inhibitor
hsa-miR-198 inhibitor
- HY-RI02419
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-7704 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-7704 inhibitor
hsa-miR-7704 inhibitor
- HY-RI01061
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4455 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4455 inhibitor
hsa-miR-4455 inhibitor
- HY-RI02438
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-7974 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-7974 inhibitor
hsa-miR-7974 inhibitor
- HY-RI00979
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4299 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4299 inhibitor
hsa-miR-4299 inhibitor
- HY-RI02417
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-7702 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-7702 inhibitor
hsa-miR-7702 inhibitor
- HY-RI02461
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-8069 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-8069 inhibitor
hsa-miR-8069 inhibitor
- HY-RI01718
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-555 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-555 inhibitor
hsa-miR-555 inhibitor
- HY-RI04138
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-8090 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-8090 inhibitor
mmu-miR-8090 inhibitor
- HY-RI01026
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4427 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4427 inhibitor
hsa-miR-4427 inhibitor
- HY-RI04385
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-3549 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-3549 inhibitor
rno-miR-3549 inhibitor
- HY-RI03347
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6341 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6341 inhibitor
mmu-miR-6341 inhibitor
- HY-RI01608
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-521 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-521 inhibitor
hsa-miR-521 inhibitor
- HY-RI01085
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4479 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4479 inhibitor
hsa-miR-4479 inhibitor
- HY-RI00774
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3665 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3665 inhibitor
hsa-miR-3665 inhibitor
- HY-RI02468
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-8076 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-8076 inhibitor
hsa-miR-8076 inhibitor
- HY-RI01576
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-5190 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-5190 inhibitor
hsa-miR-5190 inhibitor
- HY-RI01216
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4660 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4660 inhibitor
hsa-miR-4660 inhibitor
- HY-RI01065
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4460 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4460 inhibitor
hsa-miR-4460 inhibitor
- HY-RI00213
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-1291 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-1291 inhibitor
hsa-miR-1291 inhibitor
- HY-RI00879
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3920 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3920 inhibitor
hsa-miR-3920 inhibitor
- HY-RI03395
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6389 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6389 inhibitor
mmu-miR-6389 inhibitor
- HY-RI00569
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3131 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3131 inhibitor
hsa-miR-3131 inhibitor
- HY-RI01875
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-6130 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-6130 inhibitor
hsa-miR-6130 inhibitor
- HY-RI00064
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-11399 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-11399 inhibitor
hsa-miR-11399 inhibitor
- HY-RI00218
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-1293 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-1293 inhibitor
hsa-miR-1293 inhibitor
- HY-RI01453
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-484 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-484 inhibitor
hsa-miR-484 inhibitor
- HY-RI02751
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-1936 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-1936 inhibitor
mmu-miR-1936 inhibitor
- HY-RI01177
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4635 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4635 inhibitor
hsa-miR-4635 inhibitor
- HY-RI01162
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4535 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4535 inhibitor
hsa-miR-4535 inhibitor
- HY-RI01057
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4451 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4451 inhibitor
hsa-miR-4451 inhibitor
- HY-RI03500
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-678 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-678 inhibitor
mmu-miR-678 inhibitor
- HY-RI01045
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4441 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4441 inhibitor
hsa-miR-4441 inhibitor
- HY-RI00211
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-1289 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-1289 inhibitor
hsa-miR-1289 inhibitor
- HY-RI01008
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4325 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4325 inhibitor
hsa-miR-4325 inhibitor
- HY-RI04562
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-678 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-678 inhibitor
rno-miR-678 inhibitor
- HY-RI01801
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-577 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-577 inhibitor
hsa-miR-577 inhibitor
- HY-RI03362
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6356 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6356 inhibitor
mmu-miR-6356 inhibitor
- HY-RI00593
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3149 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3149 inhibitor
hsa-miR-3149 inhibitor
- HY-RI00762
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3658 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3658 inhibitor
hsa-miR-3658 inhibitor
- HY-RI01874
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-613 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-613 inhibitor
hsa-miR-613 inhibitor
- HY-RI01887
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-618 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-618 inhibitor
hsa-miR-618 inhibitor
- HY-RI03667
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-697 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-697 inhibitor
mmu-miR-697 inhibitor
- HY-RI00947
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4268 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4268 inhibitor
hsa-miR-4268 inhibitor
- HY-RI03239
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-5046 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-5046 inhibitor
mmu-miR-5046 inhibitor
- HY-RI01106
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4497 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4497 inhibitor
hsa-miR-4497 inhibitor
- HY-RI00199
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-1282 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-1282 inhibitor
hsa-miR-1282 inhibitor
- HY-RI01842
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-6069 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-6069 inhibitor
hsa-miR-6069 inhibitor
- HY-RI01253
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4683 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4683 inhibitor
hsa-miR-4683 inhibitor
- HY-RI01870
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-6126 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-6126 inhibitor
hsa-miR-6126 inhibitor
- HY-RI01775
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-5694 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-5694 inhibitor
hsa-miR-5694 inhibitor
- HY-RI01909
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-635 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-635 inhibitor
hsa-miR-635 inhibitor
- HY-RI04411
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-3574 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-3574 inhibitor
rno-miR-3574 inhibitor
- HY-RI00084
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-1204 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-1204 inhibitor
hsa-miR-1204 inhibitor
- HY-RI02510
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-924 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-924 inhibitor
hsa-miR-924 inhibitor
- HY-RI00236
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-1305 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-1305 inhibitor
hsa-miR-1305 inhibitor
- HY-RI03064
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-3472 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-3472 inhibitor
mmu-miR-3472 inhibitor
- HY-RI00896
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3936 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3936 inhibitor
hsa-miR-3936 inhibitor
- HY-RI00663
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3196 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3196 inhibitor
hsa-miR-3196 inhibitor
- HY-RI00101
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-12125 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-12125 inhibitor
hsa-miR-12125 inhibitor
- HY-RI00107
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-12131 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-12131 inhibitor
hsa-miR-12131 inhibitor
- HY-RI00196
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-1279 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-1279 inhibitor
hsa-miR-1279 inhibitor
- HY-RI01017
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4418 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4418 inhibitor
hsa-miR-4418 inhibitor
- HY-RI00192
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-1276 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-1276 inhibitor
hsa-miR-1276 inhibitor
- HY-RI01884
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-6165 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-6165 inhibitor
hsa-miR-6165 inhibitor
- HY-RI01165
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4537 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4537 inhibitor
hsa-miR-4537 inhibitor
- HY-RI01161
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4534 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4534 inhibitor
hsa-miR-4534 inhibitor
- HY-RI01107
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4498 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4498 inhibitor
hsa-miR-4498 inhibitor
- HY-RI00592
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3148 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3148 inhibitor
hsa-miR-3148 inhibitor
- HY-RI02828
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-2139 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-2139 inhibitor
mmu-miR-2139 inhibitor
- HY-RI04528
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-6317 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-6317 inhibitor
rno-miR-6317 inhibitor
- HY-RI01897
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-626 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-626 inhibitor
hsa-miR-626 inhibitor
- HY-RI04149
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-8101 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-8101 inhibitor
mmu-miR-8101 inhibitor
- HY-RI01768
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-569 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-569 inhibitor
hsa-miR-569 inhibitor
- HY-RI03374
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6368 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6368 inhibitor
mmu-miR-6368 inhibitor
- HY-RI02721
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-1899 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-1899 inhibitor
mmu-miR-1899 inhibitor
- HY-RI03419
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6412 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6412 inhibitor
mmu-miR-6412 inhibitor
- HY-RI01795
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-5739 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-5739 inhibitor
hsa-miR-5739 inhibitor
- HY-RI01533
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-5094 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-5094 inhibitor
hsa-miR-5094 inhibitor
- HY-RI04437
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-3595 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-3595 inhibitor
rno-miR-3595 inhibitor
- HY-RI04225
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-1297 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-1297 inhibitor
rno-miR-1297 inhibitor
- HY-RI02516
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-933 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-933 inhibitor
hsa-miR-933 inhibitor
- HY-RI00908
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3945 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3945 inhibitor
hsa-miR-3945 inhibitor
- HY-RI01145
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4522 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4522 inhibitor
hsa-miR-4522 inhibitor
- HY-RI03438
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6539 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6539 inhibitor
mmu-miR-6539 inhibitor
- HY-RI02758
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-1942 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-1942 inhibitor
mmu-miR-1942 inhibitor
- HY-RI03430
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6481 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6481 inhibitor
mmu-miR-6481 inhibitor
- HY-RI01208
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4656 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4656 inhibitor
hsa-miR-4656 inhibitor
- HY-RI00603
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3154 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3154 inhibitor
hsa-miR-3154 inhibitor
- HY-RI04538
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-6326 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-6326 inhibitor
rno-miR-6326 inhibitor
- HY-RI04362
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-343 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-343 inhibitor
rno-miR-343 inhibitor
- HY-RI01252
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4682 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4682 inhibitor
hsa-miR-4682 inhibitor
- HY-RI01559
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-5186 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-5186 inhibitor
hsa-miR-5186 inhibitor
- HY-RI00559
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3125 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3125 inhibitor
hsa-miR-3125 inhibitor
- HY-RI00479
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-2392 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-2392 inhibitor
hsa-miR-2392 inhibitor
- HY-RI03341
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6335 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6335 inhibitor
mmu-miR-6335 inhibitor
- HY-RI04329
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-2985 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-2985 inhibitor
rno-miR-2985 inhibitor
- HY-RI02779
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-1960 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-1960 inhibitor
mmu-miR-1960 inhibitor
- HY-RI01013
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4329 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4329 inhibitor
hsa-miR-4329 inhibitor
- HY-RI04340
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-3075 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-3075 inhibitor
rno-miR-3075 inhibitor
- HY-RI02251
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-6844 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-6844 inhibitor
hsa-miR-6844 inhibitor
- HY-RI01529
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-5092 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-5092 inhibitor
hsa-miR-5092 inhibitor
- HY-RI03625
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-695 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-695 inhibitor
mmu-miR-695 inhibitor
- HY-RI00111
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-12136 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-12136 inhibitor
hsa-miR-12136 inhibitor
- HY-RI04542
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-6330 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-6330 inhibitor
rno-miR-6330 inhibitor
- HY-RI04037
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-762 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-762 inhibitor
mmu-miR-762 inhibitor
- HY-RI04154
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-8106 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-8106 inhibitor
mmu-miR-8106 inhibitor
- HY-RI01007
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4324 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4324 inhibitor
hsa-miR-4324 inhibitor
- HY-RI00954
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4275 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4275 inhibitor
hsa-miR-4275 inhibitor
- HY-RI01152
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4525 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4525 inhibitor
hsa-miR-4525 inhibitor
- HY-RI00971
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4291 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4291 inhibitor
hsa-miR-4291 inhibitor
- HY-RI03339
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6241 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6241 inhibitor
mmu-miR-6241 inhibitor
- HY-RI00370
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-1913 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-1913 inhibitor
hsa-miR-1913 inhibitor
- HY-RI00933
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4254 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4254 inhibitor
hsa-miR-4254 inhibitor
- HY-RI03270
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-5125 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-5125 inhibitor
mmu-miR-5125 inhibitor
- HY-RI01368
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4754 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4754 inhibitor
hsa-miR-4754 inhibitor
- HY-RI01215
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-466 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-466 inhibitor
hsa-miR-466 inhibitor
- HY-RI02437
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-7973 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-7973 inhibitor
hsa-miR-7973 inhibitor
- HY-RI04543
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-6331 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-6331 inhibitor
rno-miR-6331 inhibitor
- HY-RI04552
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-665 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-665 inhibitor
rno-miR-665 inhibitor
- HY-RI00630
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3174 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3174 inhibitor
hsa-miR-3174 inhibitor
- HY-RI03365
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6359 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6359 inhibitor
mmu-miR-6359 inhibitor
- HY-RI01014
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4330 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4330 inhibitor
hsa-miR-4330 inhibitor
- HY-RI02826
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-2136 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-2136 inhibitor
mmu-miR-2136 inhibitor
- HY-RI03381
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6375 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6375 inhibitor
mmu-miR-6375 inhibitor
- HY-RI02572
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-1187 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-1187 inhibitor
mmu-miR-1187 inhibitor
- HY-RI00962
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4283 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4283 inhibitor
hsa-miR-4283 inhibitor
- HY-RI03388
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6382 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6382 inhibitor
mmu-miR-6382 inhibitor
- HY-RI01167
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4539 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4539 inhibitor
hsa-miR-4539 inhibitor
- HY-RI04561
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-676 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-676 inhibitor
rno-miR-676 inhibitor
- HY-RI01853
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-6079 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-6079 inhibitor
hsa-miR-6079 inhibitor
- HY-RI03417
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6410 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6410 inhibitor
mmu-miR-6410 inhibitor
- HY-RI01135
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4516 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4516 inhibitor
hsa-miR-4516 inhibitor
- HY-RI02407
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-760 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-760 inhibitor
hsa-miR-760 inhibitor
- HY-RI01058
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4452 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4452 inhibitor
hsa-miR-4452 inhibitor
- HY-RI01176
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4634 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4634 inhibitor
hsa-miR-4634 inhibitor
- HY-RI04159
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-8111 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-8111 inhibitor
mmu-miR-8111 inhibitor
- HY-RI01098
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4489 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4489 inhibitor
hsa-miR-4489 inhibitor
- HY-RI03372
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6366 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6366 inhibitor
mmu-miR-6366 inhibitor
- HY-RI00728
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3612 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3612 inhibitor
hsa-miR-3612 inhibitor
- HY-RI01865
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-6090 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-6090 inhibitor
hsa-miR-6090 inhibitor
- HY-RI00802
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3686 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3686 inhibitor
hsa-miR-3686 inhibitor
- HY-RI00909
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3960 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3960 inhibitor
hsa-miR-3960 inhibitor
- HY-RI01388
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4765 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4765 inhibitor
hsa-miR-4765 inhibitor
- HY-RI01097
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4488 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4488 inhibitor
hsa-miR-4488 inhibitor
- HY-RI00938
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4259 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4259 inhibitor
hsa-miR-4259 inhibitor
- HY-RI03413
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6406 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6406 inhibitor
mmu-miR-6406 inhibitor
- HY-RI01080
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4475 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4475 inhibitor
hsa-miR-4475 inhibitor
- HY-RI04373
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-349 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-349 inhibitor
rno-miR-349 inhibitor
- HY-RI03379
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6373 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6373 inhibitor
mmu-miR-6373 inhibitor
- HY-RI00877
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3918 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3918 inhibitor
hsa-miR-3918 inhibitor
- HY-RI01910
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-636 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-636 inhibitor
hsa-miR-636 inhibitor
- HY-RI02534
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-9500 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-9500 inhibitor
hsa-miR-9500 inhibitor
- HY-RI00996
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4315 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4315 inhibitor
hsa-miR-4315 inhibitor
- HY-RI01906
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-632 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-632 inhibitor
hsa-miR-632 inhibitor
- HY-RI00229
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-1299 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-1299 inhibitor
hsa-miR-1299 inhibitor
- HY-153435
-
|
|
RIP kinase
Necroptosis
|
Cancer
|
|
RIP1 kinase inhibitor 5 (example 1) is a potent inhibitor of RIP1, which is used as a checkpoint kinase to control tumor immunity . RIP1 kinase inhibitor 5 is similar with SIR1-365 (compound 13), which inhibits necrosis and iron death activity .
|
-
- HY-RI00989
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4309 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4309 inhibitor
hsa-miR-4309 inhibitor
- HY-RI01789
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-5706 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-5706 inhibitor
hsa-miR-5706 inhibitor
- HY-RI01088
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4481 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4481 inhibitor
hsa-miR-4481 inhibitor
- HY-RI03367
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6361 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6361 inhibitor
mmu-miR-6361 inhibitor
- HY-RI01059
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4453 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4453 inhibitor
hsa-miR-4453 inhibitor
- HY-RI04545
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-6333 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-6333 inhibitor
rno-miR-6333 inhibitor
- HY-RI01410
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4779 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4779 inhibitor
hsa-miR-4779 inhibitor
- HY-RI02731
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-1906 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-1906 inhibitor
mmu-miR-1906 inhibitor
- HY-RI02474
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-8082 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-8082 inhibitor
hsa-miR-8082 inhibitor
- HY-158098
-
|
|
FGFR
|
Metabolic Disease
|
|
FGFR1 inhibitor-11 (compound 5g) binds to FGFR1, inactivation of its downstream ERK1/2 and IκBα/NF-κB signaling inhibited RANKL-induced osteoclastogenesis. FGFR1 inhibitor-11 has oral bioactivity .
|
-
- HY-RI01031
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4432 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4432 inhibitor
hsa-miR-4432 inhibitor
- HY-RI01921
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-645 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-645 inhibitor
hsa-miR-645 inhibitor
- HY-RI04526
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-6315 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-6315 inhibitor
rno-miR-6315 inhibitor
- HY-RI02546
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-9900 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-9900 inhibitor
hsa-miR-9900 inhibitor
- HY-RI01129
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4510 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4510 inhibitor
hsa-miR-4510 inhibitor
- HY-RI00685
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-326 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-326 inhibitor
hsa-miR-326 inhibitor
- HY-RI03863
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-706 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-706 inhibitor
mmu-miR-706 inhibitor
- HY-RI01120
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4506 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4506 inhibitor
hsa-miR-4506 inhibitor
- HY-RI01886
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-617 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-617 inhibitor
hsa-miR-617 inhibitor
- HY-RI02411
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-765 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-765 inhibitor
hsa-miR-765 inhibitor
- HY-RI03418
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6411 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6411 inhibitor
mmu-miR-6411 inhibitor
- HY-RI02449
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-8057 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-8057 inhibitor
hsa-miR-8057 inhibitor
- HY-RI01858
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-6083 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-6083 inhibitor
hsa-miR-6083 inhibitor
- HY-RI01311
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4719 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4719 inhibitor
hsa-miR-4719 inhibitor
- HY-RI04371
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-347 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-347 inhibitor
rno-miR-347 inhibitor
- HY-RI00088
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-1208 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-1208 inhibitor
hsa-miR-1208 inhibitor
- HY-RI01530
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-5093 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-5093 inhibitor
hsa-miR-5093 inhibitor
- HY-RI03938
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-711 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-711 inhibitor
mmu-miR-711 inhibitor
- HY-RI04413
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-3576 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-3576 inhibitor
rno-miR-3576 inhibitor
- HY-RI01871
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-6127 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-6127 inhibitor
hsa-miR-6127 inhibitor
- HY-RI01267
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4692 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4692 inhibitor
hsa-miR-4692 inhibitor
- HY-RI03344
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6338 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6338 inhibitor
mmu-miR-6338 inhibitor
- HY-RI00197
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-1281 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-1281 inhibitor
hsa-miR-1281 inhibitor
- HY-RI01849
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-6075 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-6075 inhibitor
hsa-miR-6075 inhibitor
- HY-RI04530
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-6319 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-6319 inhibitor
rno-miR-6319 inhibitor
- HY-RI02518
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-934 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-934 inhibitor
hsa-miR-934 inhibitor
- HY-RI01424
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4788 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4788 inhibitor
hsa-miR-4788 inhibitor
- HY-RI04384
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-3548 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-3548 inhibitor
rno-miR-3548 inhibitor
- HY-RI03336
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6238 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6238 inhibitor
mmu-miR-6238 inhibitor
- HY-RI00780
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3671 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3671 inhibitor
hsa-miR-3671 inhibitor
- HY-RI02726
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-1901 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-1901 inhibitor
mmu-miR-1901 inhibitor
- HY-RI01048
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4444 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4444 inhibitor
hsa-miR-4444 inhibitor
- HY-RI03373
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6367 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6367 inhibitor
mmu-miR-6367 inhibitor
- HY-RI04407
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-3571 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-3571 inhibitor
rno-miR-3571 inhibitor
- HY-RI03338
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6240 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6240 inhibitor
mmu-miR-6240 inhibitor
- HY-RI03954
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-718 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-718 inhibitor
mmu-miR-718 inhibitor
- HY-RI03403
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6396 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6396 inhibitor
mmu-miR-6396 inhibitor
- HY-RI01778
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-5697 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-5697 inhibitor
hsa-miR-5697 inhibitor
- HY-RI03425
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6417 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6417 inhibitor
mmu-miR-6417 inhibitor
- HY-RI03263
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-5119 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-5119 inhibitor
mmu-miR-5119 inhibitor
- HY-RI01187
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4642 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4642 inhibitor
hsa-miR-4642 inhibitor
- HY-RI00934
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4255 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4255 inhibitor
hsa-miR-4255 inhibitor
- HY-RI01117
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4503 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4503 inhibitor
hsa-miR-4503 inhibitor
- HY-RI04586
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-876 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-876 inhibitor
rno-miR-876 inhibitor
- HY-RI03133
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-3969 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-3969 inhibitor
mmu-miR-3969 inhibitor
- HY-RI00082
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-1202 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-1202 inhibitor
hsa-miR-1202 inhibitor
- HY-RI01716
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-553 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-553 inhibitor
hsa-miR-553 inhibitor
- HY-RI02769
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-1950 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-1950 inhibitor
mmu-miR-1950 inhibitor
- HY-RI04415
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-3578 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-3578 inhibitor
rno-miR-3578 inhibitor
- HY-RI00942
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4263 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4263 inhibitor
hsa-miR-4263 inhibitor
- HY-RI00156
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-1253 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-1253 inhibitor
hsa-miR-1253 inhibitor
- HY-RI00616
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3161 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3161 inhibitor
hsa-miR-3161 inhibitor
- HY-RI01159
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4531 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4531 inhibitor
hsa-miR-4531 inhibitor
- HY-RI01445
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4801 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4801 inhibitor
hsa-miR-4801 inhibitor
- HY-RI03953
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-717 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-717 inhibitor
mmu-miR-717 inhibitor
- HY-RI01019
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4421 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4421 inhibitor
hsa-miR-4421 inhibitor
- HY-RI00290
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-1470 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-1470 inhibitor
hsa-miR-1470 inhibitor
- HY-RI03437
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6538 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6538 inhibitor
mmu-miR-6538 inhibitor
- HY-RI04427
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-3587 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-3587 inhibitor
rno-miR-3587 inhibitor
- HY-RI02827
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-2137 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-2137 inhibitor
mmu-miR-2137 inhibitor
- HY-RI01474
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-496 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-496 inhibitor
hsa-miR-496 inhibitor
- HY-RI00755
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3649 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3649 inhibitor
hsa-miR-3649 inhibitor
- HY-RI01580
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-5194 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-5194 inhibitor
hsa-miR-5194 inhibitor
- HY-RI01877
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-6132 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-6132 inhibitor
hsa-miR-6132 inhibitor
- HY-RI01000
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4318 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4318 inhibitor
hsa-miR-4318 inhibitor
- HY-RI04544
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-6332 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-6332 inhibitor
rno-miR-6332 inhibitor
- HY-RI03257
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-5113 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-5113 inhibitor
mmu-miR-5113 inhibitor
- HY-RI00874
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3915 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3915 inhibitor
hsa-miR-3915 inhibitor
- HY-RI01289
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4706 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4706 inhibitor
hsa-miR-4706 inhibitor
- HY-RI00073
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-1183 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-1183 inhibitor
hsa-miR-1183 inhibitor
- HY-RI01262
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4689 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4689 inhibitor
hsa-miR-4689 inhibitor
- HY-RI02439
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-7975 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-7975 inhibitor
hsa-miR-7975 inhibitor
- HY-RI03261
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-5116 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-5116 inhibitor
mmu-miR-5116 inhibitor
- HY-RI00555
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3122 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3122 inhibitor
hsa-miR-3122 inhibitor
- HY-RI02462
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-8070 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-8070 inhibitor
hsa-miR-8070 inhibitor
- HY-RI01763
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-5684 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-5684 inhibitor
hsa-miR-5684 inhibitor
- HY-RI00317
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-1587 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-1587 inhibitor
hsa-miR-1587 inhibitor
- HY-RI00939
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4260 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4260 inhibitor
hsa-miR-4260 inhibitor
- HY-RI01808
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-581 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-581 inhibitor
hsa-miR-581 inhibitor
- HY-RI01791
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-5708 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-5708 inhibitor
hsa-miR-5708 inhibitor
- HY-RI01114
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4500 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4500 inhibitor
hsa-miR-4500 inhibitor
- HY-RI00760
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3655 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3655 inhibitor
hsa-miR-3655 inhibitor
- HY-RI00550
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3119 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3119 inhibitor
hsa-miR-3119 inhibitor
- HY-RI00291
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-1471 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-1471 inhibitor
hsa-miR-1471 inhibitor
- HY-RI02773
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-1954 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-1954 inhibitor
mmu-miR-1954 inhibitor
- HY-RI03248
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-5103 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-5103 inhibitor
mmu-miR-5103 inhibitor
- HY-RI01347
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4741 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4741 inhibitor
hsa-miR-4741 inhibitor
- HY-RI01790
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-5707 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-5707 inhibitor
hsa-miR-5707 inhibitor
- HY-RI04150
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-8102 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-8102 inhibitor
mmu-miR-8102 inhibitor
- HY-160093
-
|
|
PTEN
Akt
PI3K
|
Metabolic Disease
|
|
SQLE-IN-1 (compound 19) is a squalene epoxidase (SQLE) inhibitor. SQLE-IN-1 inhibits the proliferation and migration of Huh7 cells. SQLE-IN-1 inhibits the cell cholesterol generation. SQLE-IN-1 increases the expression of PTEN and inhibits PI3K and AKT .
|
-
- HY-RI01131
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4512 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4512 inhibitor
hsa-miR-4512 inhibitor
- HY-RI02780
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-1961 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-1961 inhibitor
mmu-miR-1961 inhibitor
- HY-RI03414
-
|
|
MicroRNA
|
|
|
mmu-miR-6407 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6407 inhibitor
mmu-miR-6407 inhibitor
- HY-RI04541
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-6329 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-6329 inhibitor
rno-miR-6329 inhibitor
- HY-RI02539
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-9718 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-9718 inhibitor
hsa-miR-9718 inhibitor
- HY-RI00952
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4273 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4273 inhibitor
hsa-miR-4273 inhibitor
- HY-RI03393
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6387 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6387 inhibitor
mmu-miR-6387 inhibitor
- HY-RI01467
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-492 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-492 inhibitor
hsa-miR-492 inhibitor
- HY-RI04292
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-205 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-205 inhibitor
rno-miR-205 inhibitor
- HY-RI01200
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4651 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4651 inhibitor
hsa-miR-4651 inhibitor
- HY-RI02771
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-1952 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-1952 inhibitor
mmu-miR-1952 inhibitor
- HY-RI03363
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6357 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6357 inhibitor
mmu-miR-6357 inhibitor
- HY-RI00966
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4287 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4287 inhibitor
hsa-miR-4287 inhibitor
- HY-RI00967
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4288 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4288 inhibitor
hsa-miR-4288 inhibitor
- HY-RI02467
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-8075 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-8075 inhibitor
hsa-miR-8075 inhibitor
- HY-RI03504
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-681 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-681 inhibitor
mmu-miR-681 inhibitor
- HY-RI04294
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-207 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-207 inhibitor
rno-miR-207 inhibitor
- HY-RI03128
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-3964 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-3964 inhibitor
mmu-miR-3964 inhibitor
- HY-RI01754
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-563 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-563 inhibitor
hsa-miR-563 inhibitor
- HY-RI00098
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-12122 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-12122 inhibitor
hsa-miR-12122 inhibitor
- HY-RI04412
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-3575 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-3575 inhibitor
rno-miR-3575 inhibitor
- HY-RI03134
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-3970 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-3970 inhibitor
mmu-miR-3970 inhibitor
- HY-RI00074
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-1184 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-1184 inhibitor
hsa-miR-1184 inhibitor
- HY-RI03335
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6237 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6237 inhibitor
mmu-miR-6237 inhibitor
- HY-RI04339
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-3072 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-3072 inhibitor
rno-miR-3072 inhibitor
- HY-RI01835
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-602 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-602 inhibitor
hsa-miR-602 inhibitor
- HY-RI00162
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-1258 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-1258 inhibitor
hsa-miR-1258 inhibitor
- HY-RI01205
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4654 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4654 inhibitor
hsa-miR-4654 inhibitor
- HY-RI04145
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-8097 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-8097 inhibitor
mmu-miR-8097 inhibitor
- HY-RI04318
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-290 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-290 inhibitor
rno-miR-290 inhibitor
- HY-RI00636
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3179 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3179 inhibitor
hsa-miR-3179 inhibitor
- HY-RI01092
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4484 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4484 inhibitor
hsa-miR-4484 inhibitor
- HY-RI02362
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-711 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-711 inhibitor
hsa-miR-711 inhibitor
- HY-RI04160
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-8112 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-8112 inhibitor
mmu-miR-8112 inhibitor
- HY-RI01769
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-5690 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-5690 inhibitor
hsa-miR-5690 inhibitor
- HY-RI01067
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4463 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4463 inhibitor
hsa-miR-4463 inhibitor
- HY-111219
-
|
NM-702; NT-702
|
Phosphodiesterase (PDE)
|
Others
|
|
Parogrelil (hydrochloride) (NM-702) is a phosphodiesterase inhibitor with activity in inhibiting intermittent claudication. Parogrelil (hydrochloride) selectively inhibits PDE3, inhibits human platelet aggregation in vitro and rat aortic contraction, and improves walking distance and plantar surface temperature in the rat femoral artery ligation model, with better effects than cilostazol.
|
-
- HY-RI01626
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-543 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-543 inhibitor
hsa-miR-543 inhibitor
- HY-RI04162
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-8114 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-8114 inhibitor
mmu-miR-8114 inhibitor
- HY-RI01123
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4509 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4509 inhibitor
hsa-miR-4509 inhibitor
- HY-RI02472
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-8080 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-8080 inhibitor
hsa-miR-8080 inhibitor
- HY-RI04537
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-6325 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-6325 inhibitor
rno-miR-6325 inhibitor
- HY-RI01053
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4447 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4447 inhibitor
hsa-miR-4447 inhibitor
- HY-RI02410
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-764 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-764 inhibitor
hsa-miR-764 inhibitor
- HY-RI03392
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6386 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6386 inhibitor
mmu-miR-6386 inhibitor
- HY-RI00957
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4278 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4278 inhibitor
hsa-miR-4278 inhibitor
- HY-RI01242
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4675 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4675 inhibitor
hsa-miR-4675 inhibitor
- HY-RI03129
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-3965 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-3965 inhibitor
mmu-miR-3965 inhibitor
- HY-RI00753
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3646 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3646 inhibitor
hsa-miR-3646 inhibitor
- HY-RI03408
-
|
|
MicroRNA
|
|
|
mmu-miR-6401 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6401 inhibitor
mmu-miR-6401 inhibitor
- HY-RI00078
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-1193 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-1193 inhibitor
hsa-miR-1193 inhibitor
- HY-RI00897
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3937 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3937 inhibitor
hsa-miR-3937 inhibitor
- HY-RI04262
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-1896 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-1896 inhibitor
rno-miR-1896 inhibitor
- HY-RI02725
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-1900 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-1900 inhibitor
mmu-miR-1900 inhibitor
- HY-RI03410
-
|
|
MicroRNA
|
|
|
mmu-miR-6403 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6403 inhibitor
mmu-miR-6403 inhibitor
- HY-RI03507
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-684 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-684 inhibitor
mmu-miR-684 inhibitor
- HY-RI02728
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-1903 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-1903 inhibitor
mmu-miR-1903 inhibitor
- HY-RI01130
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4511 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4511 inhibitor
hsa-miR-4511 inhibitor
- HY-RI01890
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-620 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-620 inhibitor
hsa-miR-620 inhibitor
- HY-RI04529
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-6318 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-6318 inhibitor
rno-miR-6318 inhibitor
- HY-RI01811
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-583 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-583 inhibitor
hsa-miR-583 inhibitor
- HY-RI01234
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4669 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4669 inhibitor
hsa-miR-4669 inhibitor
- HY-RI01411
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4780 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4780 inhibitor
hsa-miR-4780 inhibitor
- HY-RI00819
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3714 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3714 inhibitor
hsa-miR-3714 inhibitor
- HY-RI01432
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4794 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4794 inhibitor
hsa-miR-4794 inhibitor
- HY-RI01004
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4322 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4322 inhibitor
hsa-miR-4322 inhibitor
- HY-RI00066
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-11401 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-11401 inhibitor
hsa-miR-11401 inhibitor
- HY-RI03415
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6408 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6408 inhibitor
mmu-miR-6408 inhibitor
- HY-RI00570
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3132 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3132 inhibitor
hsa-miR-3132 inhibitor
- HY-RI01046
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4442 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4442 inhibitor
hsa-miR-4442 inhibitor
- HY-RI04566
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-711 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-711 inhibitor
rno-miR-711 inhibitor
- HY-RI03422
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6415 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6415 inhibitor
mmu-miR-6415 inhibitor
- HY-RI02421
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-7706 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-7706 inhibitor
hsa-miR-7706 inhibitor
- HY-RI00964
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4285 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4285 inhibitor
hsa-miR-4285 inhibitor
- HY-RI04370
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-346 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-346 inhibitor
rno-miR-346 inhibitor
- HY-RI01391
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4767 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4767 inhibitor
hsa-miR-4767 inhibitor
- HY-RI03429
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6420 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6420 inhibitor
mmu-miR-6420 inhibitor
- HY-RI00982
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4302 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4302 inhibitor
hsa-miR-4302 inhibitor
- HY-RI04404
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-3568 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-3568 inhibitor
rno-miR-3568 inhibitor
- HY-RI03337
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6239 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6239 inhibitor
mmu-miR-6239 inhibitor
- HY-RI04389
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-3553 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-3553 inhibitor
rno-miR-3553 inhibitor
- HY-RI02713
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-1893 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-1893 inhibitor
mmu-miR-1893 inhibitor
- HY-RI02409
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-762 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-762 inhibitor
hsa-miR-762 inhibitor
- HY-RI01851
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-6077 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-6077 inhibitor
hsa-miR-6077 inhibitor
- HY-RI04142
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-8094 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-8094 inhibitor
mmu-miR-8094 inhibitor
- HY-RI00632
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3176 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3176 inhibitor
hsa-miR-3176 inhibitor
- HY-RI03131
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-3967 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-3967 inhibitor
mmu-miR-3967 inhibitor
- HY-RI00973
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4293 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4293 inhibitor
hsa-miR-4293 inhibitor
- HY-RI00641
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3182 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3182 inhibitor
hsa-miR-3182 inhibitor
- HY-RI03359
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6353 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6353 inhibitor
mmu-miR-6353 inhibitor
- HY-RI02455
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-8063 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-8063 inhibitor
hsa-miR-8063 inhibitor
- HY-RI00929
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4251 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4251 inhibitor
hsa-miR-4251 inhibitor
- HY-RI03038
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-343 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-343 inhibitor
mmu-miR-343 inhibitor
- HY-RI01359
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4748 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4748 inhibitor
hsa-miR-4748 inhibitor
- HY-RI00768
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3661 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3661 inhibitor
hsa-miR-3661 inhibitor
- HY-RI04403
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-3566 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-3566 inhibitor
rno-miR-3566 inhibitor
- HY-RI00572
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3134 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3134 inhibitor
hsa-miR-3134 inhibitor
- HY-RI04405
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-3569 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-3569 inhibitor
rno-miR-3569 inhibitor
- HY-RI03384
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6378 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6378 inhibitor
mmu-miR-6378 inhibitor
- HY-RI01400
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4773 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4773 inhibitor
hsa-miR-4773 inhibitor
- HY-RI03503
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-680 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-680 inhibitor
mmu-miR-680 inhibitor
- HY-RI02752
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-1938 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-1938 inhibitor
mmu-miR-1938 inhibitor
- HY-RI02532
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-943 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-943 inhibitor
hsa-miR-943 inhibitor
- HY-RI00739
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3618 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3618 inhibitor
hsa-miR-3618 inhibitor
- HY-RI02544
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-9898 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-9898 inhibitor
hsa-miR-9898 inhibitor
- HY-RI04089
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-767 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-767 inhibitor
mmu-miR-767 inhibitor
- HY-RI00312
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-1539 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-1539 inhibitor
hsa-miR-1539 inhibitor
- HY-RI03267
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-5123 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-5123 inhibitor
mmu-miR-5123 inhibitor
- HY-RI00072
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-1182 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-1182 inhibitor
hsa-miR-1182 inhibitor
- HY-RI00420
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-2054 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-2054 inhibitor
hsa-miR-2054 inhibitor
- HY-RI01132
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4513 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4513 inhibitor
hsa-miR-4513 inhibitor
- HY-RI01105
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4496 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4496 inhibitor
hsa-miR-4496 inhibitor
- HY-RI00992
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4312 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4312 inhibitor
hsa-miR-4312 inhibitor
- HY-RI04038
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-763 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-763 inhibitor
mmu-miR-763 inhibitor
- HY-RI00343
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-184 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-184 inhibitor
hsa-miR-184 inhibitor
- HY-RI04196
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-935 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-935 inhibitor
mmu-miR-935 inhibitor
- HY-RI02547
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-9901 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-9901 inhibitor
hsa-miR-9901 inhibitor
- HY-RI03130
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-3966 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-3966 inhibitor
mmu-miR-3966 inhibitor
- HY-RI03387
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6381 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6381 inhibitor
mmu-miR-6381 inhibitor
- HY-RI01037
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4435 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4435 inhibitor
hsa-miR-4435 inhibitor
- HY-RI01102
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4493 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4493 inhibitor
hsa-miR-4493 inhibitor
- HY-RI00103
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-12127 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-12127 inhibitor
hsa-miR-12127 inhibitor
- HY-RI00666
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3199 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3199 inhibitor
hsa-miR-3199 inhibitor
- HY-RI00959
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4280 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4280 inhibitor
hsa-miR-4280 inhibitor
- HY-RI01844
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-6070 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-6070 inhibitor
hsa-miR-6070 inhibitor
- HY-RI02717
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-1896 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-1896 inhibitor
mmu-miR-1896 inhibitor
- HY-RI00876
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3917 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3917 inhibitor
hsa-miR-3917 inhibitor
- HY-RI00669
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3201 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3201 inhibitor
hsa-miR-3201 inhibitor
- HY-RI00905
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3943 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3943 inhibitor
hsa-miR-3943 inhibitor
- HY-RI02782
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-1963 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-1963 inhibitor
mmu-miR-1963 inhibitor
- HY-RI00092
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-12116 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-12116 inhibitor
hsa-miR-12116 inhibitor
- HY-RI01880
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-614 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-614 inhibitor
hsa-miR-614 inhibitor
- HY-RI01024
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4425 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4425 inhibitor
hsa-miR-4425 inhibitor
- HY-RI01041
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4437 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4437 inhibitor
hsa-miR-4437 inhibitor
- HY-RI01209
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4657 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4657 inhibitor
hsa-miR-4657 inhibitor
- HY-RI04563
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-679 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-679 inhibitor
rno-miR-679 inhibitor
- HY-RI03342
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6336 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6336 inhibitor
mmu-miR-6336 inhibitor
- HY-RI01239
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4672 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4672 inhibitor
hsa-miR-4672 inhibitor
- HY-RI00441
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-2117 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-2117 inhibitor
hsa-miR-2117 inhibitor
- HY-RI03884
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-707 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-707 inhibitor
mmu-miR-707 inhibitor
- HY-RI04143
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-8095 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-8095 inhibitor
mmu-miR-8095 inhibitor
- HY-RI00637
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3180 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3180 inhibitor
hsa-miR-3180 inhibitor
- HY-RI00998
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4316 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4316 inhibitor
hsa-miR-4316 inhibitor
- HY-RI00980
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4300 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4300 inhibitor
hsa-miR-4300 inhibitor
- HY-RI01923
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-648 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-648 inhibitor
hsa-miR-648 inhibitor
- HY-RI00999
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4317 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4317 inhibitor
hsa-miR-4317 inhibitor
- HY-RI02790
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-1969 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-1969 inhibitor
mmu-miR-1969 inhibitor
- HY-RI03082
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-3535 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-3535 inhibitor
mmu-miR-3535 inhibitor
- HY-RI01160
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4533 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4533 inhibitor
hsa-miR-4533 inhibitor
- HY-RI02579
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-1192 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-1192 inhibitor
mmu-miR-1192 inhibitor
- HY-RI03356
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6350 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6350 inhibitor
mmu-miR-6350 inhibitor
- HY-RI00978
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4298 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4298 inhibitor
hsa-miR-4298 inhibitor
- HY-RI00867
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3910 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3910 inhibitor
hsa-miR-3910 inhibitor
- HY-RI01869
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-6125 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-6125 inhibitor
hsa-miR-6125 inhibitor
- HY-RI01025
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4426 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4426 inhibitor
hsa-miR-4426 inhibitor
- HY-RI04151
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-8103 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-8103 inhibitor
mmu-miR-8103 inhibitor
- HY-RI00960
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4281 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4281 inhibitor
hsa-miR-4281 inhibitor
- HY-RI01241
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4674 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4674 inhibitor
hsa-miR-4674 inhibitor
- HY-RI03246
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-5100 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-5100 inhibitor
mmu-miR-5100 inhibitor
- HY-RI00864
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3907 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3907 inhibitor
hsa-miR-3907 inhibitor
- HY-RI01005
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4323 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4323 inhibitor
hsa-miR-4323 inhibitor
- HY-RI01912
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-638 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-638 inhibitor
hsa-miR-638 inhibitor
- HY-RI03397
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6391 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6391 inhibitor
mmu-miR-6391 inhibitor
- HY-RI00990
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4310 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4310 inhibitor
hsa-miR-4310 inhibitor
- HY-RI03255
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-5110 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-5110 inhibitor
mmu-miR-5110 inhibitor
- HY-RI01144
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4521 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4521 inhibitor
hsa-miR-4521 inhibitor
- HY-RI00931
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4253 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4253 inhibitor
hsa-miR-4253 inhibitor
- HY-RI00069
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-1179 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-1179 inhibitor
hsa-miR-1179 inhibitor
- HY-RI01119
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4505 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4505 inhibitor
hsa-miR-4505 inhibitor
- HY-RI02732
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-1907 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-1907 inhibitor
mmu-miR-1907 inhibitor
- HY-RI00418
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-2053 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-2053 inhibitor
hsa-miR-2053 inhibitor
- HY-RI03262
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-5118 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-5118 inhibitor
mmu-miR-5118 inhibitor
- HY-RI01154
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4527 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4527 inhibitor
hsa-miR-4527 inhibitor
- HY-RI04380
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-3543 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-3543 inhibitor
rno-miR-3543 inhibitor
- HY-RI01798
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-575 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-575 inhibitor
hsa-miR-575 inhibitor
- HY-RI00757
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3651 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3651 inhibitor
hsa-miR-3651 inhibitor
- HY-RI04398
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-3560 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-3560 inhibitor
rno-miR-3560 inhibitor
- HY-RI01876
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-6131 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-6131 inhibitor
hsa-miR-6131 inhibitor
- HY-RI01767
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-5689 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-5689 inhibitor
hsa-miR-5689 inhibitor
- HY-RI03386
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6380 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6380 inhibitor
mmu-miR-6380 inhibitor
- HY-RI04164
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-8116 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-8116 inhibitor
mmu-miR-8116 inhibitor
- HY-RI00902
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3941 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3941 inhibitor
hsa-miR-3941 inhibitor
- HY-RI00949
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4270 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4270 inhibitor
hsa-miR-4270 inhibitor
- HY-RI00621
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3165 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3165 inhibitor
hsa-miR-3165 inhibitor
- HY-RI03132
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-3968 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-3968 inhibitor
mmu-miR-3968 inhibitor
- HY-RI02457
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-8065 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-8065 inhibitor
hsa-miR-8065 inhibitor
- HY-RI01158
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4530 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4530 inhibitor
hsa-miR-4530 inhibitor
- HY-RI01023
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4424 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4424 inhibitor
hsa-miR-4424 inhibitor
- HY-RI01779
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-5698 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-5698 inhibitor
hsa-miR-5698 inhibitor
- HY-RI00102
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-12126 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-12126 inhibitor
hsa-miR-12126 inhibitor
- HY-RI04432
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-3592 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-3592 inhibitor
rno-miR-3592 inhibitor
- HY-RI00137
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-1243 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-1243 inhibitor
hsa-miR-1243 inhibitor
- HY-RI00096
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-12120 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-12120 inhibitor
hsa-miR-12120 inhibitor
- HY-RI00602
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3153 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3153 inhibitor
hsa-miR-3153 inhibitor
- HY-RI00726
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3610 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3610 inhibitor
hsa-miR-3610 inhibitor
- HY-RI01527
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-5090 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-5090 inhibitor
hsa-miR-5090 inhibitor
- HY-RI00800
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3684 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3684 inhibitor
hsa-miR-3684 inhibitor
- HY-RI00944
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4265 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4265 inhibitor
hsa-miR-4265 inhibitor
- HY-RI02478
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-8086 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-8086 inhibitor
hsa-miR-8086 inhibitor
- HY-RI00232
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-1302 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-1302 inhibitor
hsa-miR-1302 inhibitor
- HY-124902
-
|
|
Antibiotic
Fungal
Bacterial
|
Infection
|
|
Valclavam is an antibiotic, which exhibits antibacterial and antifungal activities. Valclavam inhibits homoserine-O-succinyltransferase (EC 2.3.1.46), blocks the methionine synthesis, and thus inhibits Escherichia coli. Valclavam inhibits Saccharomyces cerevisiae through inhibition of RNA formation. Valclavam inhibits the movement and reproduction of nematode Caenorhabditis elegans.
|
-
- HY-RI03345
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6339 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6339 inhibitor
mmu-miR-6339 inhibitor
- HY-RI01784
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-5702 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-5702 inhibitor
hsa-miR-5702 inhibitor
- HY-RI00147
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-1248 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-1248 inhibitor
hsa-miR-1248 inhibitor
- HY-RI01168
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4540 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4540 inhibitor
hsa-miR-4540 inhibitor
- HY-RI01448
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4803 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4803 inhibitor
hsa-miR-4803 inhibitor
- HY-RI04146
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-8098 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-8098 inhibitor
mmu-miR-8098 inhibitor
- HY-RI01068
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4464 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4464 inhibitor
hsa-miR-4464 inhibitor
- HY-RI01817
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-587 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-587 inhibitor
hsa-miR-587 inhibitor
- HY-RI03389
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6383 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6383 inhibitor
mmu-miR-6383 inhibitor
- HY-RI00761
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3657 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3657 inhibitor
hsa-miR-3657 inhibitor
- HY-RI03135
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-3971 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-3971 inhibitor
mmu-miR-3971 inhibitor
- HY-RI00945
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4266 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4266 inhibitor
hsa-miR-4266 inhibitor
- HY-RI01579
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-5193 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-5193 inhibitor
hsa-miR-5193 inhibitor
- HY-RI00948
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4269 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4269 inhibitor
hsa-miR-4269 inhibitor
- HY-RI01841
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-6068 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-6068 inhibitor
hsa-miR-6068 inhibitor
- HY-RI01891
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-621 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-621 inhibitor
hsa-miR-621 inhibitor
- HY-RI03364
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6358 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6358 inhibitor
mmu-miR-6358 inhibitor
- HY-RI01515
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-5047 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-5047 inhibitor
hsa-miR-5047 inhibitor
- HY-RI02282
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-6860 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-6860 inhibitor
hsa-miR-6860 inhibitor
- HY-RI00097
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-12121 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-12121 inhibitor
hsa-miR-12121 inhibitor
- HY-RI04401
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-3562 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-3562 inhibitor
rno-miR-3562 inhibitor
- HY-RI02465
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-8073 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-8073 inhibitor
hsa-miR-8073 inhibitor
- HY-RI01084
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4478 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4478 inhibitor
hsa-miR-4478 inhibitor
- HY-RI00396
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-1976 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-1976 inhibitor
hsa-miR-1976 inhibitor
- HY-RI02549
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-9903 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-9903 inhibitor
hsa-miR-9903 inhibitor
- HY-RI00662
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3195 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3195 inhibitor
hsa-miR-3195 inhibitor
- HY-RI00986
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4306 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4306 inhibitor
hsa-miR-4306 inhibitor
- HY-RI00640
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3181 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3181 inhibitor
hsa-miR-3181 inhibitor
- HY-RI02047
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-6745 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-6745 inhibitor
hsa-miR-6745 inhibitor
- HY-RI01251
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4681 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4681 inhibitor
hsa-miR-4681 inhibitor
- HY-RI01314
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4721 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4721 inhibitor
hsa-miR-4721 inhibitor
- HY-RI04408
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-3572 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-3572 inhibitor
rno-miR-3572 inhibitor
- HY-RI01854
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-608 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-608 inhibitor
hsa-miR-608 inhibitor
- HY-RI01915
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-641 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-641 inhibitor
hsa-miR-641 inhibitor
- HY-RI04533
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-6321 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-6321 inhibitor
rno-miR-6321 inhibitor
- HY-RI04158
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-8110 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-8110 inhibitor
mmu-miR-8110 inhibitor
- HY-RI03798
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-703 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-703 inhibitor
mmu-miR-703 inhibitor
- HY-RI00912
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3974 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3974 inhibitor
hsa-miR-3974 inhibitor
- HY-RI00623
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3167 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3167 inhibitor
hsa-miR-3167 inhibitor
- HY-RI00338
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-1825 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-1825 inhibitor
hsa-miR-1825 inhibitor
- HY-RI00779
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3670 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3670 inhibitor
hsa-miR-3670 inhibitor
- HY-RI03368
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6362 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6362 inhibitor
mmu-miR-6362 inhibitor
- HY-RI00943
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4264 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4264 inhibitor
hsa-miR-4264 inhibitor
- HY-RI01115
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4501 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4501 inhibitor
hsa-miR-4501 inhibitor
- HY-RI00873
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3914 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3914 inhibitor
hsa-miR-3914 inhibitor
- HY-RI00868
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3911 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3911 inhibitor
hsa-miR-3911 inhibitor
- HY-RI04428
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-3588 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-3588 inhibitor
rno-miR-3588 inhibitor
- HY-RI03406
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6399 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6399 inhibitor
mmu-miR-6399 inhibitor
- HY-RI03340
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6244 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6244 inhibitor
mmu-miR-6244 inhibitor
- HY-RI01210
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4658 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4658 inhibitor
hsa-miR-4658 inhibitor
- HY-RI00476
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-2278 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-2278 inhibitor
hsa-miR-2278 inhibitor
- HY-RI02768
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-1949 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-1949 inhibitor
mmu-miR-1949 inhibitor
- HY-RI01064
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4458 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4458 inhibitor
hsa-miR-4458 inhibitor
- HY-RI04381
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-3544 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-3544 inhibitor
rno-miR-3544 inhibitor
- HY-RI03249
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-5104 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-5104 inhibitor
mmu-miR-5104 inhibitor
- HY-RI01837
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-604 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-604 inhibitor
hsa-miR-604 inhibitor
- HY-RI04152
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-8104 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-8104 inhibitor
mmu-miR-8104 inhibitor
- HY-RI01188
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4643 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4643 inhibitor
hsa-miR-4643 inhibitor
- HY-RI03352
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6346 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6346 inhibitor
mmu-miR-6346 inhibitor
- HY-RI00725
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3609 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3609 inhibitor
hsa-miR-3609 inhibitor
- HY-RI03420
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6413 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6413 inhibitor
mmu-miR-6413 inhibitor
- HY-RI02450
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-8058 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-8058 inhibitor
hsa-miR-8058 inhibitor
- HY-RI01166
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4538 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4538 inhibitor
hsa-miR-4538 inhibitor
- HY-RI02781
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-1962 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-1962 inhibitor
mmu-miR-1962 inhibitor
- HY-RI00233
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-1303 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-1303 inhibitor
hsa-miR-1303 inhibitor
- HY-RI01857
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-6082 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-6082 inhibitor
hsa-miR-6082 inhibitor
- HY-RI03378
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6372 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6372 inhibitor
mmu-miR-6372 inhibitor
- HY-RI04153
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-8105 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-8105 inhibitor
mmu-miR-8105 inhibitor
- HY-RI02463
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-8071 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-8071 inhibitor
hsa-miR-8071 inhibitor
- HY-RI01075
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4471 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4471 inhibitor
hsa-miR-4471 inhibitor
- HY-RI03400
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6393 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6393 inhibitor
mmu-miR-6393 inhibitor
- HY-RI03505
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-682 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-682 inhibitor
mmu-miR-682 inhibitor
- HY-RI04522
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-6215 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-6215 inhibitor
rno-miR-6215 inhibitor
- HY-RI03063
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-3471 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-3471 inhibitor
mmu-miR-3471 inhibitor
- HY-RI01030
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4431 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4431 inhibitor
hsa-miR-4431 inhibitor
- HY-RI02444
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-8052 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-8052 inhibitor
hsa-miR-8052 inhibitor
- HY-RI00664
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3197 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3197 inhibitor
hsa-miR-3197 inhibitor
- HY-122542
-
|
|
Thrombin
PAI-1
|
Cardiovascular Disease
|
|
PPACK is potent, selective and irreversible thrombin inhibitor. PPACK can be used an alternative anticoagulant to lithium heparin (LiHep) for blood gas and whole-blood electrolyte analyses. PPACK is also a plasminogen activator (rt-PA) inhibitor. PPACK can inhibit the binding of rt-PA to plasma protease inhibitors .
|
-
- HY-RI02445
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-8053 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-8053 inhibitor
hsa-miR-8053 inhibitor
- HY-RI00506
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-297 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-297 inhibitor
hsa-miR-297 inhibitor
- HY-RI00583
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3141 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3141 inhibitor
hsa-miR-3141 inhibitor
- HY-RI00340
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-1827 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-1827 inhibitor
hsa-miR-1827 inhibitor
- HY-RI01824
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-592 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-592 inhibitor
hsa-miR-592 inhibitor
- HY-RI00110
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-12135 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-12135 inhibitor
hsa-miR-12135 inhibitor
- HY-RI04144
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-8096 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-8096 inhibitor
mmu-miR-8096 inhibitor
- HY-RI01179
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4637 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4637 inhibitor
hsa-miR-4637 inhibitor
- HY-RI01418
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4784 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4784 inhibitor
hsa-miR-4784 inhibitor
- HY-RI02529
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-941 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-941 inhibitor
hsa-miR-941 inhibitor
- HY-RI01002
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4320 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4320 inhibitor
hsa-miR-4320 inhibitor
- HY-RI04372
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-3473 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-3473 inhibitor
rno-miR-3473 inhibitor
- HY-RI00507
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-298 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-298 inhibitor
hsa-miR-298 inhibitor
- HY-RI01793
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-572 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-572 inhibitor
hsa-miR-572 inhibitor
- HY-RI01765
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-5687 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-5687 inhibitor
hsa-miR-5687 inhibitor
- HY-RI01892
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-623 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-623 inhibitor
hsa-miR-623 inhibitor
- HY-RI01138
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4519 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4519 inhibitor
hsa-miR-4519 inhibitor
- HY-RI01984
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-662 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-662 inhibitor
hsa-miR-662 inhibitor
- HY-RI03273
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-5128 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-5128 inhibitor
mmu-miR-5128 inhibitor
- HY-RI03358
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6352 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6352 inhibitor
mmu-miR-6352 inhibitor
- HY-RI00622
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3166 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3166 inhibitor
hsa-miR-3166 inhibitor
- HY-RI02521
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-936 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-936 inhibitor
hsa-miR-936 inhibitor
- HY-RI02447
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-8055 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-8055 inhibitor
hsa-miR-8055 inhibitor
- HY-RI01071
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4467 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4467 inhibitor
hsa-miR-4467 inhibitor
- HY-RI01860
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-6085 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-6085 inhibitor
hsa-miR-6085 inhibitor
- HY-RI00991
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4311 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4311 inhibitor
hsa-miR-4311 inhibitor
- HY-RI03382
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6376 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6376 inhibitor
mmu-miR-6376 inhibitor
- HY-RI01782
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-5700 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-5700 inhibitor
hsa-miR-5700 inhibitor
- HY-RI01003
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4321 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4321 inhibitor
hsa-miR-4321 inhibitor
- HY-RI01770
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-5691 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-5691 inhibitor
hsa-miR-5691 inhibitor
- HY-RI04345
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-3099 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-3099 inhibitor
rno-miR-3099 inhibitor
- HY-RI01103
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4494 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4494 inhibitor
hsa-miR-4494 inhibitor
- HY-RI01020
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4422 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4422 inhibitor
hsa-miR-4422 inhibitor
- HY-RI00161
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-1257 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-1257 inhibitor
hsa-miR-1257 inhibitor
- HY-RI03519
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-690 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-690 inhibitor
mmu-miR-690 inhibitor
- HY-RI03955
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-719 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-719 inhibitor
mmu-miR-719 inhibitor
- HY-RI02797
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-1971 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-1971 inhibitor
mmu-miR-1971 inhibitor
- HY-RI03244
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-5098 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-5098 inhibitor
mmu-miR-5098 inhibitor
- HY-RI02452
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-8060 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-8060 inhibitor
hsa-miR-8060 inhibitor
- HY-RI00546
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3116 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3116 inhibitor
hsa-miR-3116 inhibitor
- HY-RI00769
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3662 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3662 inhibitor
hsa-miR-3662 inhibitor
- HY-RI04148
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-8100 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-8100 inhibitor
mmu-miR-8100 inhibitor
- HY-RI00079
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-1197 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-1197 inhibitor
hsa-miR-1197 inhibitor
- HY-RI01060
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4454 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4454 inhibitor
hsa-miR-4454 inhibitor
- HY-RI00173
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-1264 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-1264 inhibitor
hsa-miR-1264 inhibitor
- HY-RI02443
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-802 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-802 inhibitor
hsa-miR-802 inhibitor
- HY-RI03027
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-327 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-327 inhibitor
mmu-miR-327 inhibitor
- HY-RI02567
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-105 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-105 inhibitor
mmu-miR-105 inhibitor
- HY-RI00863
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-384 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-384 inhibitor
hsa-miR-384 inhibitor
- HY-RI00799
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3683 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3683 inhibitor
hsa-miR-3683 inhibitor
- HY-RI01047
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4443 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4443 inhibitor
hsa-miR-4443 inhibitor
- HY-RI01787
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-5704 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-5704 inhibitor
hsa-miR-5704 inhibitor
- HY-RI01028
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4429 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4429 inhibitor
hsa-miR-4429 inhibitor
- HY-RI03264
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-5120 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-5120 inhibitor
mmu-miR-5120 inhibitor
- HY-RI00089
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-12113 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-12113 inhibitor
hsa-miR-12113 inhibitor
- HY-RI00733
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3615 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3615 inhibitor
hsa-miR-3615 inhibitor
- HY-RI01908
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-634 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-634 inhibitor
hsa-miR-634 inhibitor
- HY-RI01146
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4523 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4523 inhibitor
hsa-miR-4523 inhibitor
- HY-RI03245
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-5099 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-5099 inhibitor
mmu-miR-5099 inhibitor
- HY-RI02458
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-8066 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-8066 inhibitor
hsa-miR-8066 inhibitor
- HY-RI01063
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4457 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4457 inhibitor
hsa-miR-4457 inhibitor
- HY-RI03343
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6337 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6337 inhibitor
mmu-miR-6337 inhibitor
- HY-RI01247
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4678 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4678 inhibitor
hsa-miR-4678 inhibitor
- HY-RI03540
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-691 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-691 inhibitor
mmu-miR-691 inhibitor
- HY-RI02451
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-8059 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-8059 inhibitor
hsa-miR-8059 inhibitor
- HY-RI00818
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3713 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3713 inhibitor
hsa-miR-3713 inhibitor
- HY-RI01774
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-5693 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-5693 inhibitor
hsa-miR-5693 inhibitor
- HY-RI02583
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-1195 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-1195 inhibitor
mmu-miR-1195 inhibitor
- HY-RI03355
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6349 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6349 inhibitor
mmu-miR-6349 inhibitor
- HY-RI01562
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-5188 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-5188 inhibitor
hsa-miR-5188 inhibitor
- HY-RI04575
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-762 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-762 inhibitor
rno-miR-762 inhibitor
- HY-RI01905
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-631 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-631 inhibitor
hsa-miR-631 inhibitor
- HY-RI00504
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-2909 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-2909 inhibitor
hsa-miR-2909 inhibitor
- HY-RI03604
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-694 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-694 inhibitor
mmu-miR-694 inhibitor
- HY-RI00108
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-12132 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-12132 inhibitor
hsa-miR-12132 inhibitor
- HY-RI01911
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-637 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-637 inhibitor
hsa-miR-637 inhibitor
- HY-RI01096
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4487 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4487 inhibitor
hsa-miR-4487 inhibitor
- HY-RI00545
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3115 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3115 inhibitor
hsa-miR-3115 inhibitor
- HY-RI00057
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-107 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-107 inhibitor
hsa-miR-107 inhibitor
- HY-RI00665
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3198 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3198 inhibitor
hsa-miR-3198 inhibitor
- HY-RI04209
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-105 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-105 inhibitor
rno-miR-105 inhibitor
- HY-RI04156
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-8108 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-8108 inhibitor
mmu-miR-8108 inhibitor
- HY-RI03421
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6414 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6414 inhibitor
mmu-miR-6414 inhibitor
- HY-RI00910
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3972 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3972 inhibitor
hsa-miR-3972 inhibitor
- HY-RI03266
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-5122 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-5122 inhibitor
mmu-miR-5122 inhibitor
- HY-RI00975
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4295 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4295 inhibitor
hsa-miR-4295 inhibitor
- HY-RI03370
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6364 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6364 inhibitor
mmu-miR-6364 inhibitor
- HY-RI00099
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-12123 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-12123 inhibitor
hsa-miR-12123 inhibitor
- HY-RI03366
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-6360 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-6360 inhibitor
mmu-miR-6360 inhibitor
- HY-RI04379
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-3542 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-3542 inhibitor
rno-miR-3542 inhibitor
- HY-RI01989
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-665 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-665 inhibitor
hsa-miR-665 inhibitor
- HY-RI03509
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-687 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-687 inhibitor
mmu-miR-687 inhibitor
- HY-RI02545
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-9899 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-9899 inhibitor
hsa-miR-9899 inhibitor
- HY-RI03157
-
|
|
MicroRNA
|
Cancer
|
|
mmu-miR-453 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
mmu-miR-453 inhibitor
mmu-miR-453 inhibitor
- HY-RI00183
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-1270 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-1270 inhibitor
hsa-miR-1270 inhibitor
- HY-RI01091
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-4483 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-4483 inhibitor
hsa-miR-4483 inhibitor
- HY-RI01862
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-6088 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-6088 inhibitor
hsa-miR-6088 inhibitor
- HY-RI04351
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-327 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
rno-miR-327 inhibitor
rno-miR-327 inhibitor
- HY-RI00801
-
|
|
MicroRNA
|
Cancer
|
|
hsa-miR-3685 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
|
-
hsa-miR-3685 inhibitor
hsa-miR-3685 inhibitor
- HY-RI04386
-
|
|
MicroRNA
|
Cancer
|
|
rno-miR-3550 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miR |
